WO2020226635A1 - Mutable collagenous tissue from echinoderms - Google Patents
Mutable collagenous tissue from echinoderms Download PDFInfo
- Publication number
- WO2020226635A1 WO2020226635A1 PCT/US2019/031194 US2019031194W WO2020226635A1 WO 2020226635 A1 WO2020226635 A1 WO 2020226635A1 US 2019031194 W US2019031194 W US 2019031194W WO 2020226635 A1 WO2020226635 A1 WO 2020226635A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- collagenous tissue
- mutable collagenous
- tissue
- mutable
- collagen
- Prior art date
Links
- 241000258955 Echinodermata Species 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 claims abstract description 135
- 238000000034 method Methods 0.000 claims abstract description 119
- 239000002537 cosmetic Substances 0.000 claims abstract description 65
- 102000012422 Collagen Type I Human genes 0.000 claims abstract description 58
- 108010022452 Collagen Type I Proteins 0.000 claims abstract description 58
- 229940096422 collagen type i Drugs 0.000 claims abstract description 48
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 210000001519 tissue Anatomy 0.000 claims description 232
- 210000002808 connective tissue Anatomy 0.000 claims description 112
- 102000008186 Collagen Human genes 0.000 claims description 104
- 108010035532 Collagen Proteins 0.000 claims description 104
- 229920001436 collagen Polymers 0.000 claims description 103
- 239000007788 liquid Substances 0.000 claims description 42
- 239000003960 organic solvent Substances 0.000 claims description 39
- 102000004190 Enzymes Human genes 0.000 claims description 38
- 108090000790 Enzymes Proteins 0.000 claims description 38
- 229940088598 enzyme Drugs 0.000 claims description 38
- 239000000243 solution Substances 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 239000007864 aqueous solution Substances 0.000 claims description 33
- 239000002738 chelating agent Substances 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- 208000027418 Wounds and injury Diseases 0.000 claims description 29
- 239000012670 alkaline solution Substances 0.000 claims description 28
- 206010052428 Wound Diseases 0.000 claims description 27
- 239000000017 hydrogel Substances 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 238000001556 precipitation Methods 0.000 claims description 20
- 239000007787 solid Substances 0.000 claims description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 17
- 239000004365 Protease Substances 0.000 claims description 16
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 14
- 235000015872 dietary supplement Nutrition 0.000 claims description 13
- 230000029663 wound healing Effects 0.000 claims description 13
- 238000004108 freeze drying Methods 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 8
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 7
- 108090000284 Pepsin A Proteins 0.000 claims description 7
- 102000057297 Pepsin A Human genes 0.000 claims description 7
- 108090000631 Trypsin Proteins 0.000 claims description 7
- 102000004142 Trypsin Human genes 0.000 claims description 7
- 238000000502 dialysis Methods 0.000 claims description 7
- 229940111202 pepsin Drugs 0.000 claims description 7
- 230000001376 precipitating effect Effects 0.000 claims description 7
- 239000012588 trypsin Substances 0.000 claims description 7
- 108010004032 Bromelains Proteins 0.000 claims description 6
- 108090000526 Papain Proteins 0.000 claims description 6
- 235000019835 bromelain Nutrition 0.000 claims description 6
- 235000019834 papain Nutrition 0.000 claims description 6
- 229940055729 papain Drugs 0.000 claims description 6
- 229960003330 pentetic acid Drugs 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 5
- 238000000746 purification Methods 0.000 abstract description 2
- 239000000284 extract Substances 0.000 description 110
- 238000005516 engineering process Methods 0.000 description 56
- 239000000872 buffer Substances 0.000 description 44
- 241000251511 Holothuroidea Species 0.000 description 41
- 210000003491 skin Anatomy 0.000 description 41
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
- 238000005119 centrifugation Methods 0.000 description 32
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 29
- 241000257465 Echinoidea Species 0.000 description 27
- -1 alkaline earth metal carbonate Chemical class 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 24
- 239000000499 gel Substances 0.000 description 22
- 150000001413 amino acids Chemical group 0.000 description 20
- 239000000126 substance Substances 0.000 description 19
- 241000283690 Bos taurus Species 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 239000008188 pellet Substances 0.000 description 18
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 16
- 238000000605 extraction Methods 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 14
- 239000008367 deionised water Substances 0.000 description 14
- 229910021641 deionized water Inorganic materials 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 241000258957 Asteroidea Species 0.000 description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 12
- 229960000583 acetic acid Drugs 0.000 description 12
- 235000011054 acetic acid Nutrition 0.000 description 12
- 229960001484 edetic acid Drugs 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 235000015165 citric acid Nutrition 0.000 description 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 10
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 229920002683 Glycosaminoglycan Polymers 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 239000000853 adhesive Substances 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 9
- 230000000699 topical effect Effects 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 244000269722 Thea sinensis Species 0.000 description 8
- 239000003929 acidic solution Substances 0.000 description 8
- 230000001070 adhesive effect Effects 0.000 description 8
- 244000309466 calf Species 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 230000001815 facial effect Effects 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 7
- 230000009102 absorption Effects 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 229940096423 bovine collagen type i Drugs 0.000 description 7
- 210000002744 extracellular matrix Anatomy 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 6
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000006468 Thea sinensis Nutrition 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000003416 augmentation Effects 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 229940093499 ethyl acetate Drugs 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 229960002591 hydroxyproline Drugs 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 239000001103 potassium chloride Substances 0.000 description 6
- 235000011164 potassium chloride Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 241001505481 Cucumaria frondosa Species 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 241000258120 Paracentrotus lividus Species 0.000 description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 241000941620 Thelenota ananas Species 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 229910052783 alkali metal Inorganic materials 0.000 description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 239000007857 degradation product Substances 0.000 description 5
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 5
- 239000006196 drop Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000006072 paste Substances 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 235000019260 propionic acid Nutrition 0.000 description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- 238000011200 topical administration Methods 0.000 description 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 4
- 241000257468 Asterias amurensis Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 239000004909 Moisturizer Substances 0.000 description 4
- 241000257458 Ophiuroidea Species 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 150000001340 alkali metals Chemical class 0.000 description 4
- 235000011399 aloe vera Nutrition 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 235000013793 astaxanthin Nutrition 0.000 description 4
- 229940022405 astaxanthin Drugs 0.000 description 4
- 239000001168 astaxanthin Substances 0.000 description 4
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000010217 densitometric analysis Methods 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000001333 moisturizer Effects 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 239000003352 sequestering agent Substances 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000008719 thickening Effects 0.000 description 4
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241001116389 Aloe Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000032544 Cicatrix Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 240000004670 Glycyrrhiza echinata Species 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 241000258128 Strongylocentrotus purpuratus Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 241001135917 Vitellaria paradoxa Species 0.000 description 3
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000000227 bioadhesive Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000004067 bulking agent Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229910017053 inorganic salt Inorganic materials 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000037230 mobility Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003961 penetration enhancing agent Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920000098 polyolefin Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 229940071643 prefilled syringe Drugs 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000004626 scanning electron microscopy Methods 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 230000003381 solubilizing effect Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 2
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 2
- 235000002629 Acer saccharinum Nutrition 0.000 description 2
- 244000046139 Acer saccharum Species 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 244000208874 Althaea officinalis Species 0.000 description 2
- 235000006576 Althaea officinalis Nutrition 0.000 description 2
- 244000105975 Antidesma platyphyllum Species 0.000 description 2
- 241000965254 Apostichopus japonicus Species 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 240000005343 Azadirachta indica Species 0.000 description 2
- 208000013883 Blast injury Diseases 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 235000007689 Borago officinalis Nutrition 0.000 description 2
- 240000004355 Borago officinalis Species 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 241001441986 Clypeasteroida Species 0.000 description 2
- 244000077995 Coix lacryma jobi Species 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 235000017788 Cydonia oblonga Nutrition 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000035874 Excoriation Diseases 0.000 description 2
- 102000009842 Fibril-Associated Collagens Human genes 0.000 description 2
- 108010020305 Fibril-Associated Collagens Proteins 0.000 description 2
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
- 241000227647 Fucus vesiculosus Species 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 241001135871 Gentiana scabra Species 0.000 description 2
- NGGYSPUAKQMTNP-UHFFFAOYSA-N Glabrene Chemical compound C1=C(O)C=C2OCC(C3=C4OC(C=CC4=C(O)C=C3)(C)C)=CC2=C1 NGGYSPUAKQMTNP-UHFFFAOYSA-N 0.000 description 2
- KKLOCFOZPFGVBB-UHFFFAOYSA-N Glabrene Natural products C1=C(O)C=C2OCC(C3=CC=C4OC(C=CC4=C3O)(C)C)=CC2=C1 KKLOCFOZPFGVBB-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- ZTVCAEHRNBOTLI-UHFFFAOYSA-L Glycine, N-(carboxymethyl)-N-(2-hydroxyethyl)-, disodium salt Chemical compound [Na+].[Na+].OCCN(CC([O-])=O)CC([O-])=O ZTVCAEHRNBOTLI-UHFFFAOYSA-L 0.000 description 2
- 235000005206 Hibiscus Nutrition 0.000 description 2
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 2
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- YNWXJFQOCHMPCK-UHFFFAOYSA-N Isoliquiritin Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-UHFFFAOYSA-N 0.000 description 2
- 241000234435 Lilium Species 0.000 description 2
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 2
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 235000014826 Mangifera indica Nutrition 0.000 description 2
- 240000007228 Mangifera indica Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 235000013500 Melia azadirachta Nutrition 0.000 description 2
- 235000014749 Mentha crispa Nutrition 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 241000258192 Parastichopus californicus Species 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 244000294611 Punica granatum Species 0.000 description 2
- 235000014360 Punica granatum Nutrition 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 241001278097 Salix alba Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000005865 Symphytum officinale Nutrition 0.000 description 2
- 240000002299 Symphytum officinale Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 244000185386 Thladiantha grosvenorii Species 0.000 description 2
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 240000001717 Vaccinium macrocarpon Species 0.000 description 2
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 244000078534 Vaccinium myrtillus Species 0.000 description 2
- 208000000558 Varicose Ulcer Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- SZHJTBRHSAKQIF-UHFFFAOYSA-N [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OB(O)O.[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OB(O)O.[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-] SZHJTBRHSAKQIF-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000020739 avocado extract Nutrition 0.000 description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000003848 cartilage regeneration Effects 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 235000004634 cranberry Nutrition 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 235000021185 dessert Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000008387 emulsifying waxe Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 102000013373 fibrillar collagen Human genes 0.000 description 2
- 108060002894 fibrillar collagen Proteins 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 229940068517 fruit extracts Drugs 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 2
- 229940093767 glabridin Drugs 0.000 description 2
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 2
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 229940098324 green tea leaf extract Drugs 0.000 description 2
- 235000009424 haa Nutrition 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- YNWXJFQOCHMPCK-LXGDFETPSA-N isoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O YNWXJFQOCHMPCK-LXGDFETPSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 235000015094 jam Nutrition 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 230000037231 joint health Effects 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000007908 nanoemulsion Substances 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000020333 oolong tea Nutrition 0.000 description 2
- 235000020569 organic green tea Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000006920 protein precipitation Effects 0.000 description 2
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 2
- 235000011962 puddings Nutrition 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940109850 royal jelly Drugs 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000035936 sexual power Effects 0.000 description 2
- 229940057910 shea butter Drugs 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 2
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000007103 stamina Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940012831 stearyl alcohol Drugs 0.000 description 2
- 235000013547 stew Nutrition 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000020238 sunflower seed Nutrition 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229940061605 tetrasodium glutamate diacetate Drugs 0.000 description 2
- UZVUJVFQFNHRSY-OUTKXMMCSA-J tetrasodium;(2s)-2-[bis(carboxylatomethyl)amino]pentanedioate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CC[C@@H](C([O-])=O)N(CC([O-])=O)CC([O-])=O UZVUJVFQFNHRSY-OUTKXMMCSA-J 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 2
- LEAHFJQFYSDGGP-UHFFFAOYSA-K trisodium;dihydrogen phosphate;hydrogen phosphate Chemical compound [Na+].[Na+].[Na+].OP(O)([O-])=O.OP([O-])([O-])=O LEAHFJQFYSDGGP-UHFFFAOYSA-K 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- JYVXNLLUYHCIIH-UHFFFAOYSA-N (+/-)-mevalonolactone Natural products CC1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- QGJDXUIYIUGQGO-UHFFFAOYSA-N 1-[2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC(C)C(=O)N1CCCC1C(O)=O QGJDXUIYIUGQGO-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
- DXANYXRZRNXGSC-UHFFFAOYSA-N 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethyl sulfate Chemical compound CC1=C(CCOS([O-])(=O)=O)SC=[N+]1CC1=CN=C(C)N=C1N DXANYXRZRNXGSC-UHFFFAOYSA-N 0.000 description 1
- DMQQXDPCRUGSQB-UHFFFAOYSA-N 2-[3-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCCN(CC(O)=O)CC(O)=O DMQQXDPCRUGSQB-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XBIUWALDKXACEA-UHFFFAOYSA-N 3-[bis(2,4-dioxopentan-3-yl)alumanyl]pentane-2,4-dione Chemical compound CC(=O)C(C(C)=O)[Al](C(C(C)=O)C(C)=O)C(C(C)=O)C(C)=O XBIUWALDKXACEA-UHFFFAOYSA-N 0.000 description 1
- GJMPSRSMBJLKKB-UHFFFAOYSA-N 3-methylphenylacetic acid Chemical compound CC1=CC=CC(CC(O)=O)=C1 GJMPSRSMBJLKKB-UHFFFAOYSA-N 0.000 description 1
- 238000010146 3D printing Methods 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000010319 Acer grandidentatum Nutrition 0.000 description 1
- 235000010328 Acer nigrum Nutrition 0.000 description 1
- 235000010157 Acer saccharum subsp saccharum Nutrition 0.000 description 1
- 241001637999 Acetabularia ryukyuensis Species 0.000 description 1
- 241001188173 Actinopyga echinites Species 0.000 description 1
- 241000342018 Aegagropila linnaei Species 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 241000722953 Akebia Species 0.000 description 1
- 241000390967 Alaria crassifolia Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241001564285 Alnus firma Species 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000013411 Alpinia speciosa Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 241000544270 Angelica acutiloba Species 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 241001490783 Antedon Species 0.000 description 1
- 241000258141 Arbacia punctulata Species 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 244000274847 Betula papyrifera Species 0.000 description 1
- 235000009113 Betula papyrifera Nutrition 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 235000010928 Betula populifolia Nutrition 0.000 description 1
- 235000002992 Betula pubescens Nutrition 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000961078 Bohadschia argus Species 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- 241000533865 Callerya reticulata Species 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 241001624533 Campylaephora hypnaeoides Species 0.000 description 1
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 241001624532 Ceramium kondoi Species 0.000 description 1
- 241001518181 Ceratodictyon spongiosum Species 0.000 description 1
- 241000342013 Chaetomorpha crassa Species 0.000 description 1
- 241000196306 Chaetomorpha moniligera Species 0.000 description 1
- 241000195627 Chlamydomonadales Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 241000369835 Chondracanthus tenellus Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241001147468 Chondrus ocellatus Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 235000009088 Citrus pyriformis Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 241001493800 Cladophoraceae Species 0.000 description 1
- 241001513081 Clypeaster rosaceus Species 0.000 description 1
- 241000212948 Cnidium Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 239000009513 Coptidis rhizoma extract Substances 0.000 description 1
- 241000199917 Costaria costata Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241001490786 Crinoidea Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 244000236931 Cydonia oblonga Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000195634 Dunaliella Species 0.000 description 1
- 241001512722 Ecklonia cava Species 0.000 description 1
- 241000439005 Ecklonia stolonifera Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000195950 Equisetum arvense Species 0.000 description 1
- 239000005768 Equisetum arvense L. Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 244000041517 Etlingera elatior Species 0.000 description 1
- 241000940372 Eucheuma denticulatum Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108090000270 Ficain Proteins 0.000 description 1
- 235000016622 Filipendula ulmaria Nutrition 0.000 description 1
- 244000061544 Filipendula vulgaris Species 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 241000208152 Geranium Species 0.000 description 1
- 241000531753 Geranium robertianum Species 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 241000691324 Gloiopeltis tenax Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 241001404255 Gracilaria vermiculophylla Species 0.000 description 1
- 241001428138 Grateloupia Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 208000023329 Gun shot wound Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 241000208681 Hamamelis virginiana Species 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 108010019494 Histatins Proteins 0.000 description 1
- 102000006492 Histatins Human genes 0.000 description 1
- 241000191118 Holothuria floridana Species 0.000 description 1
- 241001218833 Holothuria fuscopunctata Species 0.000 description 1
- 241001213462 Holothuria leucospilota Species 0.000 description 1
- 239000009141 Houttuynia cordata plant extract Substances 0.000 description 1
- 235000014486 Hydrangea macrophylla Nutrition 0.000 description 1
- 244000267823 Hydrangea macrophylla Species 0.000 description 1
- 241001479611 Iris ensata Species 0.000 description 1
- 208000035901 Ischaemic ulcer Diseases 0.000 description 1
- 241001188169 Isostichopus badionotus Species 0.000 description 1
- 241000016512 Kappaphycus striatus Species 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241001466452 Laminariaceae Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 241001072282 Limnanthes Species 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 241001570521 Lonicera periclymenum Species 0.000 description 1
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 1
- 244000302544 Luffa aegyptiaca Species 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 241001491705 Macrocystis pyrifera Species 0.000 description 1
- 102100027329 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Human genes 0.000 description 1
- 101710137760 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000382417 Malva Species 0.000 description 1
- 235000013939 Malva Nutrition 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 244000078639 Mentha spicata Species 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000989762 Monostroma nitidum Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- PSFABYLDRXJYID-VKHMYHEASA-N N-Methylserine Chemical compound CN[C@@H](CO)C(O)=O PSFABYLDRXJYID-VKHMYHEASA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- PSFABYLDRXJYID-UHFFFAOYSA-N N-methyl-DL-serine Natural products CNC(CO)C(O)=O PSFABYLDRXJYID-UHFFFAOYSA-N 0.000 description 1
- 235000017879 Nasturtium officinale Nutrition 0.000 description 1
- 240000005407 Nasturtium officinale Species 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000000641 Non-Fibrillar Collagens Human genes 0.000 description 1
- 108010002466 Non-Fibrillar Collagens Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 240000008916 Oenothera biennis Species 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000596467 Ononis Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 241001544464 Phyllacanthus imperialis Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 241001457436 Polyopes affinis Species 0.000 description 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 1
- 235000016551 Potentilla erecta Nutrition 0.000 description 1
- 240000000103 Potentilla erecta Species 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 241001099150 Prasiola japonica Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 240000005049 Prunus salicina Species 0.000 description 1
- 244000251905 Pseudocydonia sinensis Species 0.000 description 1
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 description 1
- 241000206608 Pyropia tenera Species 0.000 description 1
- 241000510091 Quadrula quadrula Species 0.000 description 1
- JYVXNLLUYHCIIH-ZCFIWIBFSA-N R-mevalonolactone, (-)- Chemical compound C[C@@]1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-ZCFIWIBFSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241001529742 Rosmarinus Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 244000157431 Rubus ellipticus Species 0.000 description 1
- 235000017848 Rubus fruticosus Nutrition 0.000 description 1
- 244000172730 Rubus fruticosus Species 0.000 description 1
- 235000003500 Ruscus aculeatus Nutrition 0.000 description 1
- 240000000353 Ruscus aculeatus Species 0.000 description 1
- 241000983755 Saccharina gyrata Species 0.000 description 1
- 241000015177 Saccharina japonica Species 0.000 description 1
- 241000209051 Saccharum Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 235000008282 Sanguisorba officinalis Nutrition 0.000 description 1
- 244000173853 Sanguisorba officinalis Species 0.000 description 1
- 241000580955 Sapindus mukorossi Species 0.000 description 1
- 240000003946 Saponaria officinalis Species 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 241000264279 Sargassum fusiforme Species 0.000 description 1
- 241000543810 Sasa veitchii Species 0.000 description 1
- 239000010404 Scutellaria baicalensis extract Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 241000196294 Spirogyra Species 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 235000020759 St. John’s wort extract Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000475042 Stolonifera Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010042343 Subcutaneous abscess Diseases 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 241000980131 Synapta maculata Species 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241001188167 Thelenota rubralineata Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 240000007313 Tilia cordata Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000249864 Tussilago Species 0.000 description 1
- 241000196259 Ulva pertusa Species 0.000 description 1
- 241001261506 Undaria pinnatifida Species 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- GZQCZDHGTYFJIF-LZWOXQAQSA-N [(2r,3s,4s)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] acetate Chemical compound CC(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O GZQCZDHGTYFJIF-LZWOXQAQSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- PAUSGZCRNOTKPK-UHFFFAOYSA-N [5-hydroxy-6-methyl-4-(octanoyloxymethyl)pyridin-3-yl]methyl octanoate Chemical compound CCCCCCCC(=O)OCC1=CN=C(C)C(O)=C1COC(=O)CCCCCCC PAUSGZCRNOTKPK-UHFFFAOYSA-N 0.000 description 1
- XYZGDYPGGXDMGG-QVTWQEFQSA-J [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CC[C@H](NC(C([O-])=O)C([O-])=O)C([O-])=O Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CC[C@H](NC(C([O-])=O)C([O-])=O)C([O-])=O XYZGDYPGGXDMGG-QVTWQEFQSA-J 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 229940089116 arnica extract Drugs 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 description 1
- 235000018889 capsanthin Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000001827 citrus limon l. burm. f. peel extract Substances 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Chemical compound 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940012466 egg shell membrane Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940045761 evening primrose extract Drugs 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 102000013370 fibrillin Human genes 0.000 description 1
- 108060002895 fibrillin Proteins 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 235000019836 ficin Nutrition 0.000 description 1
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940038487 grape extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 229940065115 grapefruit extract Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000020717 hawthorn extract Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000020721 horse chestnut extract Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940099576 lamium album extract Drugs 0.000 description 1
- 229940083980 lavender extract Drugs 0.000 description 1
- 235000020723 lavender extract Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940092251 lemon peel extract Drugs 0.000 description 1
- 235000009018 li Nutrition 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001699 lower leg Anatomy 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000001035 marshmallow Nutrition 0.000 description 1
- 239000001220 mentha spicata Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940057061 mevalonolactone Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 108700005457 microfibrillar Proteins 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940069825 okra extract Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001688 paprika extract Substances 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229940117336 parsley extract Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000015206 pear juice Nutrition 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003019 phosphosphingolipids Chemical class 0.000 description 1
- 235000018192 pine bark supplement Nutrition 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001485 poly(butyl acrylate) polymer Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- TYPBXRFGTISSFB-UHFFFAOYSA-M potassium;3-morpholin-4-ylpropane-1-sulfonic acid;hydroxide Chemical compound [OH-].[K+].OS(=O)(=O)CCCN1CCOCC1 TYPBXRFGTISSFB-UHFFFAOYSA-M 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229940106796 pycnogenol Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 108700022109 ropocamptide Proteins 0.000 description 1
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 1
- 239000001331 rosmarinus officinalis leaf Substances 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 229940084038 salix alba bark extract Drugs 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- UMCYUPVKJYJUCD-UHFFFAOYSA-M sodium 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]acetic acid hydroxide Chemical compound [OH-].[Na+].OCC(CO)(CO)NCC(O)=O UMCYUPVKJYJUCD-UHFFFAOYSA-M 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 1
- CSRCBLMBBOJYEX-UHFFFAOYSA-M sodium;2-morpholin-4-ylethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OS(=O)(=O)CCN1CCOCC1 CSRCBLMBBOJYEX-UHFFFAOYSA-M 0.000 description 1
- XBYBXDBJLZDASJ-UHFFFAOYSA-M sodium;dimethylarsinate;hydrochloride Chemical compound [Na+].Cl.C[As](C)([O-])=O XBYBXDBJLZDASJ-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229950003429 sorbitan palmitate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 229940099416 st. john's wort extract Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 235000012069 sugar maple Nutrition 0.000 description 1
- 229940057070 sugarcane extract Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- GYBINGQBXROMRS-UHFFFAOYSA-J tetrasodium;2-(1,2-dicarboxylatoethylamino)butanedioate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CC(C([O-])=O)NC(C([O-])=O)CC([O-])=O GYBINGQBXROMRS-UHFFFAOYSA-J 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229950006389 thiodiglycol Drugs 0.000 description 1
- SHWIJIJNPFXOFS-UHFFFAOYSA-N thiotaurine Chemical compound NCCS(O)(=O)=S SHWIJIJNPFXOFS-UHFFFAOYSA-N 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 239000001430 tilia cordata extract Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940117957 triethanolamine hydrochloride Drugs 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000008979 vitamin B4 Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000011738 yellow Himalayan raspberry Nutrition 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/616—Echinodermata, e.g. starfish, sea cucumbers or sea urchins
Definitions
- the present technology relates generally to the method for extraction and uses of collagen type I from marine animals.
- the present technology relates to the method for the purification of highly pure mutable collagenous tissue from echinoderms, to pharmaceutical, cosmetic and nutritional applications of the mutable collagenous tissue purified using the methods disclosed herein, and to compositions, kits and articles of manufacture made from the mutable collagenous tissue purified using the methods disclosed herein.
- Echinoderms are the members of the phylum Echinodermata , which live exclusively in the sea, with no freshwater or terrestrial representatives. Echinoderms fall into five well-defined taxonomic classes: Crinoidea (sea lilies and feather stars); Asteroidea (starfishes); Ophiuroidea (basket stars and brittle stars); Holothuroidea (sea cucumbers); and Echinoidea (sea urchins, sand dollars, and sea biscuits).
- Crinoidea sea lilies and feather stars
- Asteroidea starfishes
- Ophiuroidea basic stars and brittle stars
- Holothuroidea sesa cucumbers
- Echinoidea sea urchins, sand dollars, and sea biscuits.
- Adult echinoderms exhibit radial symmetry, typically pentamerous symmetry. Most echinoderms are bottom-dwelling, and
- the present disclosure provides a method for extracting mutable collagenous tissue from echinoderms, the method comprising: treating a connective tissue from an echinoderm with (a) an aqueous solution of an organic solvent; (b) a chelating agent; and (c) an enzyme solution, to thereby obtain a liquid mutable collagenous tissue.
- the echinoderms are selected from the group consisting of sea urchins, sea cucumbers, star fish, and a combination thereof.
- the organic solvent is selected from the group consisting of ethanol, isopropanol, acetone, ethyl acetate, and a combination thereof.
- the aqueous solution of the organic solvent comprises about 25% to about 75% organic solvent.
- the treatment time with the organic solvent is in the range of from about 1 minute to about 10 hours.
- the chelating agent is selected from the group consisting of
- EDTA ethylenediaminetetraacetic acid
- the chelating agent further comprises a buffer selected from the group consisting of Tris buffer and phosphate buffer.
- the treatment time with the chelating agent is in the range of from about 1 hour to about 10 days.
- the enzyme solution comprises trypsin, bromelain, pepsin, papain, or any combination thereof.
- the total enzyme concentration in enzyme solution is at a concentration in the range of from about 0.05% to about 10%.
- each enzyme in enzyme solution is used at a concentration in the range of from about 0.05% to about 10%.
- the treatment time with the enzyme solution is in the range of from about 12 hours to about 30 days.
- the method further comprises: (d) treating the connective tissue with an alkaline solution.
- the alkaline solution comprises an alkali metal hydroxide, an alkaline earth metal hydroxide, an alkali metal carbonate, an alkaline earth metal carbonate, an alkali metal bicarbonate, alkaline earth metal bicarbonate or a mixture thereof.
- the treatment time with the alkaline solution is in the range of from about 2 hours to about 21 days.
- the treatment of the connective tissue with an alkaline solution precedes the treatment of the connective tissue with an enzyme.
- the method further comprises: (e) precipitating collagen from the liquid mutable collagenous tissue by adding an inorganic precipitation agent.
- the inorganic precipitation agent is an inorganic salt. In some embodiments, the inorganic precipitation agent is sodium chloride, potassium chloride or calcium chloride. In some embodiments, the inorganic precipitation agent is used at a concentration in the range of from about 0.05 M to about 5 M. In some embodiments, the method further comprises separation of the precipitated collagen. In some embodiments, the precipitated collagen is separated by centrifugation at about 1000 x g to about 50,000 c g. In some embodiments, the method further comprises: (f) dialysis of the precipitated collagen. In some embodiments, the method further comprises: (g) freeze drying the dialyzed collagen to produce a solid mutable collagenous tissue.
- the solid mutable collagenous tissue is a powder or a sheet. In some embodiments, the solid mutable collagenous tissue is at least 90%, at least 95%, at least 96%, or at least 97%, at least 98%, at least 99% pure collagen type I. In some embodiments, the solid mutable collagenous tissue is at least 90% pure collagen type I. In some embodiments, the solid mutable collagenous tissue is at least 95% pure collagen type I. In some embodiments, the solid mutable collagenous tissue is at least 98% pure collagen type I.
- the present disclosure provides a mutable collagenous tissue obtainable by the method of any of the methods disclosed herein.
- the present disclosure provides a pharmaceutical, cosmeceutical or cosmetic composition
- a pharmaceutical, cosmeceutical or cosmetic composition comprising the mutable collagenous tissue obtainable by any of the methods disclosed herein.
- the composition further comprises a pharmaceutically acceptable excipient, additive, preservative, and a mixture thereof.
- the composition is formulated to a route of administration selected from the group consisting of oral, sublingual, inhalation, rectal, transmucosal, transdermal, intracavemosal, topical, and injection.
- the composition is formulated for topical administration.
- the composition is formulated as a lotion, ointment, gel, cream, liquid, emulsion, suppository, drop, spray, hydrogel, dressing, bioadhesive gel, aerosol, paste, foam, sunscreen, or powder.
- the composition is attached to a solid substrate.
- the composition is formulated as an article or a carrier selected from the group consisting of a bandage, insert, syringe-like applicator, pessary, powder, talc, cleanser, and a patch.
- the present disclosure provides a kit comprising a mutable collagenous tissue obtainable by the methods disclosed herein, or any of the compositions disclosed herein.
- the kit comprises one or more packaging agents, one or more agents for administering the mutable collagenous tissue, one or more cosmetic agents or therapeutic agents, or any combination thereof.
- the present disclosure provides a method for treating skin in a subject in need thereof, comprising administering to the subject an effective amount of a cosmetic composition comprising a mutable collagenous tissue obtainable by the methods disclosed herein, or any of the compositions disclosed herein.
- the method reduces skin wrinkles, enhances skin moisture content, reduces skin moisture evaporation, inhibits erythema, and suppresses the thickening of the skin epidermis layers, exfoliates the skin, enhances skin elasticity, inhibits erythema, alleviates skin photoaging, firms sagging skin, or any combination thereof.
- the cosmetic composition is formulated as a lotion, ointment, gel, cream, liquid, paste, drop, spray, hair restorer, lip cream, patch, thickening gel, water-in-oil emulsion, oil-in-water emulsion, solid, sheet, powder, gel, and mousse.
- the cosmetic composition is topically applied.
- the present disclosure provides a method for treating a condition in a subject in need thereof, comprising administering to the subject an effective amount of a hydrogel composition comprising a mutable collagenous tissue obtainable by the methods disclosed herein, or any of the compositions disclosed herein.
- the condition is selected from the group consisting of (a) a breast imperfections selected from the group consisting of a breast augmentation, a breast reconstruction, and defects due to implant complications; (b) a facial imperfections selected from the group consisting of a facial augmentation, wrinkles, lines, a facial reconstruction, scars, sunken cheeks, hollow cheeks, thin lips, nasal imperfections or defects, retro-orbital imperfections or defects, a facial folds, nasolabial lines, perioral lines, and a marionette line; and (c) a condition requiring an augmentation or a reconstruction of a body part selected from the group consisting of upper arm, lower arm, hand, shoulder, back, neck, torso, abdomen, buttocks, upper leg, lower leg, calves, foot, plantar fat pad, eye, and genitals.
- a breast imperfections selected from the group consisting of a breast augmentation, a breast reconstruction, and defects due to implant complications
- a facial imperfections selected from the group consisting of a facial augmentation,
- the subject seeks an enlargement, shape change or contour alteration.
- the hydrogel composition is administered by intra-epidermal, intra-dermal or subcutaneous injection.
- the method promotes cartilage regeneration.
- the method is used for the treatment of osteoarthritis.
- the present disclosure provides an applicator comprising a mutable collagenous tissue obtainable by the methods disclosed herein, or any of the compositions disclosed herein.
- the applicator is a prefilled syringe.
- the prefilled syringe comprises a hydrogel composition.
- the applicator is selected from the group consisting of a sponge, puff, tube, application nozzle, wipes, spray, a spreadable stick, pencil, and a discharge pad.
- the present disclosure provides a nutritional supplement comprising a mutable collagenous tissue obtainable by the methods disclosed herein, or any of the compositions disclosed herein.
- the nutritional supplement is formulated as powder, pill, tablet, capsule, beverage, frozen dessert, gelatin dessert, pudding, confectionery, soft gel, chewing gum, candy, gummi candy, gum, caramel, chocolate, tablet sweet, snack, baked good, jelly, jam, yogurt, soup, or stew.
- the nutritional supplement further comprises one or more ingredients selected from the group consisting of moisturizers, antioxidants, minerals, metal sequestrants, proteins, enzymes, vitamins, fats, oils, dietary fiber, fruit extracts, vegetable extracts, meat extracts, yeast extract, solvents, buffers, bulking agents, anti-microbial agents, thickeners, antioxidants, surfactants, emulsifiers, solubilizers, solubilizing aids, colorants, perfumes, flavoring agents, sugars, and preservatives.
- the nutritional supplement promotes joint health, supports connective tissues, helps maintain a strong immune system, supports restful sleep or promotes healthy digestion.
- the nutritional supplement corrects a nutritional insufficiency.
- the nutritional supplement stimulates testosterone production to maintain healthy libido, stamina or sexual performance.
- FIG. 1 A illustrates the structure of collagen.
- the collagen amino acid chains called a-chains, have a repeating XaaYaaGly amino acid sequence. While Xaa and Yaa can be any amino acids, they are frequently (2,V)-proline and (2ri',4/i)-4-hydroxyproline, respectively.
- the a-chains are assembled into a left-handed, triple helical structure.
- FIG. 1 A (bottom) is a photograph illustrating the physical appearance of a purified mutable collagenous tissue (MCT) sheet formed by a dense network of collagen fibers.
- MCT purified mutable collagenous tissue
- FIG. IB illustrates the structure of mutable collagenous tissue (MCT). As shown, the fibrils are interconnected via proteoglycan/ glycosamino glycan (GAG).
- GAG proteoglycan/ glycosamino glycan
- FIG. 1C illustrates chemical structure of glycosaminoglycans that crosslink the fibrils of MCT.
- FIG. 2 is a flow chart illustrating an exemplary process for extraction of mutable collagenous tissue. A solution of extracted mutable collagenous tissue from sea cucumber and its appearance after freeze drying to produce a white powder are shown.
- FIG. 3 shows example sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) profiles of the indicated collagen samples.
- Ladder is a molecular weight ladder used to measure molecular weight based on electrophoretic mobility. Molecular weights of ingredients of the ladder are shown.
- MC-1 corresponds to the mutable collagenous tissue (MCT) purified from sea cucumber.
- MC-2 is the purified mutable collagenous tissue (MCT) from sea urchin.
- MC-3 is purified MCT from starfish. Note the absence of protein bands below 150 kDa in MC-1, MC-2 and MC-3.
- High molecular weight > 150 kDa
- fibrillar collagen triple helix al, a2 and b
- Densitometric analysis revealed that MC-1, MC-2 and MC-3 have>98% purity (data not shown).
- Human human type I collagen isolated from human fibroblast cells (VitroCol ® , Catalog #5007-20ML, Advanced Biomatrix, USA).
- Rat tail type I collagen isolated from rat tail (Catalog #C7661 - 10MG, Sigma Aldrich, USA).
- Bovine type-I collagen isolated from bovine skin (PureCol®, Catalog #5005- 100ML, Advanced Biomatrix, Aldrich, USA).
- FIG. 4A shows a comparison of example gel electrophoresis profiles of MCT collagen isolated from sea urchin (MCT-SU) and sea cucumber (MCT-SC) against different types of native collagen profiles (I, II, III and V).
- SC Sea cucumber MCT.
- FIG. 4B shows an example analysis of purity of collagen samples as analyzed by SDS-PAGE under non-denaturing conditions.
- A. a. Asterias amurensis ;
- p. 1. Paracentrotus lividus ;
- T. a. Thelenota ananas ;
- C.f Cucumaria frondosa.
- FIG. 5 shows an example analysis of electrophoretic mobility of collagen samples by SDS-PAGE under denaturing conditions (with a b-mercaptoethanol treatment).
- MCT sea cucumber MCT.
- FIG. 6A shows example FTIR-ATR spectra for bovine type I collagen, used here as a positive control, and echinoderm mutable collagenous tissue extracted from sea cucumber.
- FIG. 6B shows example FTIR-ATR spectra for mutable collagenous tissue (MCT) isolated from sea urchin and sea cucumber.
- FIG. 7 shows the amino acid composition of mutable collagenous tissue extracted from sea urchin (MCT-SU) and sea cucumber (MCT-SC), compared to bovine collagen type I isolated from calf skin.
- FIG. 8 shows the scanning electron microscopy (SEM) images showing the surface morphology of bovine collagen type I from calf skin, used here as a reference (left image), and mutable collagenous tissue extracted from sea cucumber (right image).
- the present disclosure is based, in part, on the discovery that a combination of chemical and enzymatic extracting processes contributes to an increased yield, and higher purity of mutable collagenous tissue.
- the process described herein also protects the collagen from proteolytic or chemical degradation, and produces mutable collagenous tissue comprising high molecular weight (>150 kDa) collagen.
- the process described herein also produces mutable collagenous tissue that is free from agents that cause transmissible diseases. Accordingly, the mutable collagenous tissue extracted from echinoderms produced by the methods described herein is useful for a wide variety of applications, including nutritional, cosmetic and therapeutic uses.
- Collagen the most abundant protein in the animal kingdom. It is one of the main structural protein constituents of the extracellular matrix in connective tissues. “Collagen” is a generic term for proteins forming the characteristic triple helix of three polypeptide chains (See, e.g., FIG. 1 A), and all members of the collagen family form these supramolecular structures in the extracellular matrix, although their size, function and tissue distribution vary considerably.
- fibril-forming collagens which include collagen types I, II, III, V, and XI
- Fibril-Associated Collagens with Interrupted Triple helices FACIT collagens
- microfibrillar collagens which include collagen type VI
- short chain collagens which include collagen types X and VIII
- collagens of the basement membrane which include collagen type IV.
- the fibril-forming collagens account for about 90% of the total collagen.
- Collagen type I which is the most abundant and best studied collagen, forms more than 90% of the organic mass of bone and is the major collagen of tendons, skin, ligaments, cornea.
- collagen type I is composed of a triple helix formed of two identical chains (al), and a third chain (a2), which differs slightly in its chemical composition, which are wound around each other and linked via hydrogen bonds.
- al identical chains
- a2 third chain
- individual collagen triple helices assemble in a complex, hierarchical manner that ultimately leads to the macroscopic fibers and networks observed in tissues, such as skin and bone.
- Echinoderms are marine invertebrates widespread in all the oceans and are a significant source of food.
- Echinoderms have a peculiar connective tissue, called mutable collagenous tissue (MCT).
- MCT mutable collagenous tissue
- the mutable collagenous tissue (MCT) of echinoderms is unique in its ability to“switch” mechanical states rapidly and reversibly. This collagen allows echinoderms to quickly transition from stiff state to soft state and vice versa. For example, sea cucumbers can soften their entire body to allow movements into the tiniest of holes and cracks, yet stiffen again, e.g ., to wedge itself into a small crack.
- MCTs are a unique feature of echinoderms found in each of the five extant taxonomic classes. In contrast, human tissue like skin, tendons and ligaments, cannot switch their mechanical state.
- mutable collagenous tissue differs from, e.g. , mammalian collagen with respect to the amino acid primary sequences, associated proteins, and the extent and kind of glycosylation.
- MCT comprises discontinuous collagen fibrils organized into collagen fibers.
- the fibrils form an elastomeric network of fibrillin microfibrils, which are interconnected by a stress-transfer matrix comprising glycosaminoglycan that binds to and aggregates the fibril.
- the glycosaminoglycans are long unbranched polysaccharides consisting of a repeating disaccharide unit.
- the repeating unit consists of an amino sugar (N-acetylglucosamine or N- acetylgalactosamine) along with an uronic sugar (glucuronic acid or iduronic acid) or galactose.
- Glycosaminoglycans are highly polar and attract water. They are therefore useful to the body as a lubricant or as a shock absorber, being located primarily on the surface of cells or in the extracellular matrix (ECM).
- the term“about” in reference to a number is generally taken to include numbers that fall within a range of 1%, 5%, or 10% in either direction (greater than or less than) of the number unless otherwise stated or otherwise evident from the context (except where such number would be less than 0% or exceed 100% of a possible value).
- a“control” is an alternative sample used in an experiment for comparison purpose.
- a control can be“positive” or“negative.”
- a positive control a compound or composition known to exhibit the desired therapeutic effect
- a negative control a subject or a sample that does not receive the therapy or receives a placebo
- an“echinoderm” is a member of the phylum Echinodermata , which includes animals like sea stars, brittle stars, sea urchins, sand dollars, and sea cucumbers.
- mutable collagenous tissue or“MCT” are used interchangeably herein to mean means the extracellular matrix of connective tissue of echinoderms.
- “Purified mutable collagenous tissue” is defined as a mutable collagenous tissue that is isolated, or substantially isolated, from other proteins.
- a purified mutable collagenous tissue may be, e.g, greater than 90% pure, greater than 95% pure, or greater than 98% pure.
- the term“pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal compounds, isotonic and absorption delaying compounds, and the like, compatible with pharmaceutical administration.
- Pharmaceutically acceptable carriers and their compositions are known to one skilled in the art and are described, for example, in Remington's
- polypeptide As used herein, the terms“polypeptide”,“peptide” and“protein” are used interchangeably herein to mean a polymer comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres.
- Polypeptide refers to both short chains, commonly referred to as peptides, glycopeptides or oligomers, and to longer chains, generally referred to as proteins.
- Polypeptides may contain amino acids other than the 20 gene-encoded amino acids.
- Polypeptides include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature.
- the term“implant” refers to artificial devices or tissues which are made to replace and act as missing biological structures. These include, for example, dental implants, artificial body parts such as artificial blood vessels or nerve tissues, bone implants, and the like.
- tissue engineering and regeneration refers to the engineering and regeneration of new living tissues, such as skin, which includes, e.g., healing diseased, traumatized, unhealthy, or unaesthetic tissue.
- the terms“pharmaceutical,”“cosmetic,” or“cosmeceutical” composition refers to topical substances that are utilized for pharmaceutical and/or aesthetical purposes.
- Cosmeceutical or pharmaceutical agents may include substances that exhibit therapeutic activity so as to provide the desired pharmaceutical and/or aesthetical effect.
- Pharmaceutical, cosmetic or cosmeceutical compositions may be used for firming a defected skin or nail, make ups, gels, lacquers, eye shadows, lip glosses, lipsticks, and the like.
- the term“medical device” includes, but are not limited to, a hydrogel, bandages, wound dressings, sleeves, films, adhesives and the like.
- the present disclosure provides a method for extracting mutable collagenous tissue from echinoderms, the method comprising: (a) treating a connective tissue with an aqueous solution of an organic solvent; and (b) treating the connective tissue with a chelating agent; and (c) treating the connective tissue with an enzyme solution to obtain a liquid mutable collagenous tissue.
- Suitable echinoderms for extraction of mutable collagenous tissue include, but are not limited to, sea urchins, sea cucumbers and star fish.
- Suitable species of echinoderms for extraction of mutable collagenous tissue include, but are not limited to, Strongylocentrotus purpuratus , Arbacia franata, Phyllacanthus imperialis, Paracentrotus lividus , Actinopyga echinites, Apostichopus japonicus , Thelenota ananas , Synapta maculata, Holothuria floridana , Holothuria leucospilota , Isostichopus badionotus , Holothuria fuscopunctata , Thelenota rubralineata , Bohadschia argus, Parastichopus californicus , Asterias amurensis, and Cucumaria frondosa.
- Suitable organic solvents include, but are not limited to, ethyleneglycol, methanol, ethanol, isopropanol, pyridine, acetonitrile, nitromethane, dimethyl sulfoxide, ethylacetate, hexylene glycol, 2,2-thiodiglycol, propylene glycol, dioxane, acetone, dicholoroethane, tetrahydrofuran, dicholoromethane, chloroform, diethylether, benzene, toluene, xylene, carbontetrachloride, cyclohexane, petroleum ether, hexane, pentane, and a combination thereof.
- the organic solvent is ethanol, isopropanol, acetone, ethyl acetate or a combination thereof.
- the aqueous solution of the organic solvent kills pathogens and inactivates viruses present in the connective tissue.
- the aqueous solution of the organic solvent disinfects the connective tissue.
- the aqueous solution of the organic solvent sterilizes the connective tissue.
- the aqueous solution of the organic solvent comprises a pharmacologically acceptable disinfectant, antiseptic, antibiotic, antimicrobial, antibiotic or the like.
- the aqueous solution of the organic solvent comprises 1%- 99% of the organic solvent. In some embodiments, the aqueous solution of the organic solvent comprises about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% organic solvent. In some embodiment, the aqueous solution of the organic solvent comprises organic solvent in the range of from about 5 to about 20%, from about 10 to about 25%, from about 20 to about 50%, from about 25 to about 75%, from about 30 to about 60%, from about 40 to about 70%, or from about 50% to about 80%.
- the connective tissue is treated with the aqueous solution of an organic solvent in the range of from about 1 minute to about 10 hr.
- the connective tissue is treated with the aqueous solution of organic solvent in the range of from about 1 minute to about 3 minutes, from about 2 minutes to about 10 minutes, from about 5 minutes to about 15 minutes, from about 10 minutes to about 20 minutes, from about 15 minutes to about 30 minutes, from about 20 minutes to about 1 hour, from about 30 minutes to about 90 minutes, from about 1 hour to about 3 hours, from about 2 hours to about 5 hours, or from about 3 hours to about 10 hours.
- the connective tissue is treated with the aqueous solution of an organic solvent at a temperature in the range of from about -40 °C to about 40 °C.
- the connective tissue is treated with the aqueous solution of an organic solvent at about -40 °C, about -30 °C, about -20 °C, about -10 °C, about -5 °C, about 0 °C, about 4 °C, about 10 °C, about 15 °C, about 20 °C, about 25 °C, about 30 °C, about 35 °C, or about 40 °C.
- the connective tissue is treated with the aqueous solution of an organic solvent at a temperature in the range of from about -40 °C to about -20 °C, from about -30 °C to about -10 °C, from about -20 °C to about 0 °C, from about -10 °C to about 4 °C, from about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, from about 15 °C to about 25 °C, from about 20 °C to about 30 °C, from about 25 °C to about 35 °C, or from about 30 °C to about 40 °C.
- the connective tissue that is treated with the aqueous solution of an organic solvent is recovered by a technique that includes, but not limited to, filtration, centrifugation, and sedimentation. In some embodiments, the connective tissue is further washed with water. In some embodiments, the connective tissue that is treated with the aqueous solution of an organic solvent is subjected to centrifugation with a centrifugal force in the range of from about 1000 c g to about 20,000 c g, and retrieved from the pellet.
- the precipitated collagen is retrieved by centrifugation with a centrifugal force the range of from about 1000 c g to about 5,000 c g, from about 2500 c g to about 7,500 c g, from about 5000 x g to about 15,000 c g, or about 7,500 c g to about 20,000 x g.
- the centrifugation is carried out at temperature the range of from about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, or from about 15 °C to about 25 °C.
- Suitable chelating agents include, but are not limited to,
- EDTA ethylenediaminetetraacetic acid
- N,N,N',N'-tetraacetic acid EGTA
- HEDTA hydroxy ethylenediaminetriacetic acid
- NTA nitrilotriaacetic acid
- sodium gluconate sodium glucoheptonate
- DTP A diethylenetriaminepentaacetic acid
- ethylenediaminetetraproprionic acid ethylenediaminetetraproprionic acid
- TTHA triethylenetetraaminehexaacetic acid
- EDG ethanoldiglycine disodium salt
- DEG diethanolglycine sodium-salt
- PDTA 1,3-propylenediaminetetraacetic acid
- GLDA dicarboxymethyl glutamic acid tetrasodium salt
- MGDA methylglycine-N-N-diacetic acid trisodium salt
- IDS iminodi succinate sodium salt
- the alkali metal, ammonium and substituted ammonium salts thereof is EDTA, EGTA or DTPA.
- the chelating agent is used at a concentration of in the range of from about 0.1 mM to about 500 mM. In some embodiments, the chelating agent is used at a concentration in the range of from about 0.1 mM to about 0.5 mM, from about 0.2 mM to about 1 mM, from about 0.5 mM to about 2.5 mM, from about 1 mM to about 10 mM, from about 2 mM to about 20 mM, from about 5 mM to about 50 mM, from about 25 mM to about 100 mM, from about 50 mM to about 250 mM, or from about 100 mM to about 500 mM.
- the chelating agent is used as an aqueous buffered solution, wherein the buffer is phosphate buffer, phosphate buffered saline, Tris-HCl buffer, Sodium citrate-citric acid buffer, Sodium acetate-acetic acid buffer, Cacodylic acid sodium salt-HCl buffer, MES-NaOH buffer, Sodium dihydrogen phosphate-di sodium hydrogen phosphate buffer, Imidazole-HCl buffer, MOPS-KOH buffer, Triethanolamine hydrochloride-NaOH buffer, HEPES-NaOH buffer, Tricine-NaOH buffer, Sodium tetraborate-boric acid buffer, and Bicine-NaOH buffer.
- the buffer is phosphate buffer, phosphate buffered saline, Tris-HCl buffer, Sodium citrate-citric acid buffer, Sodium acetate-acetic acid buffer, Cacodylic acid sodium salt-HCl buffer, MES-NaOH buffer, Sodium dihydrogen phosphate-
- Suitable buffer has a pH between 3-10.
- the buffer has a pH in the range of from about 3 to about 5, from about 4 to about 6, from about 5 to about 7, to about 6 to about 8, or about 7 to about 9.
- the buffer is used at a concentration in the range of from about 5 mM to about 1 M.
- the chelating agent is used at a concentration in the range of from about 5 mM to about 1 M.
- the connective tissue is treated with the chelating agent for from about 1 hour to about 10 days.
- the connective tissue is treated with the chelating agent for a time in the range of from about 1 hour to about 3 hours, from about 2 hours to about 10 hours, from about 5 hours to about 15 hours, from about 10 hours to about 20 hours, from about 12 hours to about 30 hours, from about 18 hours to about 3 days, from about 1 day to about 4 days, from about 2 days to about 5 days, or from about 3 days to about 10 days.
- the connective tissue is treated with the chelating agent at a temperature between about 0 °C to about 40 °C. In some embodiments, the connective tissue is treated with the chelating agent at about 0 °C, about 4 °C, about 10 °C, about 15 °C, about 20 °C, about 25 °C, about 30 °C, about 35 °C, or about 40 °C.
- the connective tissue is treated with the chelating agent at a temperature in a range of from about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, from about 15 °C to about 25 °C, from about 20 °C to about 30 °C, from about 25 °C to about 35 °C, or from about 30 °C to about 40 °C.
- the connective tissue that is treated with the chelating agent is recovered by a technique that includes, but not limited to, filtration, centrifugation, and sedimentation. In some embodiments, the connective tissue is further washed with water. In some embodiments, the connective tissue that is treated with the chelating agent is subjected to centrifugation with a centrifugal force in the range of from about 1000 c g to about 20,000 c g, and retrieved from the pellet. In some embodiments, the precipitated collagen is retrieved by centrifugation at about 1000 c g to about 5,000 c g, about 2500g to about 10,000 x g, or from about 5000g to about 20,000 x g.
- the centrifugation is carried out at a temperature in the range of from about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, or from about 15 °C to about 25 °C.
- the treatment of connective tissue with an organic solvent precedes the treatment of the connective tissue with a chelating agent.
- Suitable enzymes include, but are not limited to, trypsin, bromelain, pepsin, chymotrypsin, protease VII, thermolysin, subtilisin, ficin, papain microbial proteases, and combinations thereof.
- the enzyme is used at a concentration in the range of from about 0.05 % to about 10%. In some embodiments, the enzyme is used at a concentration in the range of from about 0.05 % to about 0.25 %, from about 0.1 % to about 0.5 %, from about 0.2 % to about 1 %, from about 0.5 % to about 2.5 %, from about 1 % to about 5 %, or from about 2 % to about 10%.
- the connective tissue is treated with the enzyme for a time in the range of from about 12 hours to about 30 days to obtain a liquid mutable collagenous tissue.
- the connective tissue is treated with the enzyme for a time in the range of from about 12 hours to about 48 hours, from about 18 hours to about 3 days, from about 24 hours to about 4 days, from about 2 days to about 5 days, from about 3 days to about 10 days, from about 5 days to about 15 days, from about 7 days to about 21 days, or from about 10 days to about 30 days.
- the connective tissue is treated with the enzyme at a temperature between about 0 °C to about 70 °C.
- the connective tissue is treated with the enzyme at about 0 °C, about 4 °C, about 10 °C, about 15 °C, about 20 °C, about 25 °C, about 30 °C, about 35 °C, or about 40 °C.
- the connective tissue is treated with the enzyme at a temperature in the range of from about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, from about 15 °C to about 25 °C, from about 20 °C to about 30 °C, from about 25 °C to about 35 °C, from about 30 °C to about 40 °C, from about 35 °C to about 45 °C, from about 40 °C to about 50 °C, from about 45 °C to about 55 °C, from about 50 °C to about 60 °C, from about 55 °C to about 65 °C, or from about 60 °C to about 70 °C.
- the connective tissue that is treated with the enzyme is subjected to filtration, or centrifugation, and a liquid mutable collagenous tissue is recovered from the filtrate or supernatant.
- the connective tissue that is treated with the enzyme is subjected to centrifugation with a centrifugal force in the range of from about 1000 x g to about 20,000 c g, and the liquid mutable collagenous tissue is retrieved from the supernatant.
- the liquid mutable collagenous tissue is retrieved from supernatant following centrifugation with a centrifugal force in the range of from about 1000 x g to about 5,000 x g, from about 2500 x g to about 10,000 x g, or from about 5000 c g to about 20,000 c g.
- the centrifugation is carried out at about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, or from about 15 °C to about 25 °C.
- the treatment of connective tissue with a chelating agent precedes the treatment of the connective tissue with an enzyme.
- the method for extracting mutable collagenous tissue from echinoderms further comprises treating the connective tissue with an alkaline solution.
- Suitable alkaline solution comprises an alkaline chemical, which include, but is not limited to, an alkali metal hydroxide, such as sodium hydroxide or potassium hydroxide; ammonium hydroxide; an alkaline earth metal hydroxide, such as magnesium hydroxide or calcium hydroxide; an alkali metal, or alkaline earth metal carbonate, such as sodium carbonate or potassium carbonate; and an alkali metal or an alkaline earth metal bicarbonate, such as sodium bicarbonate, potassium bicarbonate.
- Suitable alkaline solution has a pH in the range of from about 8 to about 14.
- the suitable alkaline solution has a pH in the range of from about 8 to about 10, from about 9 to about 11, to about 10 to about 12, from about 11 to about 13 or from about 12 to about 14.
- Suitable alkaline solution has a concentration in the range of from about 0.01 M to about 10 M.
- the suitable alkaline solution has a concentration in the range of from about 0.01 M to about 0.1 M, from about 0.05 M to about 0.25 M, from about 0.1 M to about 0. 5 M, from about 0.25 M to about 1 M, from about 0.5 M to about 2.5 M, from about 1 M to about 3 M, from about 2 M to about 6 M, or from about 5 M to about 10 M.
- the connective tissue is treated with the alkaline solution for a time in the range of from about 2 hours to about 21 days.
- the connective tissue is treated with the alkaline solution for a time in the range of from about 2 hours to about 10 hours, from about 5 hours to about 24 hours, from about 12 hours to about 48 hours, from about 18 hours to about 3 days, from about 24 hours to about 4 days, from about 2 days to about 5 days, from about 3 days to about 10 days, from about 5 days to about 15 days, or from about 7 days to about 21 days.
- the connective tissue is treated with the alkaline solution at a temperature between about 0 °C to about 40 °C. In some embodiments, the connective tissue is treated with the alkaline solution at about 0 °C, about 4 °C, about 10 °C, about 15 °C, about 20 °C, about 25 °C, about 30 °C, about 35 °C, or about 40 °C. In some
- the connective tissue is treated with the alkaline solution at a temperature in the range of from about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, from about 15 °C to about 25 °C, from about 20 °C to about 30 °C, from about 25 °C to about 35 °C, or from about 30 °C to about 40 °C.
- the treatment of connective tissue with a chelating agent precedes the treatment of the connective tissue with an alkaline solution, and the treatment of the connective tissue with an alkaline solution precedes the treatment of the connective tissue with an enzyme.
- the method for extracting mutable collagenous tissue from echinoderms further comprises precipitating collagen from the liquid mutable collagenous tissue by adding an inorganic precipitation agent.
- the precipitated collagen is the native high molecular weight collagen.
- Suitable inorganic precipitation agent is an inorganic salt.
- the inorganic precipitation agent is a halide, sulfate, or phosphate salt of an alkali metal or an alkaline earth metal.
- the inorganic precipitation agent is sodium chloride, potassium chloride, magnesium chloride, calcium chloride, or a combination thereof.
- the inorganic precipitation agent is used at a concentration in the range of from about 0.05 M to about 5 M.
- the suitable alkaline solution has a concentration in the range of from about 0.05 M to about 0.25 M, from about 0.1 M to about 0. 5 M, from about 0.25 M to about 1 M, from about 0.5 M to about 2.5 M, from about 1 M to about 3 M, or from about 2 M to about 5 M.
- the liquid mutable collagenous tissue is incubated with the inorganic precipitation agent for a time in the range of from about 2 minutes to about 24 hr.
- the connective tissue is treated with the alkaline solution for a time in the range of from about 2 minutes to about 10 minutes, from about 5 minutes to about 20 minutes, from about 10 minutes to about 45 minutes, from about 30 minutes to about 2 hours, from about 1 hour to about 3 hours, from about 2 hours to about 5 hours, from about 3 hours to about 10 hours, from about 5 hours to about 15 hours, or from about 8 hours to about 24 hours.
- the liquid mutable collagenous tissue is incubated with the inorganic precipitation agent at a temperature between about 0 °C to about 40 °C. In some embodiments, the liquid mutable collagenous tissue is incubated with the inorganic precipitation agent at a temperature in the range of about 0 °C, about 4 °C, from about 10 °C, from about 15 °C, from about 20 °C, from about 25 °C, from about 30 °C, from about 35 °C, or about 40 °C.
- the liquid mutable collagenous tissue is incubated with the inorganic precipitation agent at a temperature between about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, from about 15 °C to about 25 °C, from about 20 °C to about 30 °C, from about 25 °C to about 35 °C, or from about 30 °C to about 40 °C.
- the precipitated collagen is separated from supernatant by centrifugation and recovery of the pellet. In some embodiments, the precipitated collagen is separated by centrifugation at a centrifugal force in the range of from about 1000 x g to about 50,000 x g, and retrieved from the pellet. In some embodiments, the precipitated collagen is retrieved by centrifugation at a centrifugal force in the range of from about 1000 c g to about 5,000 x g, from about 2500 x g to about 10,000 c g, from about 5000 x g to about 20,000 c g, or from about 10,000 x g to about 50,000 x g.
- the centrifugation is carried out at a temperature in the range of from about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, or from about 15 °C to about 25 °C.
- the pellet is resuspended in an acidic solution.
- the acidic solution comprises an acid, which includes, but is not limited to acetic acid, citric acid, propionic acid, lactic acid, and hydrochloric acid.
- the acidic solution comprises an acid in the concentration range of from about 0.01 M to about 5 M.
- the acidic solution comprises an acid in the concentration range of from about 0.01 M to about 0.1 M, from about 0.05 M to about 0.25 M, from about 0.1 M to about 0.5 M, from about 0.25 M to about 1 M, from about 0.5 M to about 2.5 M, from about 1 M to about 3 M, or from about 2 M to about 5 M.
- the acidic solution has a pH in the range of from about 1 to about 3, from about 2 to about 4, from about 3 to about 5, or from about 4 to about 6.
- the acidic solution is ice cold.
- the temperature of the acidic solution has is about 0 °C, about 4 °C, about 10 °C, about 15 °C, about 20 °C, or about 25 °C.
- the treatment of connective tissue with an enzyme precedes precipitating the native high molecular weight collagen from the liquid mutable collagenous tissue by adding an inorganic precipitation agent.
- the method for extracting mutable collagenous tissue from echinoderms further comprises dialysis of the pellet, which is resuspended in an acidic solution.
- the pellet is dialyzed against water or an aqueous buffer.
- the buffer is phosphate buffer, phosphate buffered saline, Tris-HCl buffer, Sodium citrate - citric acid buffer, Sodium acetate - acetic acid buffer, Cacodylic acid sodium salt - HC1 buffer, MES - NaOH buffer, Sodium dihydrogen phosphate - disodium hydrogen phosphate buffer, Imidazole - HC1 buffer, MOPS - KOH buffer, Triethanolamine hydrochloride - NaOH buffer, HEPES - NaOH buffer, Tricine - NaOH buffer, Sodium tetraborate - boric acid buffer, and Bicine - NaOH buffer.
- the buffer has a pH between 3-9.
- the buffer has a pH in the range of from about 3 to about 5, from about 4 to about 6, from about 5 to about 7, to about 6 to about 8, or from about 7 to about 9. In some embodiments, the buffer is used at a concentration in the range of from about 5 mM to about 250 mM. In some embodiments, the buffer has a concentration in the range of from about 5 mM to about 50 mM, from about 25 mM to about 100 mM, or from about 50 mM to about 250 mM.
- the dialysis is carried out at a temperature between about 0 °C to about 40 °C. In some embodiments, the dialysis is carried out at about 0 °C, about 4 °C, about 10 °C, about 15 °C, about 20 °C, about 25 °C, about 30 °C, about 35 °C, or about 40 °C.
- the dialysis is carried out at a temperature in a range of from about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, from about 15 °C to about 25 °C, from about 20 °C to about 30 °C, from about 25 °C to about 35 °C, or from about 30 °C to about 40 °C.
- the method for extracting mutable collagenous tissue from echinoderms further comprises freeze drying to produce solid mutable collagenous tissue.
- the mutable collagenous tissue obtained by this process is highly pure (See FIG. 3).
- the solid mutable collagenous tissue is a sheet composed of collagen type I.
- the solid mutable collagenous tissue is a powder composed of collagen type I.
- mutable collagenous tissue obtained by the method disclosed here is at least 90% pure collagen type I.
- mutable collagenous tissue obtained by the method disclosed here is at least 92% pure collagen type I.
- mutable collagenous tissue obtained by the method disclosed here is at least 95% pure collagen type I.
- mutable collagenous tissue obtained by the method disclosed here is at least 98% pure collagen type I.
- the method for extracting mutable collagenous tissue from echinoderms comprises the following steps in the following order: a. Treating a connective tissue with an aqueous solution of an organic solvent; b. Treating the connective tissue with a chelating agent; and
- the method for extracting mutable collagenous tissue from echinoderms comprises the following steps in the following order:
- the method for extracting mutable collagenous tissue from echinoderms comprises the following steps in the following order:
- the method for extracting mutable collagenous tissue from echinoderms comprises the following steps in the following order:
- the method for extracting mutable collagenous tissue from echinoderms comprises the following steps in the following order:
- treating a connective tissue with an aqueous solution of the organic solvent comprises (i) collecting the echinoderm specimens, and dissecting them, (ii) isolating connective tissue from the body wall, (iii) treating a connective tissue with an aqueous solution of an organic solvent (comprising ethanol, isopropanol, acetone and/or ethyl acetate, in concentrations ranging 30 to 50%) for 10 to 60 minutes, (iv) centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min, (v) collecting the connective tissue, and (vi) and washing with in deionized water.
- an organic solvent comprising ethanol, isopropanol, acetone and/or ethyl acetate, in concentrations ranging 30 to 50%
- treating a connective tissue with a chelating agent comprises (i) treating a connective tissue with an aqueous solution of a chelating agent (comprising ethylene glycol tetraacetic acid (EGTA), ethylene diamine tetraacetic acid (EDTA) and/or diethylene triamine pentaacetic acid (DTP A), together in phosphate buffer saline (PBS), tris buffer or acetate buffer) for 12 to 24 hours, (ii) centrifugation at about 1000 to about 20,000 c g for about 10 min to 60 min, (iii) collecting the connective tissue, and (iv) and washing with in deionized water.
- a chelating agent comprising ethylene glycol tetraacetic acid (EGTA), ethylene diamine tetraacetic acid (EDTA) and/or diethylene triamine pentaacetic acid (DTP A)
- PBS phosphate buffer saline
- DTP A diethylene triamine penta
- treating a connective tissue with an alkaline solution which comprises (i) treating a connective tissue with an alkaline solution (comprising 0.1 M to 1.0 M sodium hydroxide and/or sodium bicarbonate) for 24 to 48 hours, (ii) centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min, iii) collecting the connective tissue, and (iv) and washing with in deionized water.
- treating a connective tissue with an enzyme to yield a liquid mutable collagenous tissue comprises (i) treating a connective tissue with an enzyme
- precipitating collagen from the liquid mutable collagenous tissue by adding an inorganic precipitation agent comprises (i) adding sodium chloride, potassium chloride and/or calcium chloride to a concentration of 0.5 to 1.0 M to the liquid mutable collagenous tissue, (ii) centrifugation at about 1000 to about 20,000 c g for about 10 min to 60 min, iii) collecting the pellet, and (iv) and resuspending the pellet in 0.1 to 0.5 M acetic acid, citric acid, propionic acid and/or hydrochloric acid to obtain a resuspended pellet.
- the method for extracting mutable collagenous tissue from echinoderms comprises the following steps in the following order:
- Treating a connective tissue with an aqueous solution of an organic solvent which comprises (i) collecting the echinoderm specimens, and dissecting them, (ii) isolating connective tissue from the body wall, (iii) treating a connective tissue with an aqueous solution of an organic solvent (comprising ethanol, isopropanol, acetone and/or ethyl acetate, in concentrations ranging 30 to 50%) for 10 to 60 minutes, (iv) centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min, (v) collecting the connective tissue, and (vi) and washing with in deionized water;
- Treating the connective tissue with a chelating agent which comprises (i) treating a connective tissue with an aqueous solution of a chelating agent (comprising ethylene glycol tetraacetic acid (EGTA), ethylene diamine tetraacetic acid (EDTA) and/or diethylene triamine pentaacetic acid (DTP A), together in phosphate buffer saline (PBS), tris buffer or acetate buffer) for 12 to 24 hours, (ii) centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min, (iii) collecting the connective tissue, and (iv) and washing with in deionized water;
- a chelating agent comprising ethylene glycol tetraacetic acid (EGTA), ethylene diamine tetraacetic acid (EDTA) and/or diethylene triamine pentaacetic acid (DTP A)
- PBS phosphate buffer saline
- DTP A diethylene triamine pent
- Treating the connective tissue with an alkaline solution which comprises (i) treating a connective tissue with an alkaline solution (comprising 0.1 M to 1.0 M sodium hydroxide and/or sodium bicarbonate) for 24 to 48 hours, (ii) centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min, iii) collecting the connective tissue, and (iv) and washing with in deionized water;
- collagenous tissue which comprises (i) treating a connective tissue with an enzyme (comprising 0.5 to 1.0% trypsin, bromelain, pepsin or papain in a suitable buffer) for 48 to 72 hours, (ii) centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min, (iii) collecting the supernatant, which is the liquid mutable collagenous tissue;
- an enzyme comprising 0.5 to 1.0% trypsin, bromelain, pepsin or papain in a suitable buffer
- centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min
- collecting the supernatant which is the liquid mutable collagenous tissue
- Precipitating collagen from the liquid mutable collagenous tissue by adding an inorganic precipitation agent which comprises (i) adding sodium chloride, potassium chloride and/or calcium chloride to a concentration of 0.5 to 1.0 M, (ii) centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min, iii) collecting the pellet, and (iv) and resuspending the pellet in 0.1 to 0.5 M acetic acid, citric acid, propionic acid and/or hydrochloric acid to obtain a resuspended pellet;
- an inorganic precipitation agent which comprises (i) adding sodium chloride, potassium chloride and/or calcium chloride to a concentration of 0.5 to 1.0 M, (ii) centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min, iii) collecting the pellet, and (iv) and resuspending the pellet in 0.1 to 0.5 M acetic acid, citric acid, propionic acid and/
- the method for extracting mutable collagenous tissue from echinoderms comprises the steps of: 1) soaking isolated connective tissue in organic extracting solution for disinfection and extraction of fat-related compounds; 2) pre-treating the connective tissue extract with a chelating buffer solution to eliminate heavy metals and related impurities; 3) soaking the connective tissue extract alkaline solution to eliminate non- collagenous tissue; 4) soaking the connective tissue extract in an enzyme to yield to a liquid mutable collagenous tissue; 5) extracting the native high molecular weight collagen from liquid mutable collagenous tissue isolate by adding inorganic precipitation agent; 6) dissolving of the isolated native collagen in collagen dissolving solution, and 7) isolating high-purity native collagen powder by dialysis followed by freeze drying.
- the connective tissue is excised from echinoderm species including, but not limited to, sea urchins, sea cucumbers and/or star fish.
- Species of echinoderms for extraction of mutable collagenous tissue could be selected from the group composed by, but not limited to, Strongylocentrotus purpuratus , Paracentrotus lividus , Apostichopus japonicus , Thelenota ananas , Parastichopus californicus , Asterias amurensis, Cucumaria frondosa.
- the organic extracting solution is composed by aqueous solutions of ethanol, isopropanol, acetone or ethyl acetate, in concentrations ranging 30 to 50% and total reaction time between 10 to 60 minutes.
- the chelating buffer solution can be composed by a chelating agent from the group consisting of ethylene glycol tetraacetic acid (EGTA), ethylene diamine tetraacetic acid (EDTA) or diethylene triamine pentaacetic acid (DTP A), together with a buffer solution composed by phosphate buffer saline (PBS), tris buffer or acetate buffer, in ratios ranging 1 :5 to 1 : 10, respectively, and total reaction time between 12 to 24 hours.
- EGTA ethylene glycol tetraacetic acid
- EDTA ethylene diamine tetraacetic acid
- DTP A diethylene triamine pentaacetic acid
- the alkaline solution is composed of a caustic aqueous solution comprising sodium hydroxide or sodium bicarbonate at a concentration ranging from 0.1 to 1.0 M and total reaction time between 24 to 48 hours.
- the enzyme includes but not limited to, trypsin, bromelain, pepsin or papain at concentrations ranging from 0.5 to 1.0% and total reaction time between 48 to 72 hours.
- the inorganic precipitation agent is an inorganic salt, including, but not limited to, sodium chloride, potassium chloride or calcium chloride, at concentrations ranging from 0.5 to 1.0 M.
- collagen dissolving solution is composed by an acid including, but not limited to, acetic acid, citric acid, propionic acid or hydrochloric acid, in
- the mutable collagenous tissue purified by the methods disclosed herein shows a macromolecular structure of collagen type I.
- the mutable collagenous tissue purified by the methods disclosed herein shows a macromolecular structure of collagen type I, exhibits high purity (>98%), showing no degradation of the main collagen structure (chemical or biological) or the presence of contaminants from extraction processes (small proteins or peptides).
- the mutable collagenous tissue purified by the methods disclosed herein shows high molecular weight (>150kDa),
- the mutable collagenous tissue purified by the methods disclosed herein shows high molecular weight (>150 kDa), as shown by SDS gel electrophoresis.
- the mutable collagenous tissue purified by the methods disclosed herein exhibits al, and a2 chains, as shown by SDS-PAGE electrophoresis. In some embodiments, the mutable collagenous tissue purified by the methods disclosed herein exhibits protein bands in a, b and g regions, as shown by SDS-PAGE electrophoresis. In some embodiments, the mutable collagenous tissue purified by the methods disclosed herein exhibits protein bands at or above 150 kDa, as shown by SDS-PAGE electrophoresis. In some embodiments, the mutable collagenous tissue purified by the methods disclosed herein exhibits less than 2% impurities and degradation products that run substantially below 150 kDa, as shown by SDS-PAGE electrophoresis.
- the present disclosure provides a mutable collagenous tissue obtainable by any of the methods described above.
- the mutable collagenous tissue obtainable by any of the methods described herein is a liquid mutable collagenous tissue, a sheet of mutable collagenous tissue, a mutable collagenous tissue powder or a combination thereof.
- the present disclosure provides a pharmaceutical, cosmeceutical or cosmetic composition
- a pharmaceutical, cosmeceutical or cosmetic composition comprising the mutable collagenous tissue obtainable by any of the methods described herein.
- the provides a pharmaceutical, cosmeceutical or cosmetic composition comprises from about 0.01% to about 99.9% by weight of the composition mutable collagenous tissue obtainable by any of the methods described herein.
- the mutable collagenous tissue obtainable is mixed with one or more pharmaceutically acceptable excipients, additives, and/or preservatives.
- the excipients include diluents, lubricants, binders, disintegrates, buffers, dispersants, surfactants, coloring agents, perfumes, aromatics, or sweeteners.
- Suitable pharmaceutically acceptable excipients or pharmaceutically acceptable carriers may include solvents, dispersion media, coatings, isotonic and absorption delaying agents and the like, and combinations comprising one or more of the foregoing carriers as described, for instance, in Remington’s Pharmaceutical Sciences , 15th Ed. Easton: Mack Publishing Co. pp. 1405-1412 and 1461-1487 (1975), and The National Formulary XIV 14th Ed., Washington: American Pharmaceutical Association (1975).
- Suitable carriers include, but are not limited to, calcium carbonate, carboxymethylcellulose, cellulose, citric acid, dextrate, dextrose, ethyl alcohol, glucose, hydroxymethylcellulose, lactose, magnesium stearate, maltodextrin, mannitol, microcrystalline cellulose, oleate, polyethylene glycols, potassium diphosphate, potassium phosphate, saccharose, sodium diphosphate, sodium phosphate, sorbitol, starch, stearic acid and its salts, sucrose, talc, vegetable oils, water, and combinations comprising one or more of the foregoing carriers. Except insofar as any conventional media or agent is incompatible with the emulsions of the present invention, their use in pharmaceutical, cosmeceutical or cosmetic compositions is contemplated.
- Supplementary active ingredients also can be incorporated into the pharmaceutical, cosmeceutical or cosmetic compositions.
- the pharmaceutical, cosmeceutical or cosmetic compositions comprising the mutable collagenous tissue disclosed herein described herein can be formulated for various routes of administration. Suitable routes of administration include, but are not limited to, oral, sublingual, inhalation, rectal, transmucosal, transdermal, intracavemosal, topical, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.
- administration include, but are not limited to, lotions, ointments, gels, creams, liquids, emulsions, suppositories, drops, sprays, hydrogel, bioadhesive gels, aerosols, pastes, foams, sunscreens, and powders, or in the form of an article or carrier, such as a bandage, insert, syringe-like applicator, pessary, powder, talc or other solid, cleanser (leave on and wash off product), and agents that favor penetration within the pilosebaceous gland.
- lotions, ointments, gels, creams, liquids, emulsions, suppositories drops, sprays, hydrogel, bioadhesive gels, aerosols, pastes, foams, sunscreens, and powders, or in the form of an article or carrier, such as a bandage, insert, syringe-like applicator, pessary, powder, talc or other solid,
- the pharmaceutical, cosmeceutical or cosmetic compositions for topical administration may additionally comprise organic solvents, emulsifiers, gelling agents, moisturizers, stabilizers, surfactants, wetting agents, preservatives, time release agents, and minor amounts of humectants, sequestering agents, dyes, perfumes, and other components commonly used in cosmetic or pharmaceutical compositions for topical and mucosal administration.
- the pharmaceutical, cosmeceutical or cosmetic compositions may comprise a penetration-enhancing agent for enhancing penetration of the nanoemulsion through the stratum corneum and into the epidermis or dermis.
- Suitable penetration enhancing agents include, but are not limited to, alcohols such as ethanol, triglycerides, fatty acids (e.g ., lauric acid, oleic acid, myristic acid), fatty alcohols (e.g., myristyl or oleoyl alcohols), fatty esters (e.g., isopropyl myristate), lipids, anionic and nonionic surfactants and aloe compositions.
- the amount of the penetration-enhancing agent may comprise from about 0.5% to about 40% by weight of the composition.
- Topical administration includes administration to the skin, mucosa, and squamous epithelium, including surface of the hair follicle and pilosebaceous unit.
- the composition enters the epidermis, dermis, mucosa, squamous epithelium, or any combination thereof. In some embodiments, the composition permeates into the epidermis and dermis via the follicular route using skin pores and hair follicles. In some embodiments, the composition diffuses through the skin, skin pores, nail, scalp, hair follicles, lateral or proximal folds, nail, hyponichium, or a combination thereof.
- the composition for delivery via a“patch” comprising the mutable collagenous tissue is envisioned.
- a“patch” comprises at least a topical composition and a covering layer, such that the patch can be placed over the area to be treated.
- the patch is designed to maximize delivery through the stratum corneum and into the epidermis or dermis, while minimizing absorption into the circulatory system, and little to no skin irritation, reducing lag time, promoting uniform absorption, and reducing mechanical rub-off and dehydration.
- Adhesives for use with the drug -in-adhesive type patches are well known in the art.
- Suitable adhesive include, but are not limited to, polyisobutylenes, silicones, and acrylics. These adhesives can function under a wide range of conditions, such as, high and low humidity, bathing, sweating etc.
- the adhesive is a composition based on natural or synthetic rubber; a polyacrylate such as, polybutylacrylate, polymethylacrylate, poly-2 - ethylhexyl acrylate; polyvinylacetate; polydimethylsiloxane; or and hydrogels ( e.g ., high molecular weight polyvinylpyrrolidone and oligomeric polyethylene oxide).
- the most preferred adhesive is a pressure sensitive acrylic adhesive, for example Durotak® adhesives (e.g., Durotak® 2052, National Starch and Chemicals).
- the adhesive may comprise a thickener, such as a silica thickener (e.g., Aerosil, Degussa, Ridgefield Park, N. J.) or a crosslinker such as aluminumacetylacetonate.
- Suitable release liners include but are not limited to occlusive, opaque, or clear polyester films with a thin coating of pressure sensitive release liner (e.g., silicone- fluorsilicone, and perfluorcarbon based polymers.
- pressure sensitive release liner e.g., silicone- fluorsilicone, and perfluorcarbon based polymers.
- Backing films may be occlusive or permeable and are derived from synthetic polymers like polyolefin oils polyester, polyethylene, polyvinylidine chloride, and
- Occlusive backing films such as synthetic polyesters, result in hydration of the outer layers of the stratum comeum while non-occlusive backings allow the area to breath (i.e., promote water vapor transmission from the skin surface).
- the backing film is an occlusive polyolefin foil (Alevo, Dreieich, Germany).
- the polyolefin foil is preferably about 0.6 to about 1 mm thick.
- the shape of the patch can be flat or three-dimensional, round, oval, square, and have concave or convex outer shapes, or the patch or bandage can also be segmented by the user into corresponding shapes with or without additional auxiliary means.
- the pharmaceutical, cosmeceutical or cosmetic compositions may be applied in a single administration or in multiple administrations.
- the pharmaceutical, cosmeceutical or cosmetic compositions can be applied for any suitable time period, such as once or multiples times per day.
- the compositions can be applied for at least once a week, at least twice a week, at least once a day, at least twice a day, multiple times daily, multiple times weekly, biweekly, at least once a month, or any combination thereof.
- the pharmaceutical, cosmeceutical or cosmetic compositions are applied for a period of time of about one month, about two months, about three months, about four months, about five months, about six months, about seven months, about eight months, about nine months, about ten months, about eleven months, about one year, about 1.5 years, about 2 years, about 2.5 years, about 3 years, about 3.5 years, about 4 years, about 4.5 years, and about 5 years. Between applications, the application area may be washed to remove any residual mutable collagenous tissue.
- the pharmaceutical, cosmeceutical or cosmetic compositions are applied to the skin area in an amount of from about 0.001 mL/cm 2 to about 5.0 mL/cm 2 .
- An exemplary application amount and area is about 0.2 mL/cm 2 , although any amount from 0.001 mL/cm 2 up to about 5.0 mL/cm 2 can be applied.
- the nanoemulsion may be occluded or semi-occluded. Occlusion or semi-occlusion may be performed by overlaying a bandage, polyoleofm film, impermeable barrier, or semi-impermeable barrier to the topical preparation.
- the treated area is covered with a dressing.
- the pharmaceutical, cosmeceutical or cosmetic compositions described herein are formulated for mucosal delivery, for example by contacting any one of the compositions described herein to a nasal mucosal epithelium, a bronchial or pulmonary mucosal epithelium, an oral, gastric, intestinal or rectal mucosal epithelium, or a vaginal mucosal epithelium.
- the compositions described herein are formulated for intranasal delivery, (e.g., nasal mucosal delivery or intranasal mucosal delivery).
- compositions for oral administration include, but are not limited to, tablets, pills, soft or hard capsules, granules, powders, solution, or emulsion.
- compositions for topical administration include a hydrogel, an implant, an artificial body part, a tissue engineering and regeneration system, and a wound dressing, or a medical device.
- compositions comprising the mutable collagenous tissue disclosed herein can include a carrier, which can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
- a carrier which can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thiomerasol, and the like
- the mutable collagenous tissue disclosed herein can be formulated in a carrier system.
- the carrier can be a colloidal system.
- the carrier can also be a polymer, e.g ., a biodegradable, biocompatible polymer matrix.
- one or more therapeutic agent can be embedded in the polymer matrix, while maintaining the agent’s structural integrity.
- the polymer may be natural, such as polypeptides, proteins or polysaccharides, or synthetic, such as poly a-hydroxy acids. Examples include carriers made of, e.g. , fibronectin, elastin, cellulose acetate, cellulose nitrate, polysaccharides, fibrin, and combinations thereof.
- the polymer is poly-lactic acid (PLA) or copoly lactic/glycolic acid (PGLA).
- PVA poly-lactic acid
- PGLA copoly lactic/glycolic acid
- the polymeric matrices can be prepared and isolated in a variety of forms and sizes, including liposomes, nanofibers, microspheres and nanospheres. See Reddy, Ann. Pharmacother ., 34(7-8):915-923 (2000)).
- the Mutable Collagenous Tissue of the present technology is a unique natural extracellular matrix composed of collagen type I, and glycosaminoglycan, which is bound to the collagen type I. This structure creates an optimal environment for new collagen biosynthesis, promoting integrin binding, which impart the necessary pharmacological properties helpful for the pharmacological and cosmetic applications disclosed herein.
- the Mutable Collagenous Tissue of the present technology is biodegradable and exhibits weak antigenicity, making it a suitable for biomedical applications.
- the Mutable Collagenous Tissue of the present technology is useful in methods relating to the wound healing, tissue repair and the treatment of conditions associated to chronic wounds, diabetic wounds, etc.
- the present technology relates to the treatment of a wound in a subject in need thereof through the administration of therapeutically effective amounts of a wound healing formulation comprising the Mutable Collagenous Tissue of the present technology.
- the methods enhance cell attachment and proliferation, or promotion of cell-specific morphology and function.
- the wound deals damage to one or more cell type, including but not limited to endothelial cells, hepatocytes, and muscle cells.
- the wounds to be treated include, but are not limited to, an incision wound, a chop wound, a puncture wound, a contused wound, a laceration wound, an impalement injury, dermabrasion, decollement, an abrasion, a crushed wound, contusion, a firearm wound, a blast injury, a biting wound, excoriation, an explosion injury, a bruise, an external wound, a bedsore, a surgical wound, a burn wound, a gunshot wound, subcutaneous abscess, sutured tear, contaminated tear, stasis ulcer, leg ulcer, foot ulcer, venous ulcer, diabetic ulcer, ischemic ulcer, pressure ulcer, an acute/chronic wound, an open injury and a closed injury.
- the wound is a chronic wound or a diabetic wound.
- the Mutable Collagenous Tissue of the present technology is formulated as a wound healing formulation, including but not limited to, traditional dressing, antimicrobial dressing, anti-inflammatory and analgesic dressing, wound-drug delivery, medicated suture, or tissue-engineered skin substitute.
- the Mutable Collagenous Tissue of the present technology is formulated as a wound healing formulation, including but not limited to, a lotion, ointment, gel, cream, liquid, emulsion, suppository, drop, spray, hydrogel, dressing, bioadhesive gel, aerosol, paste, foam, sunscreen, or powder.
- the amount of Mutable Collagenous Tissue of the present technology in the wound healing formulation may be about 0.1 wt.%, about 0.2 wt.%, about 0.3 wt.%, about 0.4 wt.%, about 0.5 wt.%, about 0.6 wt.%, about 0.7 wt.%, about 0.8 wt.%, about 0.9 wt.%, about 1 wt.%, about 2 wt.%, about 3 wt.%, about 4 wt.%, about 5 wt.%, about 6 wt.%, about 7 wt.%, about 8 wt.%, about 9 wt.%, about 10 wt.%, about 11 wt.%, about 12 wt.%, about 13 wt.%, about 14 wt.%, about 15 wt.%, about 16 wt.%, about 17 wt.%, about 18 wt.%, about 19 wt
- the wound healing formulation may include about 0.001 wt.% to about 5 wt.% of a wound healing promoter.
- exemplary wound-healing promoters include, but are not limited to, an anti-inflammatory drug (e.g ., acetaminophen), zinc, zinc oxide, an inorganic zinc salt e.g ., ZnCb), a zinc complex, vitamin E, vitamin C, a fibroblast growth factor, a platelet- derived growth factor (see, e.g., Gowda, San tosh, et al.
- the total amount of wound healing promoter(s) in wound healing formulation may be about 0.001 wt.%, about 0.002 wt.%, about 0.003 wt.%, about 0.004 wt.%, about 0.005 wt.%, about 0.006 wt.%, about 0.007 wt.%, about 0.008 wt.%, about 0.009 wt.%, about 0.01 wt.%, about 0.02 wt.%, about 0.03 wt.%, about 0.04 wt.%, about 0.05 wt.%, about 0.06 wt.%, about 0.07 wt.%, about 0.08 wt.%, about 0.09 wt.%, about 0.1 wt.%, about 0.2
- the wound healing formulation may include a solvent and an effective amount of at least one agent selected from the group consisting of a growth factor, an antimicrobial agent, a peptide, a biopolymer, a binder, a colorant, a deodorant agent, a filler, a plasticizer, a viscosity modifier, or any combination thereof.
- the solvent may be an aqueous solvent or an organic solvent.
- the aqueous solvent may include a dilute organic acid, for example, acetic acid, citric acid, or a combination thereof.
- the antimicrobial agent may include one or more of polyhexamethylene biguanide, acetic acid, benzoic acid, povidone iodine, natamycin, nisin, citric acid, sorbic acid, propionic acid, honey, sulfites, or any combination thereof.
- the peptide may be one or more of defensins, histatins, cathelicidin LL-37, or any combination thereof.
- the Mutable Collagenous Tissue of the present technology is useful in methods relating to cosmetics and skin health. Accordingly, in one aspect, the present technology relates to the treatment of skin in a subject in need thereof, through the administration of cosmetically effective amounts of a cosmetic composition comprising the Mutable
- the methods include, but are not limited to, reducing skin wrinkles, enhancing skin moisture content, reducing skin moisture evaporation, inhibiting erythema, and suppressing the thickening of skin epidermis layers, exfoliating skin, enhancing skin elasticity, inhibiting erythema, and/or alleviating skin photoaging.
- the cosmetic composition is topically applied.
- the cosmetic composition comprising the Mutable Collagenous Tissue of the present technology is formulated as a lotion, ointment, gel, cream, liquid, paste, drop, spray, hair restorer, lip cream, patch, thickening gel, water-in-oil emulsion, oil-in-water emulsion, solid, sheet, powder, gel, and mousse.
- the amount of Mutable Collagenous Tissue of the present technology present in the cosmetic composition is about 0.1 wt.%, about 0.2 wt.%, about 0.3 wt.%, about 0.4 wt.%, about 0.5 wt.%, about 0.6 wt.%, about 0.7 wt.%, about 0.8 wt.%, about 0.9 wt.%, about 1 wt.%, about 2 wt.%, about 3 wt.%, about 4 wt.%, about 5 wt.%, about 6 wt.%, about 7 wt.%, about 8 wt.%, about 9 wt.%, about 10 wt.%, about 11 wt.%, about 12 wt.%, about 13 wt.%, about 14 wt.%, about 15 wt.%, about 16 wt.%, about 17 wt.%, about 18 wt.%, about
- the amount of Mutable Collagenous Tissue of the present technology present in the cosmetic composition is about 0.1 wt.% to about 0.5 wt.%, about 0.25 wt.% to about 2 wt.%, about 1 wt.% to about 5 wt.%, about 2.5 wt.% to about 10 wt.%, about 5 wt.% to about 25 wt.%, or about 10 wt.% to about 50 wt.%.
- the cosmetic composition further comprises cosmetically acceptable carriers or additives selected from the group consisting of moisturizers, antioxidants, cell activators, whitening agents, UV inhibitors, active oxygen removing agents, metal sequestrants, anti-inflammatory agents, antihistamines, vitamins, plant extracts, skin astringents, skin function-enhancing agents, disinfectants, oils, solvents, buffers, bulking agents, anti-microbial agents, thickeners, antioxidants, surfactants, emulsifiers, solubilizers, solubilizing aids, colorants (dyes and pigments), perfumes, and preservatives.
- cosmetically acceptable carriers or additives selected from the group consisting of moisturizers, antioxidants, cell activators, whitening agents, UV inhibitors, active oxygen removing agents, metal sequestrants, anti-inflammatory agents, antihistamines, vitamins, plant extracts, skin astringents, skin function-enhancing agents, disinfectants, oils, solvents, buffers, bulking agents, anti-microbial agents, thickeners, antioxidants
- Suitable cosmetically acceptable carriers or additives are glycerol, 1,3-butylene glycol, proteins or their derivatives or hydrolyzates (e.g ., elastin or keratin, etc.),
- mucopolysaccharides and their derivatives e.g., hyaluronic acid, hydrolyzed hyaluronic acid, chondroitin sulfate, etc.
- amino acids and their derivatives e.g, histidine, serine, glycine, theanine, aspartic acid, arginine, lysine, pyrrolidone carboxylic acid, N-methyl-L-serine, etc.
- carbohydrates e.g, sorbitol, erythritol, trehalose, inositol, glucose, xylitol, N-acetyl glucosamine, raffmose, sucrose and its derivatives, dextrin and its derivatives, honey, etc.
- phosphorylated oligosaccharides and their mineral salts D-panthenol and its derivatives, glycolipids, ceramides, glycosyl ceramides, sweet Hydrangea leaf extract, almond
- John's wort extract Lamium album extract, Ononis extract, chamomile extract, oats extract, glabridin, glabrene, liquiritin, isoliquiritin and licorice extracts containing the same, water-soluble and oil-soluble licorice extracts, bramble extract, yellow Himalayan raspberry extract, honeysuckle (Lonicera japonica Thunb) extract, quince seed (Cydonia oblonga ) extract, Sophora flavescens extract, gardenia extract, Sasa veitchii extract, water-soluble chlorophyll, maple leaf extract, Citrus extract, grapefruit extract, watercress extract, Gentiana scabra extract, geranium herb extract, burdock extract, sesame extract, wheat extract, wheat germ extract, comfrey (Symphytum officinale ) extract, Asiasari radix extract, cactus extract, Saponaria officinalis extract, salvia (sage) extract
- red algae such as Ceylon moss, Kappaphycus striatum, Eucheuma denticulatum, Chondrus ocellatus Holmes, Chondracanthus tenellus, Nithophyllum, Pyropia tenera, Polyopes affinis, Grateloupia crispata, Gloiopeltis tenax, Gracilaria vermiculophylla, Ceratodictyon spongiosum, Ceramium kondoi, and
- Campylaephora hypnaeoides green algae such as chlorella, green laver, Dunaliella
- Chlorococcales Ulva pertusa, Prasiola japonica, Aegagropila linnaei, Cladophoraceae, Acetabularia ryukyuensis, Chaetomorpha crassa, Chaetomorpha moniligera, Monostroma nitidum, and Spirogyra; blue green algae such as spirulina), plant fermented liquids such as pear juice fermented liquid, hibiscus fermented liquid, rice fermented liquid, vitamin E and its derivatives, vitamin A and its derivatives, carotenoids ( e.g ., carotene, lycopene, astaxanthin, capsanthin, etc.), vitamin B (e.g., thiamine hydrochloride, thiamine sulfate, riboflavin, riboflavin acetate, pyridoxine hydrochloride, pyridoxine dioctanoate, flavin a
- the cosmetic composition comprises ingredients one or more selected from the group consisting of the Mutable Collagenous Tissue of the present technology, organic aloe leaf juice (Aloe barbadensis ), coconut oil (Cocos nucifera ), apricot kernel oil (Prunus armeniaca ), glycerin, emulsifying wax (e.g., cetyl alcohol, stearyl alcohol, polysorbate 60), stearic acid, vitamin E (Tocopherol), sunflower seed oil (Helianthus annum ), phenoxyethanol, glycolic acid, tartaric acid, malic acid, organic shea butter
- organic seaweed extract Flucus vesiculosus
- organic green tea leaf extract Cassi sinensis
- organic white willow bark extract Salix alba
- organic alcohol organic neem seed oil
- organic rosemary leaf extract Rosmarinus officinalis
- xanthan gum tetrasodium glutamate diacetate, tranexamic acid, and astaxanthin.
- the cosmetic composition comprises ingredients one or more selected from the group consisting of ihe Mutable Collagenous Tissue of the present technology, organic aloe leaf juice, organic coconut oil, organic alcohol, cetearyl olivate, sorbitan olivate, cetyl palmitate, sorbitan palmitate, organic olive fruit oil (Olea europaea), stearic acid, organic green tea leaf extract (Camellia sinensis), pomegranate seed extract (Punica granatum), xanthan gum, soluble collagen, ascorbic acid, tocopheryl acetate, royal jelly, and astaxanthin.
- ingredients one or more selected from the group consisting of ihe Mutable Collagenous Tissue of the present technology, organic aloe leaf juice, organic coconut oil, organic alcohol, cetearyl olivate, sorbitan olivate, cetyl palmitate, sorbitan palmitate, organic olive fruit oil (Olea europaea), stearic acid, organic green tea leaf extract
- the cosmetic composition comprises ingredients one or more selected from the group consisting of the Mutable Collagenous Tissue of the present technology, water, organic coconut oil, grapeseed oil (Vitis vinifera), emulsifying wax (e.g, cetyl alcohol, stearyl alcohol, polysorbate 60), stearic acid, glycerin, xanthan gum, phenoxyethanol, tetrasodium glutamate diacetate, soluble collagen, ascorbic acid, tocopheryl acetate, royal jelly, and astaxanthin.
- the cosmetic composition intensely hydrates skin to create a softer and smoother look, reducing the appearance of scars.
- the composition hydrates and soothes skin to create a visibly supple texture around the eye, diminishing the appearance of puffmess, temporary redness and uneven skin tone.
- the cream revitalizes skin on contact and helps improve skin appearance.
- the composition promotes smooth and hydrated skin, reducing the appearance of dark spots and hyperpigmentation for a more radiant look.
- the present technology relates to hydrogel compositions comprising the Mutable Collagenous Tissue of the present technology for injection.
- the hydrogel compositions and methods may be applied to subjects seeking a small/moderate enlargement, shape change or contour alteration of a body part or region.
- the conditions that are treated with the hydrogel compositions and methods include, but are not limited to, breast imperfections, e.g ., a breast augmentation, a breast reconstruction, defects due to implant complications; a facial imperfections, e.g., a facial augmentation, wrinkles, lines, a facial reconstruction, scars, sunken cheeks, hollow cheeks, thin lips, nasal imperfections or defects, retro-orbital imperfections or defects, a facial folds, nasolabial lines, perioral lines, and/or a marionette line; skin imperfections, e.g., an augmentation or a reconstruction of the upper arm, lower arm, hand, shoulder, back, neck, torso including abdomen, buttocks, upper leg, lower leg including calves, foot including plantar fat pad, eye, genitals, or other body part, region or area.
- the method comprises intra-epidermal, intra-dermal, and/or subcutaneous injection of cosmetically sufficient amount of the hydrogel
- the cosmetically sufficient amounts of the hydrogel composition are determined based on the alteration and/or improvement desired, the reduction and/or elimination of a soft tissue condition symptom desired, the clinical and/or cosmetic effect desired by the individual and/or physician, and the body part or region being treated.
- the injection of cosmetically sufficient amount of the hydrogel compositions causes one or more of gain of skin elasticity and recoil, improved barrier function, decreased transepidermal water loss, desired small/moderate enlargement, desired shape change or contour alteration, desired, reduction of wrinkles, firming of skin, etc.
- the hydrogel compositions promote cartilage regeneration.
- the hydrogel compositions are used for the treatment of osteoarthritis.
- the amount of Mutable Collagenous Tissue of the present technology present in hydrogel composition is about 0.1 wt.%, about 0.2 wt.%, about 0.3 wt.%, about 0.4 wt.%, about 0.5 wt.%, about 0.6 wt.%, about 0.7 wt.%, about 0.8 wt.%, about 0.9 wt.%, about 1 wt.%, about 2 wt.%, about 3 wt.%, about 4 wt.%, about 5 wt.%, about 6 wt.%, about 7 wt.%, about 8 wt.%, about 9 wt.%, about 10 wt.%, about 11 wt.%, about 12 wt.%, about 13 wt.%, about 14 wt.%, about 15 wt.%, about 16 wt.%, about 17 wt.%, about 18 wt.%, about
- the amount of Mutable Collagenous Tissue of the present technology present in the hydrogel composition is about 0.1 wt.% to about 0.5 wt.%, about 0.25 wt.% to about 2 wt.%, about 1 wt.% to about 5 wt.%, about 2.5 wt.% to about 10 wt.%, about 5 wt.% to about 25 wt.%, or about 10 wt.% to about 50 wt.%.
- the amount of the hydrogel composition administered is, e.g., about 0.01 g, about 0.05 g, about 0.1 g, about 0.5 g, about 1 g, about 5 g, about 10 g, about 20 g, about 30 g, about 40 g, about 50 g, about 60 g, about 70 g, about 80 g, about 90 g, about 100 g, about 150 g, or about 200 g.
- the amount of a hydrogel composition administered is, e.g., about 0.01 g to about 0.1 g, about 0.05 g to about 0.5 g, about 0.1 g to about 1 g, about 0.5 g to about 5 g, about 1 g to about 10 g, about 5 g to about 50 g, about 10 g to about 100 g, or about 50 g to about 200 g.
- the amount of a hydrogel composition administered is, e.g., about 0.01 mL, about 0.05 mL, about 0.1 mL, about 0.5 mL, about 1 mL, about 5 mL, about 10 mL, about 20 mL, about 30 mL, about 40 mL, about 50 mL, about 60 mL, about 70 g, about 80 mL, about 90 mL, about 100 mL, about 150 mL, or about 200 mL.
- the amount of a hydrogel composition administered is, e.g., about 0.01 mL to about 0.1 mL, about 0.05 mL to about 0.5 mL, about 0.1 mL to about 1 mL, about 0.5 mL to about 5 mL, about 1 mL to about 10 mL, about 5 mL to about 50 mL, about 10 mL to about 100 mL, or about 50 mL to about 200 mL.
- the present technology relates to nutritional supplements comprising the Mutable Collagenous Tissue of the present technology.
- the nutritional supplement is formulated as powder, pill, tablet, capsule, beverage, frozen dessert, gelatin dessert, pudding, confectionery, soft gel, chewing gum, candy, gummi candy, gum, caramel, chocolate, tablet sweet, snack, baked good, jelly, jam, yogurt, soup, or stew.
- the nutritional supplement may further comprise moisturizers, antioxidants, minerals, metal sequestrants, proteins, enzymes, vitamins, fats, oils, dietary fiber, fruit extracts, vegetable extracts, meat extracts, yeast extract, solvents, buffers, bulking agents, anti-microbial agents, thickeners, antioxidants, surfactants, emulsifiers, solubilizers, solubilizing aids, colorants (dyes and pigments), perfumes, flavoring agents, sugars, and preservatives.
- the nutritional supplement promotes joint health, supports connective tissues, helps maintain a strong immune system, supports restful sleep and/or healthy digestion. In some embodiments, the nutritional supplement corrects nutritional insufficiency. In some embodiments, the nutritional supplement stimulates testosterone production to maintain healthy libido, stamina and sexual performance.
- the present technology relates to use of the Mutable Collagenous Tissue of the present technology, or any of the compositions disclosed herein, as an extracellular matrix for cell culture and tissue engineering. In one aspect, the present technology relates to use of the Mutable Collagenous Tissue of the present technology, or any of the compositions disclosed herein, as bio-ink for electrospinning and 3D-printing.
- kits comprising a mutable collagenous tissue purified according to any of the methods disclosed herein, and/or any of the compositions disclosed herein.
- the kits comprise the mutable collagenous tissue and/ or the compositions that are packed in suitable containers, or a dispenser device.
- the kits contain the composition along with instructions for use.
- the kits these components may be stored in unit or multi-dose containers, for example, sealed ampoules, vials, bottles, syringes, and test tubes, as an aqueous, preferably sterile, solution or as a lyophilized, preferably sterile, composition for reconstitution.
- the kit may further comprise a second container which holds a diluent suitable for diluting the composition towards a higher volume. Suitable diluents include, but are not limited to, a pharmaceutically acceptable excipient of the composition and a saline solution. Furthermore, the kit may comprise instructions for diluting the composition and/or instructions for administering the composition, whether diluted or not.
- the containers may be formed from a variety of materials such as glass or plastic and may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper which may be pierced by a hypodermic injection needle).
- the kit may further comprise more containers comprising a pharmaceutically acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, culture medium for one or more of the suitable hosts.
- a pharmaceutically acceptable buffer such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, culture medium for one or more of the suitable hosts.
- the kits may optionally include instructions customarily included in commercial packages of therapeutic or cosmetic products, that contain information about, for example, the indications, usage, dosage, manufacture, administration, contraindications and/or warnings concerning the use of such therapeutic or cosmetic products.
- the kit can also comprise, e.g ., a buffering agent, a preservative or a stabilizing agent.
- the kit can also contain a control sample or a series of control samples, which can be assayed and compared to the test sample.
- Each component of the kit can be enclosed within an individual container and all of the various containers can be within a single package, along with instructions for interpreting the results of the assays performed using the kit.
- the kits of the present technology may contain a written product on or in the kit container. The written product describes how to use the reagents contained in the kit. In certain embodiments, the use of the reagents can be according to the methods of the present technology.
- the kit includes a container comprising the compositions of the present disclosure.
- the container may be light impermeable, air-tight and/or leak resistant.
- Exemplary containers include, but are not limited to, syringes, vials, or pouches.
- the kit comprises a handheld injection device.
- the present disclosure provides a prefilled syringe comprising hydrogel comprising the Mutable Collagenous Tissue of the present technology.
- the present disclosure provides applicators for applying the Mutable Collagenous Tissue of the present technology.
- the applicator is selected from sponge, puff, tube, application nozzle, wipes, spray, a spreadable stick, pencil, and discharge pad.
- the applicator may be part of a kit for preparing and/or administering any of the compositions of the present disclosure. Examples
- the present technology is further illustrated by the following Examples, which should not be construed as limiting in any way.
- the examples herein are provided to illustrate advantages of the present technology and to further assist a person of ordinary skill in the art with preparing or using the compositions and systems of the present technology.
- the examples should in no way be construed as limiting the scope of the present technology, as defined by the appended claims.
- the examples can include or incorporate any of the variations, aspects, or embodiments of the present technology described above.
- the variations, aspects, or embodiments described above may also further each include or incorporate the variations of any or all other variations, aspects or embodiments of the present technology.
- Step 1 Sea urchin specimens ( Strongylocentrotus purpuratus and/or Paracentrotus lividus) were collected and stored at -20°C for transportation. The sea urchin specimens were thawed and dissected to eliminate internal tissue. Connective tissue from the body wall was isolated.
- Step 2 Connective tissue from Step 1 was soaked in aqueous isopropyl alcohol (50% v/v) solution for 30 minutes at 4°C, cut into small pieces and stored at -20°C for 12 hours.
- Step 3 The frozen connective tissue was then soaked in ice-cold deionized water at 4°C for 30 minutes, and centrifuged at 4,500 x g at 4°C for 15 minutes. The supernatant was discarded.
- Step 4 The connective tissue from the pellet of Step 3 (50 g) was then suspended in a 2-liter ice-cold, aqueous solution of 1 mM EGTA in PBS buffer and incubated at 4°C for 12 hours with gentle stirring. The mixture was then centrifuged at 4,500 x g at 4°C for 30 minutes, and the supernatant was discarded.
- Step 5 Solid connective tissue from the pellet of Step 4 was dispersed in 2 liters of an ice-cold, aqueous 1.0 M sodium bicarbonate solution and incubated at 4°C with gentle stirring for 24 hours. The mixture was centrifuged at 4,500 x g, 4°C for 30 minutes, and the supernatant was discarded.
- Step 6 The pellet from Step 5 of Example 1 was suspended in a 0.5 M citric acid solution containing trypsin (0.5% w/v) and reacted at 25°C with stirring for 48 hours. The reaction mixture was subjected to centrifugation at 9,000 x g, 4°C for 60 minutes. The supernatant is the extracted mutable collagenous tissue.
- Step 1 Sea cucumber specimens ( Thelenota ananas and/or Cucumaria frondosa ) were collected and stored at -20°C for transportation. As shown in Fig. 2, the sea cucumber specimens were thawed and dissected to eliminate internal tissue. Connective tissue from the body wall isolated.
- Step 2 Connective tissue from Step 1 were then soaked in ice-cold, aqueous ethanol (45% v/v) solution for 30 minutes, cut into small pieces and stored at -20°C for 12 hours.
- Step 3 Frozen connective tissue from Step 2 were soaked in deionized water for 30 minutes, centrifuged at 9,000 c g, 4°C for 30 minutes and the supernatant was discarded.
- Step 4 Connective tissue from the pellet of Step 3 (50 g) was suspended in a 2-liter aqueous solution of 0.8 mM EDTA in 10 mM Tris buffer and mixed for 24 hours under gentle stirring. After the reaction time is completed the mixture is centrifuged at 9,000 x g, 4°C for 30 minutes and the supernatant is discarded.
- Step 5 Solid connective tissue from Step 4 was dispersed in an aqueous 0.1 M sodium hydroxide solution and incubated with gentle stirring at 4°C for 48 hours. The resultant mixture was subjected to centrifugation at 9,000 x g, 4°C for 30 minutes, and the supernatant was discarded.
- Step 6 Remaining collective tissue from Step 5 was suspended in an acetic acid solution (0.1 M) containing pepsin (0.5% w/v) and reacted with stirring for 72 hours. The reaction mixture was subjected to centrifugation at 12,000 x g at 4°C for 60 minutes. The supernatant is the purified mutable collagenous tissue (See the solution in the beaker in FIG. 2) ⁇
- Step 1 Extracted mutable collagenous tissue solution in 0.5 M citric acid from (See Example 1, Step 6, supra) was mixed with 0.5 M potassium chloride at a 1 :5 molar ratio, to induce protein precipitation. The mixture was then separated by centrifugation at 4,500 x g, 4°C for 60 minutes. The supernatant is discarded.
- Step 2 Protein precipitate from Step 1 was dissolved in of 0.5 M citric acid solution and dialyzed against deionized water at 4°C for 72 hours using cellulose membranes with 10 kDa molecular weight cut-off to obtain mutable collagenous tissue solution.
- Step 3 Native mutable collagenous tissue solution from Step 2 was be frozen at - 20°C and subjected to freeze drying to obtain a sheet of mutable collagenous tissue from sea urchin, which had a fibrous character similar to collagen type I (data not shown). The mutable collagenous tissue collagen sheet was ground to prepare mutable collagenous tissue powder.
- Step 4 to determine content and purity of the mutable collagenous tissue, it dissolved in 0.1 M acetic acid, resolved using SDS-PAGE. The gels were stained using Coomassie blue stain. As shown in FIG. 3 (MC-2), the mutable collagenous tissue contained protein bands at and above 150 kDa. Compared to commercially available pure samples of collagen type I from bovine, rat and human tissue (collectively, the controls), the purified sea urchin mutable collagenous tissue of the current disclosure did not show bands of impurities/ degradation products below 150 kDa. Moreover, as shown in FIG.
- the purified sea urchin mutable collagenous tissue featured higher levels of bands corresponding to al, a2 chains, as well as b bands. This pattern is consistent with the purified sea urchin mutable collagenous tissue being collagen type I. Densitometric analysis showed that the purified sea urchin collagen type I was more than 98% pure (data not shown).
- Step 1 Extracted mutable collagenous tissue solution in 0.1 M acetic acid ( See FIG.
- Example 2 (third panel), and Example 2, Step 6, supra) was mixed with sodium chloride (0.1 M) to induce protein precipitation.
- the mixture was subjected to centrifugation at 9,000 x g, 4°C for 60 minutes. The supernatant was discarded.
- Step 2 Protein precipitate from Step 1 was dissolved in 5 ml ice-cold 0.1 M acetic acid and dialyzed against deionized water at 4°C for 48 hours using cellulose membranes with 10 kDa molecular weight cut-off to obtain native collagen solution.
- Step 3 Native collagen solution from Step 2 was frozen at -20°C followed by freeze drying to obtain a sheet of mutable collagenous tissue from sea cucumber. As shown in FIG.
- the sheet of mutable collagenous tissue from sea cucumber had a fibrous character similar to collagen type I.
- the mutable collagenous tissue collagen sheet was ground to prepare mutable collagenous tissue powder.
- Step 4 to determine content and purity of the mutable collagenous tissue from sea cucumber, it dissolved in 0.1 M acetic acid, resolved using SDS-PAGE. The gels were stained using Coomassie blue stain. As shown in FIG. 3 (MC-1), the mutable collagenous tissue from sea cucumber contained protein bands at and above 150 kDa. Compared to commercially available pure samples of collagen type I from bovine, rat and human tissue (the controls), the purified mutable collagenous tissue from sea cucumber of the current disclosure did not show bands of impurities/ degradation products below 150 kDa.
- the purified sea urchin mutable collagenous tissue featured higher levels of bands corresponding to al, a2 chains, as well as b bands. This pattern is consistent with the purified sea cucumber mutable collagenous tissue being collagen type I. Densitometric analysis showed that the purified sea cucumber collagen type I was more than 98% pure (data not shown).
- Collagen content and purity was evaluated by SDS-PAGE.
- Collagen samples were dissolved in acetic acid (0.1 M) to a final concentration of 1 mg/mL and mixed 1 : 1 with Load Running Buffer (Bio Rad, USA).
- Running buffer (1 x) was prepared from concentrated 10* buffer stock solution Tris-Glycine-SDS (Bio Rad, USA). Liquid samples were filtered through a 0.45 pm filter and 7 pL were pipetted into each designated well on a pre-casted polyacrylamide 7.5% Mini-Protean TGX gels (Bio Rad, USA).
- Collagen samples were subjected to electrophoretic characterization of collagen samples. Native collagen types I, II, III and V were used as controls for comparison.
- Collagen type I collagen contains, (a 1 )(I)2(a2)(I) i .
- echinoderm mutable collagenous tissue corresponded with the typical profile of pure collagen type I, as evidenced from the molecular profile study.
- SDS-PAGE pattern exhibited an intense band near 100 kDa followed by a faint band, which correspond to al and a2 chains, respectively.
- a band observed near 200 kDa corresponds to b-chain (dimers of al -chains; data not shown).
- FTIR-ATR Fourier-Transform Infrared Spectroscopy in the attenuated reflectron mode
- the FTIR spectrum of the bovine collagen exhibits a characteristic chemical profile for collagens, and sea cucumber mutable collagenous tissue also confirms with the typical profile of collagen type I.
- the slight differences in the FTIR profile of sea cucumber mutable collagenous tissue, compared to bovine collagen I are likely to be associated to different amino acid distributions and triple helix arrangements. Since FTIR analysis only shows the general chemical composition of collagen, no significant differences were expected.
- FTIR-ATR analyses were performed.
- sea urchin and sea cucumber MCT showed very comparable profiles to each other, which included most of the characteristic FTIR peaks typically found in collagen type I.
- amino acid composition of echinoderm mutable collagenous tissue from sea cucumber and sea urchin was analyzed.
- Bovine collagen isolated from calf skin was used as a standard.
- Table 1 the amino acid composition of echinoderm mutable collagenous tissue from sea cucumber and sea urchin was very similar to each other.
- bovine collagen isolated from calf skin and echinoderm mutable collagenous tissue See Table 1.
- Table 1 Amino acid composition of mutable collagenous tissue, and bovine collagen isolated from calf skin.
- MCT Major amino acids of MCT were glycine (19.0%), glutamic acid (14.0%), proline (12.0%), alanine (9.0%), aspartic acid (9.0%), Arginine (8.0%) and hydroxyproline (6.7%).
- the primary structure of type I collagen is characterized as containing domains with continuous repeating of Gly-X-Y sequence (where X is mostly proline and Y is mostly hydroxyproline), and the very short N- and C-terminal regions called telopeptides (15 to 26 amino acid residues).
- the Gly-X-Y repeating sequence in al chain plays an important role in triple helix formation of secondary structure. Zitnay et al ., Acta Biomateralia, 65: 76-87 (2016); Leon-Mancilla et al ., Journal of Applied Research and Technology 14: 77-85 (2016).
- As an amino acid with the lowest molecular weight glycine residues arranged in the center of triple helix can help helix structure to fold compactly. Cheng et al ., Plos One 12(1):
- glycine is the major amino acid in bovine collagen. According to previous references, the glycine content in bovine collagen ranges from 14 to 33%, about one-quarter of total amino acid, that was consistent with MCT glycine content (19%). Imino acids (proline and hydroxyproline) are important amino acids composing Gly-X-Y repeat sequences in a chain, based on that they could maintain the stability of collagen triple helix with their pyrrolidine rings. Nimptsch et al ., Cellular Tissue Research 343 : 605-617 (2011).
- proline and hydroxyproline are found to be related to environmental temperature. Zhong et al., Food Chem 80(4): C671-C679 (2015). However, when compared to bovine collagen, the ratio of Gly to imino acid (Hyp/Pro) in MCT content was lower, thus suggesting a more efficient stabilization of the Gly-based triple helix by imino acids in MCT.
- Scanning electron microscopy produces images of a sample by scanning the surface with a focused beam of electrons. The electrons interact with atoms in the sample, producing signals that contain information about the sample's surface topography and composition.
- the surface morphology of mutable collagenous tissue extracted from sea cucumber was characterized by SEM imaging, in comparison with collagen type I from calf skin, used as a reference. As shown in FIG. 8, mutable collagenous tissue exhibited a fibrillar collagen structure similar to that of the reference bovine collagen type I; however, the mutable collagenous tissue showed higher porosity and homogeneity than the reference collagen sample (See FIG. 8). The fibers in the mutable collagenous tissue were bigger and longer compared to the reference. Collagen porosity and pore homogeneity is an important performance parameter for wound dressing applications, due to its direct relation with cell attachment and proliferation.
- echinoderms which is suitable for the compositions and kits disclosed herein for applications such as wound dressing, cosmetics, nutrition etc.
- a group having 1-3 cells refers to groups having 1, 2, or 3 cells.
- a group having 1-5 cells refers to groups having 1, 2, 3, 4, or 5 cells, and so forth.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
Abstract
The present disclosure relates generally to methods for extracting or purifying collagen type I from marine animals, and uses of the purified collagen type I. Disclosed herein are the methods for the purification of highly pure mutable collagenous tissue from echinoderms. The current disclosure also relates to pharmaceutical, cosmetic and nutritional applications of the mutable collagenous tissue purified using the methods disclosed herein, and to compositions, kits and articles of manufacture made from the mutable collagenous tissue purified using the methods disclosed herein.
Description
MUTABLE COLLAGENOUS TISSUE FROM ECHINODERMS
TECHNICAL FIELD
[0001] The present technology relates generally to the method for extraction and uses of collagen type I from marine animals. In particular, the present technology relates to the method for the purification of highly pure mutable collagenous tissue from echinoderms, to pharmaceutical, cosmetic and nutritional applications of the mutable collagenous tissue purified using the methods disclosed herein, and to compositions, kits and articles of manufacture made from the mutable collagenous tissue purified using the methods disclosed herein.
BACKGROUND
[0002] The following description of the background of the present technology is provided simply as an aid in understanding the present technology and is not admitted to describe or constitute prior art to the present technology.
[0003] Echinoderms are the members of the phylum Echinodermata , which live exclusively in the sea, with no freshwater or terrestrial representatives. Echinoderms fall into five well-defined taxonomic classes: Crinoidea (sea lilies and feather stars); Asteroidea (starfishes); Ophiuroidea (basket stars and brittle stars); Holothuroidea (sea cucumbers); and Echinoidea (sea urchins, sand dollars, and sea biscuits). Adult echinoderms exhibit radial symmetry, typically pentamerous symmetry. Most echinoderms are bottom-dwelling, and live in very shallow water to very deep sea. Dried, powdered bodies and extracts of sea cucumbers have been made into oils, lotions or other topical salves. The genomes of many echinoderms have been sequenced, and transcriptome profiling has also been performed.
SUMMARY OF THE DISCLOSURE
[0004] In one aspect, the present disclosure provides a method for extracting mutable collagenous tissue from echinoderms, the method comprising: treating a connective tissue from an echinoderm with (a) an aqueous solution of an organic solvent; (b) a chelating agent; and (c) an enzyme solution, to thereby obtain a liquid mutable collagenous tissue. In some
embodiments, the echinoderms are selected from the group consisting of sea urchins, sea cucumbers, star fish, and a combination thereof. In some embodiments, the organic solvent is selected from the group consisting of ethanol, isopropanol, acetone, ethyl acetate, and a combination thereof. In some embodiments, the aqueous solution of the organic solvent comprises about 25% to about 75% organic solvent. In some embodiments, the treatment time with the organic solvent is in the range of from about 1 minute to about 10 hours. In some embodiments, the chelating agent is selected from the group consisting of
ethylenediaminetetraacetic acid (EDTA), ethyleneglycol-bis-(beta -aminoethylether)
N,N,N',N''-tetraacetic acid (EGTA), diethylenetriaminepentaacetic acid (DTP A), and a combination thereof. In some embodiments, the chelating agent further comprises a buffer selected from the group consisting of Tris buffer and phosphate buffer. In some
embodiments, the treatment time with the chelating agent is in the range of from about 1 hour to about 10 days.
[0005] In some embodiments, the enzyme solution comprises trypsin, bromelain, pepsin, papain, or any combination thereof. In some embodiments, the total enzyme concentration in enzyme solution is at a concentration in the range of from about 0.05% to about 10%. In some embodiments, each enzyme in enzyme solution is used at a concentration in the range of from about 0.05% to about 10%. In some embodiments, the treatment time with the enzyme solution is in the range of from about 12 hours to about 30 days. In some
embodiments, the method further comprises: (d) treating the connective tissue with an alkaline solution. In some embodiments, the alkaline solution comprises an alkali metal hydroxide, an alkaline earth metal hydroxide, an alkali metal carbonate, an alkaline earth metal carbonate, an alkali metal bicarbonate, alkaline earth metal bicarbonate or a mixture thereof. In some embodiments, the treatment time with the alkaline solution is in the range of from about 2 hours to about 21 days. In some embodiments, the treatment of the connective tissue with an alkaline solution precedes the treatment of the connective tissue with an enzyme. In some embodiments, the method further comprises: (e) precipitating collagen from the liquid mutable collagenous tissue by adding an inorganic precipitation agent. In some embodiments, the inorganic precipitation agent is an inorganic salt. In some embodiments, the inorganic precipitation agent is sodium chloride, potassium chloride or calcium chloride. In some embodiments, the inorganic precipitation agent is used at a concentration in the
range of from about 0.05 M to about 5 M. In some embodiments, the method further comprises separation of the precipitated collagen. In some embodiments, the precipitated collagen is separated by centrifugation at about 1000 x g to about 50,000 c g. In some embodiments, the method further comprises: (f) dialysis of the precipitated collagen. In some embodiments, the method further comprises: (g) freeze drying the dialyzed collagen to produce a solid mutable collagenous tissue. In some embodiments, the solid mutable collagenous tissue is a powder or a sheet. In some embodiments, the solid mutable collagenous tissue is at least 90%, at least 95%, at least 96%, or at least 97%, at least 98%, at least 99% pure collagen type I. In some embodiments, the solid mutable collagenous tissue is at least 90% pure collagen type I. In some embodiments, the solid mutable collagenous tissue is at least 95% pure collagen type I. In some embodiments, the solid mutable collagenous tissue is at least 98% pure collagen type I.
[0006] In one aspect, the present disclosure provides a mutable collagenous tissue obtainable by the method of any of the methods disclosed herein.
[0007] In one aspect, the present disclosure provides a pharmaceutical, cosmeceutical or cosmetic composition comprising the mutable collagenous tissue obtainable by any of the methods disclosed herein. In some embodiments, the composition further comprises a pharmaceutically acceptable excipient, additive, preservative, and a mixture thereof. In some embodiments, the composition is formulated to a route of administration selected from the group consisting of oral, sublingual, inhalation, rectal, transmucosal, transdermal, intracavemosal, topical, and injection. In some embodiments, the composition is formulated for topical administration. In some embodiments, the composition is formulated as a lotion, ointment, gel, cream, liquid, emulsion, suppository, drop, spray, hydrogel, dressing, bioadhesive gel, aerosol, paste, foam, sunscreen, or powder. In some embodiments, the composition is attached to a solid substrate. In some embodiments, the composition is formulated as an article or a carrier selected from the group consisting of a bandage, insert, syringe-like applicator, pessary, powder, talc, cleanser, and a patch.
[0008] In one aspect, the present disclosure provides a kit comprising a mutable collagenous tissue obtainable by the methods disclosed herein, or any of the compositions disclosed herein. Tn some embodiments, the kit comprises one or more packaging agents, one
or more agents for administering the mutable collagenous tissue, one or more cosmetic agents or therapeutic agents, or any combination thereof.
[0009] In one aspect, the present disclosure provides a method for treating skin in a subject in need thereof, comprising administering to the subject an effective amount of a cosmetic composition comprising a mutable collagenous tissue obtainable by the methods disclosed herein, or any of the compositions disclosed herein. In some embodiments, the method reduces skin wrinkles, enhances skin moisture content, reduces skin moisture evaporation, inhibits erythema, and suppresses the thickening of the skin epidermis layers, exfoliates the skin, enhances skin elasticity, inhibits erythema, alleviates skin photoaging, firms sagging skin, or any combination thereof. In some embodiments, the cosmetic composition is formulated as a lotion, ointment, gel, cream, liquid, paste, drop, spray, hair restorer, lip cream, patch, thickening gel, water-in-oil emulsion, oil-in-water emulsion, solid, sheet, powder, gel, and mousse. In some embodiments, the cosmetic composition is topically applied.
[0010] In one aspect, the present disclosure provides a method for treating a condition in a subject in need thereof, comprising administering to the subject an effective amount of a hydrogel composition comprising a mutable collagenous tissue obtainable by the methods disclosed herein, or any of the compositions disclosed herein. In some embodiments, the condition is selected from the group consisting of (a) a breast imperfections selected from the group consisting of a breast augmentation, a breast reconstruction, and defects due to implant complications; (b) a facial imperfections selected from the group consisting of a facial augmentation, wrinkles, lines, a facial reconstruction, scars, sunken cheeks, hollow cheeks, thin lips, nasal imperfections or defects, retro-orbital imperfections or defects, a facial folds, nasolabial lines, perioral lines, and a marionette line; and (c) a condition requiring an augmentation or a reconstruction of a body part selected from the group consisting of upper arm, lower arm, hand, shoulder, back, neck, torso, abdomen, buttocks, upper leg, lower leg, calves, foot, plantar fat pad, eye, and genitals. In some embodiments, the subject seeks an enlargement, shape change or contour alteration. In some embodiments, the hydrogel composition is administered by intra-epidermal, intra-dermal or subcutaneous injection. In some embodiments, the method promotes cartilage regeneration. In some embodiments, the method is used for the treatment of osteoarthritis.
[0011] In one aspect, the present disclosure provides an applicator comprising a mutable collagenous tissue obtainable by the methods disclosed herein, or any of the compositions disclosed herein. In some embodiments, the applicator is a prefilled syringe. In some embodiments, the prefilled syringe comprises a hydrogel composition. In some embodiments, the applicator is selected from the group consisting of a sponge, puff, tube, application nozzle, wipes, spray, a spreadable stick, pencil, and a discharge pad.
[0012] In one aspect, the present disclosure provides a nutritional supplement comprising a mutable collagenous tissue obtainable by the methods disclosed herein, or any of the compositions disclosed herein. In some embodiments, the nutritional supplement is formulated as powder, pill, tablet, capsule, beverage, frozen dessert, gelatin dessert, pudding, confectionery, soft gel, chewing gum, candy, gummi candy, gum, caramel, chocolate, tablet sweet, snack, baked good, jelly, jam, yogurt, soup, or stew. In some embodiments, the nutritional supplement further comprises one or more ingredients selected from the group consisting of moisturizers, antioxidants, minerals, metal sequestrants, proteins, enzymes, vitamins, fats, oils, dietary fiber, fruit extracts, vegetable extracts, meat extracts, yeast extract, solvents, buffers, bulking agents, anti-microbial agents, thickeners, antioxidants, surfactants, emulsifiers, solubilizers, solubilizing aids, colorants, perfumes, flavoring agents, sugars, and preservatives. In some embodiments, the nutritional supplement promotes joint health, supports connective tissues, helps maintain a strong immune system, supports restful sleep or promotes healthy digestion. In some embodiments, the nutritional supplement corrects a nutritional insufficiency. In some embodiments, the nutritional supplement stimulates testosterone production to maintain healthy libido, stamina or sexual performance.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. 1 A (top) illustrates the structure of collagen. The collagen amino acid chains, called a-chains, have a repeating XaaYaaGly amino acid sequence. While Xaa and Yaa can be any amino acids, they are frequently (2,V)-proline and (2ri',4/i)-4-hydroxyproline, respectively. The a-chains are assembled into a left-handed, triple helical structure.
Individual triple helices assemble in a complex, hierarchical manner, into collagen fibrils and collagen fibers, as shown. FIG. 1 A (bottom) is a photograph illustrating the physical
appearance of a purified mutable collagenous tissue (MCT) sheet formed by a dense network of collagen fibers.
[0014] FIG. IB illustrates the structure of mutable collagenous tissue (MCT). As shown, the fibrils are interconnected via proteoglycan/ glycosamino glycan (GAG).
[0015] FIG. 1C illustrates chemical structure of glycosaminoglycans that crosslink the fibrils of MCT.
[0016] FIG. 2 is a flow chart illustrating an exemplary process for extraction of mutable collagenous tissue. A solution of extracted mutable collagenous tissue from sea cucumber and its appearance after freeze drying to produce a white powder are shown.
[0017] FIG. 3 shows example sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) profiles of the indicated collagen samples. Ladder is a molecular weight ladder used to measure molecular weight based on electrophoretic mobility. Molecular weights of ingredients of the ladder are shown. MC-1 corresponds to the mutable collagenous tissue (MCT) purified from sea cucumber. MC-2 is the purified mutable collagenous tissue (MCT) from sea urchin. MC-3 is purified MCT from starfish. Note the absence of protein bands below 150 kDa in MC-1, MC-2 and MC-3. High molecular weight (> 150 kDa), fibrillar collagen triple helix (al, a2 and b) are shown. Densitometric analysis revealed that MC-1, MC-2 and MC-3 have>98% purity (data not shown). Human: human type I collagen isolated from human fibroblast cells (VitroCol®, Catalog #5007-20ML, Advanced Biomatrix, USA). Rat tail: type I collagen isolated from rat tail (Catalog #C7661 - 10MG, Sigma Aldrich, USA). Bovine: type-I collagen isolated from bovine skin (PureCol®, Catalog #5005- 100ML, Advanced Biomatrix, Aldrich, USA).
[0018] FIG. 4A shows a comparison of example gel electrophoresis profiles of MCT collagen isolated from sea urchin (MCT-SU) and sea cucumber (MCT-SC) against different types of native collagen profiles (I, II, III and V). SC = Sea cucumber MCT.
[0019] FIG. 4B shows an example analysis of purity of collagen samples as analyzed by SDS-PAGE under non-denaturing conditions. H = human; B = bovine; A. a. = Asterias amurensis ; p. 1. = Paracentrotus lividus ; T. a. = Thelenota ananas ; C.f = Cucumaria frondosa.
[0020] FIG. 5 shows an example analysis of electrophoretic mobility of collagen samples by SDS-PAGE under denaturing conditions (with a b-mercaptoethanol treatment). MCT =
sea cucumber MCT. R = rat collagen type I; C = chicken collagen type I; H = human collagen type I; and B = bovine collagen type I.
[0021] FIG. 6A shows example FTIR-ATR spectra for bovine type I collagen, used here as a positive control, and echinoderm mutable collagenous tissue extracted from sea cucumber.
[0022] FIG. 6B shows example FTIR-ATR spectra for mutable collagenous tissue (MCT) isolated from sea urchin and sea cucumber.
[0023] FIG. 7 shows the amino acid composition of mutable collagenous tissue extracted from sea urchin (MCT-SU) and sea cucumber (MCT-SC), compared to bovine collagen type I isolated from calf skin.
[0024] FIG. 8 shows the scanning electron microscopy (SEM) images showing the surface morphology of bovine collagen type I from calf skin, used here as a reference (left image), and mutable collagenous tissue extracted from sea cucumber (right image).
DETAILED DESCRIPTION
[0025] The present disclosure is based, in part, on the discovery that a combination of chemical and enzymatic extracting processes contributes to an increased yield, and higher purity of mutable collagenous tissue. The process described herein also protects the collagen from proteolytic or chemical degradation, and produces mutable collagenous tissue comprising high molecular weight (>150 kDa) collagen. The process described herein also produces mutable collagenous tissue that is free from agents that cause transmissible diseases. Accordingly, the mutable collagenous tissue extracted from echinoderms produced by the methods described herein is useful for a wide variety of applications, including nutritional, cosmetic and therapeutic uses.
[0026] Embodiments according to the present disclosure will be described more fully hereinafter. Aspects of the disclosure may, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. It is to be understood that this present technology is not limited to particular methods, reagents, compounds compositions or biological systems, which can, of course, vary. The terminology used in the
description herein is for the purpose of describing particular embodiments only and is not intended to be limiting.
[0027] Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the present application and relevant art and should not be interpreted in an idealized or overly formal sense unless expressly so defined herein. While not explicitly defined below, such terms should be interpreted according to their common meaning.
[0028] Collagen the most abundant protein in the animal kingdom. It is one of the main structural protein constituents of the extracellular matrix in connective tissues. “Collagen” is a generic term for proteins forming the characteristic triple helix of three polypeptide chains (See, e.g., FIG. 1 A), and all members of the collagen family form these supramolecular structures in the extracellular matrix, although their size, function and tissue distribution vary considerably. There are dozens of types of collagens, which are classified into fibril-forming collagens, which include collagen types I, II, III, V, and XI; Fibril-Associated Collagens with Interrupted Triple helices (FACIT collagens), which include collagen types IX, XII, XIV, XVI, XIX, and XX; microfibrillar collagens, which include collagen type VI; short chain collagens, which include collagen types X and VIII; collagens of the basement membrane, which include collagen type IV.
[0029] The fibril-forming collagens account for about 90% of the total collagen.
Collagen type I, which is the most abundant and best studied collagen, forms more than 90% of the organic mass of bone and is the major collagen of tendons, skin, ligaments, cornea. As shown in FIG. 1 A, collagen type I is composed of a triple helix formed of two identical chains (al), and a third chain (a2), which differs slightly in its chemical composition, which are wound around each other and linked via hydrogen bonds. In animals, individual collagen triple helices assemble in a complex, hierarchical manner that ultimately leads to the macroscopic fibers and networks observed in tissues, such as skin and bone. (See, e. g., FIG. 1A).
[0030] Echinoderms are marine invertebrates widespread in all the oceans and are a significant source of food. Echinoderms have a peculiar connective tissue, called mutable collagenous tissue (MCT). The mutable collagenous tissue (MCT) of echinoderms is unique in its ability to“switch” mechanical states rapidly and reversibly. This collagen allows echinoderms to quickly transition from stiff state to soft state and vice versa. For example, sea cucumbers can soften their entire body to allow movements into the tiniest of holes and cracks, yet stiffen again, e.g ., to wedge itself into a small crack. MCTs are a unique feature of echinoderms found in each of the five extant taxonomic classes. In contrast, human tissue like skin, tendons and ligaments, cannot switch their mechanical state. Recent studies have shown that a gel-like matrix between the collagen fibrils is the key factor in imparting the echinoderms mutable character. In addition to the functions difference, mutable collagenous tissue differs from, e.g. , mammalian collagen with respect to the amino acid primary sequences, associated proteins, and the extent and kind of glycosylation.
[0031] As shown in FIG. 1 A, MCT comprises discontinuous collagen fibrils organized into collagen fibers. As shown in FIG. IB, the fibrils form an elastomeric network of fibrillin microfibrils, which are interconnected by a stress-transfer matrix comprising glycosaminoglycan that binds to and aggregates the fibril. As shown in FIG. 1C, the glycosaminoglycans, are long unbranched polysaccharides consisting of a repeating disaccharide unit. The repeating unit consists of an amino sugar (N-acetylglucosamine or N- acetylgalactosamine) along with an uronic sugar (glucuronic acid or iduronic acid) or galactose. Glycosaminoglycans are highly polar and attract water. They are therefore useful to the body as a lubricant or as a shock absorber, being located primarily on the surface of cells or in the extracellular matrix (ECM).
[0032] It is to be appreciated that certain aspects, modes, embodiments, variations and features of the present methods are described below in various levels of detail in order to provide a substantial understanding of the present technology.
[0033] In practicing the present methods, many conventional techniques in molecular biology, protein biochemistry, cell biology, immunology, microbiology and recombinant DNA are used. See, e.g., Sambrook and Russell eds. (2001) Molecular Cloning: A
Laboratory Manual, 3rd edition; the series Ausubel et al. eds. (2007) Current Protocols in Molecular Biology, the series Methods in Enzymology (Academic Press, Inc., N. Y.);
MacPherson et al. (1991) PCR 1: A Practical Approach (IRL Press at Oxford University Press); MacPherson et al. (1995) PCR 2: A Practical Approach ; Harlow and Lane eds. (1999) Antibodies, A Laboratory Manual, Freshney (2005) Culture of Animal Cells: A Manual of Basic Technique, 5th edition; Gait ed. (1984) Oligonucleotide Synthesis ; U.S. Patent No. 4,683,195; Hames and Higgins eds. (1984) Nucleic Acid Hybridization, Anderson (1999) Nucleic Acid Hybridization, Hames and Higgins eds. (1984) Transcription and Translation; Immobilized Cells and Enzymes (IRL Press (1986)); Perbal (1984) A Practical Guide to Molecular Cloning; Miller and Calos eds. (1987) Gene Transfer Vectors for Mammalian Cells (Cold Spring Harbor Laboratory); Makrides ed. (2003) Gene Transfer and Expression in Mammalian Cells; Mayer and Walker eds. (1987) Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); and Herzenberg et al. eds (1996) Weir’s Handbook of Experimental Immunology. Methods to detect and measure levels of polypeptide gene expression products (i.e., gene translation level) are well-known in the art and include the use of polypeptide detection methods such as antibody detection and quantification techniques. ( ee also, Strachan & Read, Human Molecular Genetics, Second Edition. (John Wiley and Sons, Inc., NY, 1999)).
DEFINITIONS
[0034] As used herein, the singular forms“a,”“an,” and“the” designate both the singular and the plural, unless expressly stated to designate the singular only.
[0035] As used herein, the term“about” in reference to a number is generally taken to include numbers that fall within a range of 1%, 5%, or 10% in either direction (greater than or less than) of the number unless otherwise stated or otherwise evident from the context (except where such number would be less than 0% or exceed 100% of a possible value).
[0036] As used herein,“and/or” refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of
combinations when interpreted in the alternative (“or”).
[0037] As used herein, a“control” is an alternative sample used in an experiment for comparison purpose. A control can be“positive” or“negative.” For example, where the purpose of the experiment is to determine a correlation of the efficacy of a therapeutic agent for the treatment for a particular type of disease, a positive control (a compound or
composition known to exhibit the desired therapeutic effect) and a negative control (a subject or a sample that does not receive the therapy or receives a placebo) are typically employed.
[0038] As used herein, an“echinoderm” is a member of the phylum Echinodermata , which includes animals like sea stars, brittle stars, sea urchins, sand dollars, and sea cucumbers.
[0039] As used herein,“mutable collagenous tissue,” or“MCT” are used interchangeably herein to mean means the extracellular matrix of connective tissue of echinoderms.“Purified mutable collagenous tissue” is defined as a mutable collagenous tissue that is isolated, or substantially isolated, from other proteins. A purified mutable collagenous tissue may be, e.g, greater than 90% pure, greater than 95% pure, or greater than 98% pure.
[0040] As used herein, the term“pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal compounds, isotonic and absorption delaying compounds, and the like, compatible with pharmaceutical administration. Pharmaceutically acceptable carriers and their compositions are known to one skilled in the art and are described, for example, in Remington's
Pharmaceutical Sciences (20th edition, ed. A. Gennaro, 2000, Lippincott, Williams & Wilkins, Philadelphia, Pa.).
[0041] As used herein, the terms“polypeptide”,“peptide” and“protein” are used interchangeably herein to mean a polymer comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. Polypeptide refers to both short chains, commonly referred to as peptides, glycopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. Polypeptides include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature.
[0042] As used herein, the term“implant” refers to artificial devices or tissues which are made to replace and act as missing biological structures. These include, for example, dental implants, artificial body parts such as artificial blood vessels or nerve tissues, bone implants, and the like.
[0043] As used herein, the term“tissue engineering and regeneration” refers to the engineering and regeneration of new living tissues, such as skin, which includes, e.g., healing diseased, traumatized, unhealthy, or unaesthetic tissue.
[0044] As used herein, the terms“pharmaceutical,”“cosmetic,” or“cosmeceutical” composition refers to topical substances that are utilized for pharmaceutical and/or aesthetical purposes. Cosmeceutical or pharmaceutical agents may include substances that exhibit therapeutic activity so as to provide the desired pharmaceutical and/or aesthetical effect. Pharmaceutical, cosmetic or cosmeceutical compositions may be used for firming a defected skin or nail, make ups, gels, lacquers, eye shadows, lip glosses, lipsticks, and the like.
[0045] As used herein, the term“medical device” includes, but are not limited to, a hydrogel, bandages, wound dressings, sleeves, films, adhesives and the like.
Methods of Extracting and/or Purifying Mutable Collagenous Tissue from Echinoderms
[0046] In one aspect, the present disclosure provides a method for extracting mutable collagenous tissue from echinoderms, the method comprising: (a) treating a connective tissue with an aqueous solution of an organic solvent; and (b) treating the connective tissue with a chelating agent; and (c) treating the connective tissue with an enzyme solution to obtain a liquid mutable collagenous tissue.
[0047] Suitable echinoderms for extraction of mutable collagenous tissue include, but are not limited to, sea urchins, sea cucumbers and star fish. Suitable species of echinoderms for extraction of mutable collagenous tissue include, but are not limited to, Strongylocentrotus purpuratus , Arbacia punctulata, Phyllacanthus imperialis, Paracentrotus lividus , Actinopyga echinites, Apostichopus japonicus , Thelenota ananas , Synapta maculata, Holothuria floridana , Holothuria leucospilota , Isostichopus badionotus , Holothuria fuscopunctata , Thelenota rubralineata , Bohadschia argus, Parastichopus californicus , Asterias amurensis, and Cucumaria frondosa.
[0048] Suitable organic solvents include, but are not limited to, ethyleneglycol, methanol, ethanol, isopropanol, pyridine, acetonitrile, nitromethane, dimethyl sulfoxide, ethylacetate, hexylene glycol, 2,2-thiodiglycol, propylene glycol, dioxane, acetone, dicholoroethane, tetrahydrofuran, dicholoromethane, chloroform, diethylether, benzene, toluene, xylene, carbontetrachloride, cyclohexane, petroleum ether, hexane, pentane, and a combination
thereof. In some embodiments, the organic solvent is ethanol, isopropanol, acetone, ethyl acetate or a combination thereof.
[0049] The aqueous solution of the organic solvent kills pathogens and inactivates viruses present in the connective tissue. In some embodiments, the aqueous solution of the organic solvent disinfects the connective tissue. In some embodiments, the aqueous solution of the organic solvent sterilizes the connective tissue. In some embodiments, the aqueous solution of the organic solvent comprises a pharmacologically acceptable disinfectant, antiseptic, antibiotic, antimicrobial, antibiotic or the like.
[0050] In some embodiments, the aqueous solution of the organic solvent comprises 1%- 99% of the organic solvent. In some embodiments, the aqueous solution of the organic solvent comprises about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% organic solvent. In some embodiment, the aqueous solution of the organic solvent comprises organic solvent in the range of from about 5 to about 20%, from about 10 to about 25%, from about 20 to about 50%, from about 25 to about 75%, from about 30 to about 60%, from about 40 to about 70%, or from about 50% to about 80%.
[0051] In some embodiments, the connective tissue is treated with the aqueous solution of an organic solvent in the range of from about 1 minute to about 10 hr. In some
embodiments, the connective tissue is treated with the aqueous solution of organic solvent in the range of from about 1 minute to about 3 minutes, from about 2 minutes to about 10 minutes, from about 5 minutes to about 15 minutes, from about 10 minutes to about 20 minutes, from about 15 minutes to about 30 minutes, from about 20 minutes to about 1 hour, from about 30 minutes to about 90 minutes, from about 1 hour to about 3 hours, from about 2 hours to about 5 hours, or from about 3 hours to about 10 hours.
[0052] In some embodiments, the connective tissue is treated with the aqueous solution of an organic solvent at a temperature in the range of from about -40 °C to about 40 °C. In some embodiments, the connective tissue is treated with the aqueous solution of an organic solvent at about -40 °C, about -30 °C, about -20 °C, about -10 °C, about -5 °C, about 0 °C, about 4 °C, about 10 °C, about 15 °C, about 20 °C, about 25 °C, about 30 °C, about 35 °C, or about 40 °C. In some embodiments, the connective tissue is treated with the aqueous solution of an organic solvent at a temperature in the range of from about -40 °C to about -20 °C, from
about -30 °C to about -10 °C, from about -20 °C to about 0 °C, from about -10 °C to about 4 °C, from about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, from about 15 °C to about 25 °C, from about 20 °C to about 30 °C, from about 25 °C to about 35 °C, or from about 30 °C to about 40 °C.
[0053] In some embodiments, the connective tissue that is treated with the aqueous solution of an organic solvent is recovered by a technique that includes, but not limited to, filtration, centrifugation, and sedimentation. In some embodiments, the connective tissue is further washed with water. In some embodiments, the connective tissue that is treated with the aqueous solution of an organic solvent is subjected to centrifugation with a centrifugal force in the range of from about 1000 c g to about 20,000 c g, and retrieved from the pellet. In some embodiments, the precipitated collagen is retrieved by centrifugation with a centrifugal force the range of from about 1000 c g to about 5,000 c g, from about 2500 c g to about 7,500 c g, from about 5000 x g to about 15,000 c g, or about 7,500 c g to about 20,000 x g. In some embodiments, the centrifugation is carried out at temperature the range of from about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, or from about 15 °C to about 25 °C.
[0054] Suitable chelating agents include, but are not limited to,
ethylenediaminetetraacetic acid (EDTA), ethyleneglycol-bis-(beta -aminoethylether)
N,N,N',N''-tetraacetic acid (EGTA), hydroxy ethylenediaminetriacetic acid (HEDTA), nitrilotriaacetic acid (NTA), sodium gluconate, sodium glucoheptonate,
diethylenetriaminepentaacetic acid (DTP A), ethylenediaminetetraproprionic acid,
triethylenetetraaminehexaacetic acid (TTHA), ethanoldiglycine disodium salt (EDG), diethanolglycine sodium-salt (DEG), and 1,3-propylenediaminetetraacetic acid (PDTA), dicarboxymethyl glutamic acid tetrasodium salt (GLDA), methylglycine-N-N-diacetic acid trisodium salt (MGDA), and iminodi succinate sodium salt (IDS), and the alkali metal, ammonium and substituted ammonium salts thereof. In some embodiments, the chelating agent is EDTA, EGTA or DTPA.
[0055] In some embodiments, the chelating agent is used at a concentration of in the range of from about 0.1 mM to about 500 mM. In some embodiments, the chelating agent is used at a concentration in the range of from about 0.1 mM to about 0.5 mM, from about 0.2 mM to about 1 mM, from about 0.5 mM to about 2.5 mM, from about 1 mM to about 10 mM,
from about 2 mM to about 20 mM, from about 5 mM to about 50 mM, from about 25 mM to about 100 mM, from about 50 mM to about 250 mM, or from about 100 mM to about 500 mM.
[0056] In some embodiments, the chelating agent is used as an aqueous buffered solution, wherein the buffer is phosphate buffer, phosphate buffered saline, Tris-HCl buffer, Sodium citrate-citric acid buffer, Sodium acetate-acetic acid buffer, Cacodylic acid sodium salt-HCl buffer, MES-NaOH buffer, Sodium dihydrogen phosphate-di sodium hydrogen phosphate buffer, Imidazole-HCl buffer, MOPS-KOH buffer, Triethanolamine hydrochloride-NaOH buffer, HEPES-NaOH buffer, Tricine-NaOH buffer, Sodium tetraborate-boric acid buffer, and Bicine-NaOH buffer.
[0057] Suitable buffer has a pH between 3-10. In some embodiments, the buffer has a pH in the range of from about 3 to about 5, from about 4 to about 6, from about 5 to about 7, to about 6 to about 8, or about 7 to about 9.
[0058] In some embodiments, the buffer is used at a concentration in the range of from about 5 mM to about 1 M. In some embodiments, the chelating agent is used at a
concentration of about 5 mM to about 20 mM, from about 10 mM to about 50 mM, from about 25 mM to about 100 mM, from about 50 mM to about 250 mM, from about 100 mM to about 500 mM, or from about 200 mM to about 1 M.
[0059] In some embodiments, the connective tissue is treated with the chelating agent for from about 1 hour to about 10 days. In some embodiments, the connective tissue is treated with the chelating agent for a time in the range of from about 1 hour to about 3 hours, from about 2 hours to about 10 hours, from about 5 hours to about 15 hours, from about 10 hours to about 20 hours, from about 12 hours to about 30 hours, from about 18 hours to about 3 days, from about 1 day to about 4 days, from about 2 days to about 5 days, or from about 3 days to about 10 days.
[0060] In some embodiments, the connective tissue is treated with the chelating agent at a temperature between about 0 °C to about 40 °C. In some embodiments, the connective tissue is treated with the chelating agent at about 0 °C, about 4 °C, about 10 °C, about 15 °C, about 20 °C, about 25 °C, about 30 °C, about 35 °C, or about 40 °C. In some embodiments, the connective tissue is treated with the chelating agent at a temperature in a range of from about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from
about 10 °C to about 20 °C, from about 15 °C to about 25 °C, from about 20 °C to about 30 °C, from about 25 °C to about 35 °C, or from about 30 °C to about 40 °C.
[0061] In some embodiments, the connective tissue that is treated with the chelating agent is recovered by a technique that includes, but not limited to, filtration, centrifugation, and sedimentation. In some embodiments, the connective tissue is further washed with water. In some embodiments, the connective tissue that is treated with the chelating agent is subjected to centrifugation with a centrifugal force in the range of from about 1000 c g to about 20,000 c g, and retrieved from the pellet. In some embodiments, the precipitated collagen is retrieved by centrifugation at about 1000 c g to about 5,000 c g, about 2500g to about 10,000 x g, or from about 5000g to about 20,000 x g. In some embodiments, the centrifugation is carried out at a temperature in the range of from about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, or from about 15 °C to about 25 °C.
[0062] In some embodiments, the treatment of connective tissue with an organic solvent precedes the treatment of the connective tissue with a chelating agent.
[0063] Suitable enzymes include, but are not limited to, trypsin, bromelain, pepsin, chymotrypsin, protease VII, thermolysin, subtilisin, ficin, papain microbial proteases, and combinations thereof.
[0064] In some embodiments, the enzyme is used at a concentration in the range of from about 0.05 % to about 10%. In some embodiments, the enzyme is used at a concentration in the range of from about 0.05 % to about 0.25 %, from about 0.1 % to about 0.5 %, from about 0.2 % to about 1 %, from about 0.5 % to about 2.5 %, from about 1 % to about 5 %, or from about 2 % to about 10%.
[0065] In some embodiments, the connective tissue is treated with the enzyme for a time in the range of from about 12 hours to about 30 days to obtain a liquid mutable collagenous tissue. In some embodiments, the connective tissue is treated with the enzyme for a time in the range of from about 12 hours to about 48 hours, from about 18 hours to about 3 days, from about 24 hours to about 4 days, from about 2 days to about 5 days, from about 3 days to about 10 days, from about 5 days to about 15 days, from about 7 days to about 21 days, or from about 10 days to about 30 days.
[0066] In some embodiments, the connective tissue is treated with the enzyme at a temperature between about 0 °C to about 70 °C. In some embodiments, the connective tissue is treated with the enzyme at about 0 °C, about 4 °C, about 10 °C, about 15 °C, about 20 °C, about 25 °C, about 30 °C, about 35 °C, or about 40 °C. In some embodiments, the connective tissue is treated with the enzyme at a temperature in the range of from about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, from about 15 °C to about 25 °C, from about 20 °C to about 30 °C, from about 25 °C to about 35 °C, from about 30 °C to about 40 °C, from about 35 °C to about 45 °C, from about 40 °C to about 50 °C, from about 45 °C to about 55 °C, from about 50 °C to about 60 °C, from about 55 °C to about 65 °C, or from about 60 °C to about 70 °C.
[0067] In some embodiments, the connective tissue that is treated with the enzyme is subjected to filtration, or centrifugation, and a liquid mutable collagenous tissue is recovered from the filtrate or supernatant. In some embodiments, the connective tissue that is treated with the enzyme is subjected to centrifugation with a centrifugal force in the range of from about 1000 x g to about 20,000 c g, and the liquid mutable collagenous tissue is retrieved from the supernatant. In some embodiments, the liquid mutable collagenous tissue is retrieved from supernatant following centrifugation with a centrifugal force in the range of from about 1000 x g to about 5,000 x g, from about 2500 x g to about 10,000 x g, or from about 5000 c g to about 20,000 c g. In some embodiments, the centrifugation is carried out at about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, or from about 15 °C to about 25 °C.
[0068] In some embodiments, the treatment of connective tissue with a chelating agent precedes the treatment of the connective tissue with an enzyme.
[0069] In some embodiments, the method for extracting mutable collagenous tissue from echinoderms further comprises treating the connective tissue with an alkaline solution.
Suitable alkaline solution comprises an alkaline chemical, which include, but is not limited to, an alkali metal hydroxide, such as sodium hydroxide or potassium hydroxide; ammonium hydroxide; an alkaline earth metal hydroxide, such as magnesium hydroxide or calcium hydroxide; an alkali metal, or alkaline earth metal carbonate, such as sodium carbonate or potassium carbonate; and an alkali metal or an alkaline earth metal bicarbonate, such as sodium bicarbonate, potassium bicarbonate. Suitable alkaline solution has a pH in the range
of from about 8 to about 14. In some embodiments, the suitable alkaline solution has a pH in the range of from about 8 to about 10, from about 9 to about 11, to about 10 to about 12, from about 11 to about 13 or from about 12 to about 14. Suitable alkaline solution has a concentration in the range of from about 0.01 M to about 10 M. In some embodiments, the suitable alkaline solution has a concentration in the range of from about 0.01 M to about 0.1 M, from about 0.05 M to about 0.25 M, from about 0.1 M to about 0. 5 M, from about 0.25 M to about 1 M, from about 0.5 M to about 2.5 M, from about 1 M to about 3 M, from about 2 M to about 6 M, or from about 5 M to about 10 M.
[0070] In some embodiments, the connective tissue is treated with the alkaline solution for a time in the range of from about 2 hours to about 21 days. In some embodiments, the connective tissue is treated with the alkaline solution for a time in the range of from about 2 hours to about 10 hours, from about 5 hours to about 24 hours, from about 12 hours to about 48 hours, from about 18 hours to about 3 days, from about 24 hours to about 4 days, from about 2 days to about 5 days, from about 3 days to about 10 days, from about 5 days to about 15 days, or from about 7 days to about 21 days.
[0071] In some embodiments, the connective tissue is treated with the alkaline solution at a temperature between about 0 °C to about 40 °C. In some embodiments, the connective tissue is treated with the alkaline solution at about 0 °C, about 4 °C, about 10 °C, about 15 °C, about 20 °C, about 25 °C, about 30 °C, about 35 °C, or about 40 °C. In some
embodiments, the connective tissue is treated with the alkaline solution at a temperature in the range of from about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, from about 15 °C to about 25 °C, from about 20 °C to about 30 °C, from about 25 °C to about 35 °C, or from about 30 °C to about 40 °C.
[0072] In some embodiments, the treatment of connective tissue with a chelating agent precedes the treatment of the connective tissue with an alkaline solution, and the treatment of the connective tissue with an alkaline solution precedes the treatment of the connective tissue with an enzyme.
[0073] In some embodiments, the method for extracting mutable collagenous tissue from echinoderms further comprises precipitating collagen from the liquid mutable collagenous
tissue by adding an inorganic precipitation agent. In some embodiment, the precipitated collagen is the native high molecular weight collagen.
[0074] Suitable inorganic precipitation agent is an inorganic salt. In some embodiments, the inorganic precipitation agent is a halide, sulfate, or phosphate salt of an alkali metal or an alkaline earth metal. In some embodiments, the inorganic precipitation agent is sodium chloride, potassium chloride, magnesium chloride, calcium chloride, or a combination thereof. In some embodiments, the inorganic precipitation agent is used at a concentration in the range of from about 0.05 M to about 5 M. In some embodiments, the suitable alkaline solution has a concentration in the range of from about 0.05 M to about 0.25 M, from about 0.1 M to about 0. 5 M, from about 0.25 M to about 1 M, from about 0.5 M to about 2.5 M, from about 1 M to about 3 M, or from about 2 M to about 5 M.
[0075] In some embodiments, the liquid mutable collagenous tissue is incubated with the inorganic precipitation agent for a time in the range of from about 2 minutes to about 24 hr.
In some embodiments, the connective tissue is treated with the alkaline solution for a time in the range of from about 2 minutes to about 10 minutes, from about 5 minutes to about 20 minutes, from about 10 minutes to about 45 minutes, from about 30 minutes to about 2 hours, from about 1 hour to about 3 hours, from about 2 hours to about 5 hours, from about 3 hours to about 10 hours, from about 5 hours to about 15 hours, or from about 8 hours to about 24 hours.
[0076] In some embodiments, the liquid mutable collagenous tissue is incubated with the inorganic precipitation agent at a temperature between about 0 °C to about 40 °C. In some embodiments, the liquid mutable collagenous tissue is incubated with the inorganic precipitation agent at a temperature in the range of about 0 °C, about 4 °C, from about 10 °C, from about 15 °C, from about 20 °C, from about 25 °C, from about 30 °C, from about 35 °C, or about 40 °C. In some embodiments, the liquid mutable collagenous tissue is incubated with the inorganic precipitation agent at a temperature between about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, from about 15 °C to about 25 °C, from about 20 °C to about 30 °C, from about 25 °C to about 35 °C, or from about 30 °C to about 40 °C.
[0077] In some embodiment, the precipitated collagen is separated from supernatant by centrifugation and recovery of the pellet. In some embodiments, the precipitated collagen is
separated by centrifugation at a centrifugal force in the range of from about 1000 x g to about 50,000 x g, and retrieved from the pellet. In some embodiments, the precipitated collagen is retrieved by centrifugation at a centrifugal force in the range of from about 1000 c g to about 5,000 x g, from about 2500 x g to about 10,000 c g, from about 5000 x g to about 20,000 c g, or from about 10,000 x g to about 50,000 x g. In some embodiments, the centrifugation is carried out at a temperature in the range of from about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, or from about 15 °C to about 25 °C.
[0078] In some embodiments, the pellet is resuspended in an acidic solution. In some embodiments, the acidic solution comprises an acid, which includes, but is not limited to acetic acid, citric acid, propionic acid, lactic acid, and hydrochloric acid. In some
embodiments, the acidic solution comprises an acid in the concentration range of from about 0.01 M to about 5 M. The acidic solution comprises an acid in the concentration range of from about 0.01 M to about 0.1 M, from about 0.05 M to about 0.25 M, from about 0.1 M to about 0.5 M, from about 0.25 M to about 1 M, from about 0.5 M to about 2.5 M, from about 1 M to about 3 M, or from about 2 M to about 5 M. in some embodiment, the acidic solution has a pH in the range of from about 1 to about 3, from about 2 to about 4, from about 3 to about 5, or from about 4 to about 6. In some embodiments, the acidic solution is ice cold. In some embodiments, the temperature of the acidic solution has is about 0 °C, about 4 °C, about 10 °C, about 15 °C, about 20 °C, or about 25 °C.
[0079] In some embodiments, the treatment of connective tissue with an enzyme precedes precipitating the native high molecular weight collagen from the liquid mutable collagenous tissue by adding an inorganic precipitation agent.
[0080] In some embodiments, the method for extracting mutable collagenous tissue from echinoderms further comprises dialysis of the pellet, which is resuspended in an acidic solution. In some embodiments, the pellet is dialyzed against water or an aqueous buffer. In some embodiments, the buffer is phosphate buffer, phosphate buffered saline, Tris-HCl buffer, Sodium citrate - citric acid buffer, Sodium acetate - acetic acid buffer, Cacodylic acid sodium salt - HC1 buffer, MES - NaOH buffer, Sodium dihydrogen phosphate - disodium hydrogen phosphate buffer, Imidazole - HC1 buffer, MOPS - KOH buffer, Triethanolamine hydrochloride - NaOH buffer, HEPES - NaOH buffer, Tricine - NaOH buffer, Sodium
tetraborate - boric acid buffer, and Bicine - NaOH buffer. In some embodiments, the buffer has a pH between 3-9. In some embodiments, the buffer has a pH in the range of from about 3 to about 5, from about 4 to about 6, from about 5 to about 7, to about 6 to about 8, or from about 7 to about 9. In some embodiments, the buffer is used at a concentration in the range of from about 5 mM to about 250 mM. In some embodiments, the buffer has a concentration in the range of from about 5 mM to about 50 mM, from about 25 mM to about 100 mM, or from about 50 mM to about 250 mM.
[0081] In some embodiments, the dialysis is carried out at a temperature between about 0 °C to about 40 °C. In some embodiments, the dialysis is carried out at about 0 °C, about 4 °C, about 10 °C, about 15 °C, about 20 °C, about 25 °C, about 30 °C, about 35 °C, or about 40 °C. In some embodiments, the dialysis is carried out at a temperature in a range of from about 0 °C to about 8 °C, from about 4 °C to about 10 °C, from about 5 °C to about 15 °C, from about 10 °C to about 20 °C, from about 15 °C to about 25 °C, from about 20 °C to about 30 °C, from about 25 °C to about 35 °C, or from about 30 °C to about 40 °C.
[0082] In some embodiments, the method for extracting mutable collagenous tissue from echinoderms further comprises freeze drying to produce solid mutable collagenous tissue.
[0083] The mutable collagenous tissue obtained by this process is highly pure (See FIG. 3). In some embodiments, the solid mutable collagenous tissue is a sheet composed of collagen type I. In some embodiments, the solid mutable collagenous tissue is a powder composed of collagen type I. In some embodiments, mutable collagenous tissue obtained by the method disclosed here is at least 90% pure collagen type I. In some embodiments, mutable collagenous tissue obtained by the method disclosed here is at least 92% pure collagen type I. In some embodiments, mutable collagenous tissue obtained by the method disclosed here is at least 95% pure collagen type I. In some embodiments, mutable collagenous tissue obtained by the method disclosed here is at least 98% pure collagen type I.
[0084] In some embodiments, the method for extracting mutable collagenous tissue from echinoderms comprises the following steps in the following order: a. Treating a connective tissue with an aqueous solution of an organic solvent; b. Treating the connective tissue with a chelating agent; and
c. Treating the connective tissue with an enzyme to yield a liquid mutable
collagenous tissue.
[0078] In some embodiments, the method for extracting mutable collagenous tissue from echinoderms comprises the following steps in the following order:
a. Treating a connective tissue with an aqueous solution of an organic solvent; b. Treating the connective tissue with a chelating agent;
c. Treating the connective tissue with an alkaline solution; and
d. Treating the connective tissue with an enzyme to yield a liquid mutable collagenous tissue.
[0079] In some embodiments, the method for extracting mutable collagenous tissue from echinoderms comprises the following steps in the following order:
a. Treating a connective tissue with an aqueous solution of an organic solvent; b. Treating the connective tissue with a chelating agent;
c. Treating the connective tissue with an enzyme to yield a liquid mutable collagenous tissue; and
d. Dialyzing the mutable collagenous tissue against deionized water to obtain a native mutable collagenous tissue solution.
[0080] In some embodiments, the method for extracting mutable collagenous tissue from echinoderms comprises the following steps in the following order:
a. Treating a connective tissue with an aqueous solution of an organic solvent; b. Treating the connective tissue with a chelating agent;
c. Treating the connective tissue with an enzyme to yield a liquid mutable collagenous tissue;
d. Dialyzing the mutable collagenous tissue against deionized water to obtain a native mutable collagenous tissue solution; and
e. Freeze drying the native collagen solution to obtain native mutable collagenous tissue sheet or powder.
[0081] In some embodiments, the method for extracting mutable collagenous tissue from echinoderms comprises the following steps in the following order:
a. Treating a connective tissue with an aqueous solution of an organic solvent; b. Treating the connective tissue with a chelating agent;
c. Treating the connective tissue with an alkaline solution;
d. Treating the connective tissue with an enzyme to yield a liquid mutable collagenous tissue;
e. Precipitating collagen from the liquid mutable collagenous tissue by adding an inorganic precipitation agent;
f. Dialyzing the mutable collagenous tissue against deionized water to obtain a native mutable collagenous tissue solution;
g. Freeze drying the native collagen solution to obtain native mutable collagenous tissue sheet or powder.
[0082] In some embodiments, treating a connective tissue with an aqueous solution of the organic solvent comprises (i) collecting the echinoderm specimens, and dissecting them, (ii) isolating connective tissue from the body wall, (iii) treating a connective tissue with an aqueous solution of an organic solvent (comprising ethanol, isopropanol, acetone and/or ethyl acetate, in concentrations ranging 30 to 50%) for 10 to 60 minutes, (iv) centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min, (v) collecting the connective tissue, and (vi) and washing with in deionized water.
[0083] In some embodiments, treating a connective tissue with a chelating agent comprises (i) treating a connective tissue with an aqueous solution of a chelating agent (comprising ethylene glycol tetraacetic acid (EGTA), ethylene diamine tetraacetic acid (EDTA) and/or diethylene triamine pentaacetic acid (DTP A), together in phosphate buffer saline (PBS), tris buffer or acetate buffer) for 12 to 24 hours, (ii) centrifugation at about 1000 to about 20,000 c g for about 10 min to 60 min, (iii) collecting the connective tissue, and (iv) and washing with in deionized water.
[0084] In some embodiments, treating a connective tissue with an alkaline solution, which comprises (i) treating a connective tissue with an alkaline solution (comprising 0.1 M to 1.0 M sodium hydroxide and/or sodium bicarbonate) for 24 to 48 hours, (ii) centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min, iii) collecting the connective tissue, and (iv) and washing with in deionized water.
[0085] In some embodiments, treating a connective tissue with an enzyme to yield a liquid mutable collagenous tissue comprises (i) treating a connective tissue with an enzyme
(comprising 0.5 to 1.0% trypsin, bromelain, pepsin or papain in a suitable buffer) for 48 to 72
hours, (ii) centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min, (iii) collecting the supernatant, which is the liquid mutable collagenous tissue.
[0086] In some embodiments, precipitating collagen from the liquid mutable collagenous tissue by adding an inorganic precipitation agent comprises (i) adding sodium chloride, potassium chloride and/or calcium chloride to a concentration of 0.5 to 1.0 M to the liquid mutable collagenous tissue, (ii) centrifugation at about 1000 to about 20,000 c g for about 10 min to 60 min, iii) collecting the pellet, and (iv) and resuspending the pellet in 0.1 to 0.5 M acetic acid, citric acid, propionic acid and/or hydrochloric acid to obtain a resuspended pellet.
[0087] In some embodiments, the method for extracting mutable collagenous tissue from echinoderms comprises the following steps in the following order:
a. Treating a connective tissue with an aqueous solution of an organic solvent, which comprises (i) collecting the echinoderm specimens, and dissecting them, (ii) isolating connective tissue from the body wall, (iii) treating a connective tissue with an aqueous solution of an organic solvent (comprising ethanol, isopropanol, acetone and/or ethyl acetate, in concentrations ranging 30 to 50%) for 10 to 60 minutes, (iv) centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min, (v) collecting the connective tissue, and (vi) and washing with in deionized water;
b. Treating the connective tissue with a chelating agent, which comprises (i) treating a connective tissue with an aqueous solution of a chelating agent (comprising ethylene glycol tetraacetic acid (EGTA), ethylene diamine tetraacetic acid (EDTA) and/or diethylene triamine pentaacetic acid (DTP A), together in phosphate buffer saline (PBS), tris buffer or acetate buffer) for 12 to 24 hours, (ii) centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min, (iii) collecting the connective tissue, and (iv) and washing with in deionized water;
c. Treating the connective tissue with an alkaline solution, which comprises (i) treating a connective tissue with an alkaline solution (comprising 0.1 M to 1.0 M sodium hydroxide and/or sodium bicarbonate) for 24 to 48 hours, (ii) centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min,
iii) collecting the connective tissue, and (iv) and washing with in deionized water;
d. Treating the connective tissue with an enzyme to yield a liquid mutable
collagenous tissue, which comprises (i) treating a connective tissue with an enzyme (comprising 0.5 to 1.0% trypsin, bromelain, pepsin or papain in a suitable buffer) for 48 to 72 hours, (ii) centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min, (iii) collecting the supernatant, which is the liquid mutable collagenous tissue;
e. Precipitating collagen from the liquid mutable collagenous tissue by adding an inorganic precipitation agent, which comprises (i) adding sodium chloride, potassium chloride and/or calcium chloride to a concentration of 0.5 to 1.0 M, (ii) centrifugation at about 1000 to about 20,000 x g for about 10 min to 60 min, iii) collecting the pellet, and (iv) and resuspending the pellet in 0.1 to 0.5 M acetic acid, citric acid, propionic acid and/or hydrochloric acid to obtain a resuspended pellet;
f. Dialyzing the resuspended pellet against deionized water for 72 hours using cellulose membranes with 10 kDa molecular weight cut-off to obtain a native mutable collagenous tissue solution;
g. Freeze drying the native collagen solution to obtain native mutable collagenous tissue powder.
[0088] In some embodiments, the method for extracting mutable collagenous tissue from echinoderms comprises the steps of: 1) soaking isolated connective tissue in organic extracting solution for disinfection and extraction of fat-related compounds; 2) pre-treating the connective tissue extract with a chelating buffer solution to eliminate heavy metals and related impurities; 3) soaking the connective tissue extract alkaline solution to eliminate non- collagenous tissue; 4) soaking the connective tissue extract in an enzyme to yield to a liquid mutable collagenous tissue; 5) extracting the native high molecular weight collagen from liquid mutable collagenous tissue isolate by adding inorganic precipitation agent; 6) dissolving of the isolated native collagen in collagen dissolving solution, and 7) isolating high-purity native collagen powder by dialysis followed by freeze drying.
[0089] In some embodiments, the connective tissue is excised from echinoderm species including, but not limited to, sea urchins, sea cucumbers and/or star fish. Species of echinoderms for extraction of mutable collagenous tissue could be selected from the group composed by, but not limited to, Strongylocentrotus purpuratus , Paracentrotus lividus , Apostichopus japonicus , Thelenota ananas , Parastichopus californicus , Asterias amurensis, Cucumaria frondosa.
[0090] In some embodiments, the organic extracting solution is composed by aqueous solutions of ethanol, isopropanol, acetone or ethyl acetate, in concentrations ranging 30 to 50% and total reaction time between 10 to 60 minutes.
[0091] In some embodiments, the chelating buffer solution can be composed by a chelating agent from the group consisting of ethylene glycol tetraacetic acid (EGTA), ethylene diamine tetraacetic acid (EDTA) or diethylene triamine pentaacetic acid (DTP A), together with a buffer solution composed by phosphate buffer saline (PBS), tris buffer or acetate buffer, in ratios ranging 1 :5 to 1 : 10, respectively, and total reaction time between 12 to 24 hours.
[0092] In some embodiments, the alkaline solution is composed of a caustic aqueous solution comprising sodium hydroxide or sodium bicarbonate at a concentration ranging from 0.1 to 1.0 M and total reaction time between 24 to 48 hours.
[0093] In some embodiments, the enzyme, includes but not limited to, trypsin, bromelain, pepsin or papain at concentrations ranging from 0.5 to 1.0% and total reaction time between 48 to 72 hours.
[0094] In some embodiments, the inorganic precipitation agent is an inorganic salt, including, but not limited to, sodium chloride, potassium chloride or calcium chloride, at concentrations ranging from 0.5 to 1.0 M.
[0095] In some embodiments, collagen dissolving solution is composed by an acid including, but not limited to, acetic acid, citric acid, propionic acid or hydrochloric acid, in
concentrations ranging 0.1 to 0.5 M.
[0096] In some embodiments, the mutable collagenous tissue purified by the methods disclosed herein shows a macromolecular structure of collagen type I.
[0097] In some embodiments, the mutable collagenous tissue purified by the methods disclosed herein shows a macromolecular structure of collagen type I, exhibits high purity
(>98%), showing no degradation of the main collagen structure (chemical or biological) or the presence of contaminants from extraction processes (small proteins or peptides).
[0098] In some embodiments, the mutable collagenous tissue purified by the methods disclosed herein shows high molecular weight (>150kDa),
[0099] In some embodiments, the mutable collagenous tissue purified by the methods disclosed herein shows high molecular weight (>150 kDa), as shown by SDS gel electrophoresis.
[0100] In some embodiments, the mutable collagenous tissue purified by the methods disclosed herein exhibits al, and a2 chains, as shown by SDS-PAGE electrophoresis. In some embodiments, the mutable collagenous tissue purified by the methods disclosed herein exhibits protein bands in a, b and g regions, as shown by SDS-PAGE electrophoresis. In some embodiments, the mutable collagenous tissue purified by the methods disclosed herein exhibits protein bands at or above 150 kDa, as shown by SDS-PAGE electrophoresis. In some embodiments, the mutable collagenous tissue purified by the methods disclosed herein exhibits less than 2% impurities and degradation products that run substantially below 150 kDa, as shown by SDS-PAGE electrophoresis.
[0101] In one aspect, the present disclosure provides a mutable collagenous tissue obtainable by any of the methods described above. In some embodiments, the mutable collagenous tissue obtainable by any of the methods described herein is a liquid mutable collagenous tissue, a sheet of mutable collagenous tissue, a mutable collagenous tissue powder or a combination thereof.
Compositions
[0102] In one aspect, the present disclosure provides a pharmaceutical, cosmeceutical or cosmetic composition comprising the mutable collagenous tissue obtainable by any of the methods described herein. In some embodiments, the provides a pharmaceutical, cosmeceutical or cosmetic composition comprises from about 0.01% to about 99.9% by weight of the composition mutable collagenous tissue obtainable by any of the methods described herein. In some embodiments, the mutable collagenous tissue obtainable is mixed with one or more pharmaceutically acceptable excipients, additives, and/or preservatives. In
some embodiments, the excipients include diluents, lubricants, binders, disintegrates, buffers, dispersants, surfactants, coloring agents, perfumes, aromatics, or sweeteners.
[0103] Suitable pharmaceutically acceptable excipients or pharmaceutically acceptable carriers, may include solvents, dispersion media, coatings, isotonic and absorption delaying agents and the like, and combinations comprising one or more of the foregoing carriers as described, for instance, in Remington’s Pharmaceutical Sciences , 15th Ed. Easton: Mack Publishing Co. pp. 1405-1412 and 1461-1487 (1975), and The National Formulary XIV 14th Ed., Washington: American Pharmaceutical Association (1975). Suitable carriers include, but are not limited to, calcium carbonate, carboxymethylcellulose, cellulose, citric acid, dextrate, dextrose, ethyl alcohol, glucose, hydroxymethylcellulose, lactose, magnesium stearate, maltodextrin, mannitol, microcrystalline cellulose, oleate, polyethylene glycols, potassium diphosphate, potassium phosphate, saccharose, sodium diphosphate, sodium phosphate, sorbitol, starch, stearic acid and its salts, sucrose, talc, vegetable oils, water, and combinations comprising one or more of the foregoing carriers. Except insofar as any conventional media or agent is incompatible with the emulsions of the present invention, their use in pharmaceutical, cosmeceutical or cosmetic compositions is contemplated.
Supplementary active ingredients also can be incorporated into the pharmaceutical, cosmeceutical or cosmetic compositions.
[0104] The pharmaceutical, cosmeceutical or cosmetic compositions comprising the mutable collagenous tissue disclosed herein described herein can be formulated for various routes of administration. Suitable routes of administration include, but are not limited to, oral, sublingual, inhalation, rectal, transmucosal, transdermal, intracavemosal, topical, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.
[0105] The pharmaceutical, cosmeceutical or cosmetic compositions for topical
administration include, but are not limited to, lotions, ointments, gels, creams, liquids, emulsions, suppositories, drops, sprays, hydrogel, bioadhesive gels, aerosols, pastes, foams, sunscreens, and powders, or in the form of an article or carrier, such as a bandage, insert, syringe-like applicator, pessary, powder, talc or other solid, cleanser (leave on and wash off product), and agents that favor penetration within the pilosebaceous gland.
[0106] The pharmaceutical, cosmeceutical or cosmetic compositions for topical administration may additionally comprise organic solvents, emulsifiers, gelling agents, moisturizers, stabilizers, surfactants, wetting agents, preservatives, time release agents, and minor amounts of humectants, sequestering agents, dyes, perfumes, and other components commonly used in cosmetic or pharmaceutical compositions for topical and mucosal administration.
[0107] In some embodiments, the pharmaceutical, cosmeceutical or cosmetic compositions may comprise a penetration-enhancing agent for enhancing penetration of the nanoemulsion through the stratum corneum and into the epidermis or dermis. Suitable penetration enhancing agents include, but are not limited to, alcohols such as ethanol, triglycerides, fatty acids ( e.g ., lauric acid, oleic acid, myristic acid), fatty alcohols (e.g., myristyl or oleoyl alcohols), fatty esters (e.g., isopropyl myristate), lipids, anionic and nonionic surfactants and aloe compositions. The amount of the penetration-enhancing agent may comprise from about 0.5% to about 40% by weight of the composition.
[0108] Topical administration includes administration to the skin, mucosa, and squamous epithelium, including surface of the hair follicle and pilosebaceous unit. In some
embodiments, the composition enters the epidermis, dermis, mucosa, squamous epithelium, or any combination thereof. In some embodiments, the composition permeates into the epidermis and dermis via the follicular route using skin pores and hair follicles. In some embodiments, the composition diffuses through the skin, skin pores, nail, scalp, hair follicles, lateral or proximal folds, nail, hyponichium, or a combination thereof.
[0109] In some embodiments, the composition for delivery via a“patch” comprising the mutable collagenous tissue is envisioned. As used herein a“patch” comprises at least a topical composition and a covering layer, such that the patch can be placed over the area to be treated. Preferably, the patch is designed to maximize delivery through the stratum corneum and into the epidermis or dermis, while minimizing absorption into the circulatory system, and little to no skin irritation, reducing lag time, promoting uniform absorption, and reducing mechanical rub-off and dehydration.
[0110] Adhesives for use with the drug -in-adhesive type patches are well known in the art. Suitable adhesive include, but are not limited to, polyisobutylenes, silicones, and acrylics. These adhesives can function under a wide range of conditions, such as, high and low
humidity, bathing, sweating etc. Preferably the adhesive is a composition based on natural or synthetic rubber; a polyacrylate such as, polybutylacrylate, polymethylacrylate, poly-2 - ethylhexyl acrylate; polyvinylacetate; polydimethylsiloxane; or and hydrogels ( e.g ., high molecular weight polyvinylpyrrolidone and oligomeric polyethylene oxide). The most preferred adhesive is a pressure sensitive acrylic adhesive, for example Durotak® adhesives (e.g., Durotak® 2052, National Starch and Chemicals). The adhesive may comprise a thickener, such as a silica thickener (e.g., Aerosil, Degussa, Ridgefield Park, N. J.) or a crosslinker such as aluminumacetylacetonate.
[0111] Suitable release liners include but are not limited to occlusive, opaque, or clear polyester films with a thin coating of pressure sensitive release liner (e.g., silicone- fluorsilicone, and perfluorcarbon based polymers.
[0112] Backing films may be occlusive or permeable and are derived from synthetic polymers like polyolefin oils polyester, polyethylene, polyvinylidine chloride, and
polyurethane or from natural materials like cotton, wool, etc. Occlusive backing films, such as synthetic polyesters, result in hydration of the outer layers of the stratum comeum while non-occlusive backings allow the area to breath (i.e., promote water vapor transmission from the skin surface). More preferably the backing film is an occlusive polyolefin foil (Alevo, Dreieich, Germany). The polyolefin foil is preferably about 0.6 to about 1 mm thick.
[0113] The shape of the patch can be flat or three-dimensional, round, oval, square, and have concave or convex outer shapes, or the patch or bandage can also be segmented by the user into corresponding shapes with or without additional auxiliary means.
[0114] The pharmaceutical, cosmeceutical or cosmetic compositions may be applied in a single administration or in multiple administrations. The pharmaceutical, cosmeceutical or cosmetic compositions can be applied for any suitable time period, such as once or multiples times per day. The compositions can be applied for at least once a week, at least twice a week, at least once a day, at least twice a day, multiple times daily, multiple times weekly, biweekly, at least once a month, or any combination thereof. The pharmaceutical, cosmeceutical or cosmetic compositions are applied for a period of time of about one month, about two months, about three months, about four months, about five months, about six months, about seven months, about eight months, about nine months, about ten months, about eleven months, about one year, about 1.5 years, about 2 years, about 2.5 years, about 3 years,
about 3.5 years, about 4 years, about 4.5 years, and about 5 years. Between applications, the application area may be washed to remove any residual mutable collagenous tissue.
[0115] Preferably, the pharmaceutical, cosmeceutical or cosmetic compositions are applied to the skin area in an amount of from about 0.001 mL/cm2 to about 5.0 mL/cm2. An exemplary application amount and area is about 0.2 mL/cm2, although any amount from 0.001 mL/cm2 up to about 5.0 mL/cm2 can be applied. Following topical administration, the nanoemulsion may be occluded or semi-occluded. Occlusion or semi-occlusion may be performed by overlaying a bandage, polyoleofm film, impermeable barrier, or semi-impermeable barrier to the topical preparation. Preferably, after application, the treated area is covered with a dressing.
[0116] In some embodiments, the pharmaceutical, cosmeceutical or cosmetic compositions described herein are formulated for mucosal delivery, for example by contacting any one of the compositions described herein to a nasal mucosal epithelium, a bronchial or pulmonary mucosal epithelium, an oral, gastric, intestinal or rectal mucosal epithelium, or a vaginal mucosal epithelium. In some embodiments, the compositions described herein are formulated for intranasal delivery, (e.g., nasal mucosal delivery or intranasal mucosal delivery).
[0117] The pharmaceutical, cosmeceutical or cosmetic compositions for oral administration include, but are not limited to, tablets, pills, soft or hard capsules, granules, powders, solution, or emulsion.
[0118] In some embodiments pharmaceutical, cosmeceutical or cosmetic compositions for topical administration include a hydrogel, an implant, an artificial body part, a tissue engineering and regeneration system, and a wound dressing, or a medical device.
[0119] The compositions comprising the mutable collagenous tissue disclosed herein can include a carrier, which can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thiomerasol, and the like. In many cases, it will be
advantageous to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
[0120] The mutable collagenous tissue disclosed herein can be formulated in a carrier system. The carrier can be a colloidal system. The carrier can also be a polymer, e.g ., a biodegradable, biocompatible polymer matrix. In one embodiment, one or more therapeutic agent can be embedded in the polymer matrix, while maintaining the agent’s structural integrity. The polymer may be natural, such as polypeptides, proteins or polysaccharides, or synthetic, such as poly a-hydroxy acids. Examples include carriers made of, e.g. , fibronectin, elastin, cellulose acetate, cellulose nitrate, polysaccharides, fibrin, and combinations thereof. In one embodiment, the polymer is poly-lactic acid (PLA) or copoly lactic/glycolic acid (PGLA). The polymeric matrices can be prepared and isolated in a variety of forms and sizes, including liposomes, nanofibers, microspheres and nanospheres. See Reddy, Ann. Pharmacother ., 34(7-8):915-923 (2000)).
Exemplary Uses of the Mutable Collagenous Tissue of the Present Technology
[0121] The Mutable Collagenous Tissue of the present technology, is a unique natural extracellular matrix composed of collagen type I, and glycosaminoglycan, which is bound to the collagen type I. This structure creates an optimal environment for new collagen biosynthesis, promoting integrin binding, which impart the necessary pharmacological properties helpful for the pharmacological and cosmetic applications disclosed herein. The Mutable Collagenous Tissue of the present technology is biodegradable and exhibits weak antigenicity, making it a suitable for biomedical applications.
[0122] The following properties of the Mutable Collagenous Tissue of the present technology, significantly increase the effectiveness of the Mutable Collagenous Tissue of the present technology in wound healing: biocompatibility, ability to promote of cell attachment, physical and chemical stability, improved mechanical properties, and the antimicrobial, and hemostatic properties of the glycosaminoglycan component present in the Mutable
Collagenous Tissue of the present technology.
[0123] The Mutable Collagenous Tissue of the present technology is useful in methods relating to the wound healing, tissue repair and the treatment of conditions associated to chronic wounds, diabetic wounds, etc. In one aspect, the present technology relates to the
treatment of a wound in a subject in need thereof through the administration of therapeutically effective amounts of a wound healing formulation comprising the Mutable Collagenous Tissue of the present technology. In some embodiments, the methods enhance cell attachment and proliferation, or promotion of cell-specific morphology and function. In some embodiments, the wound deals damage to one or more cell type, including but not limited to endothelial cells, hepatocytes, and muscle cells.
[0124] In some embodiments, the wounds to be treated include, but are not limited to, an incision wound, a chop wound, a puncture wound, a contused wound, a laceration wound, an impalement injury, dermabrasion, decollement, an abrasion, a crushed wound, contusion, a firearm wound, a blast injury, a biting wound, excoriation, an explosion injury, a bruise, an external wound, a bedsore, a surgical wound, a burn wound, a gunshot wound, subcutaneous abscess, sutured tear, contaminated tear, stasis ulcer, leg ulcer, foot ulcer, venous ulcer, diabetic ulcer, ischemic ulcer, pressure ulcer, an acute/chronic wound, an open injury and a closed injury. In some embodiments, the wound is a chronic wound or a diabetic wound.
[0125] In some embodiments, the Mutable Collagenous Tissue of the present technology is formulated as a wound healing formulation, including but not limited to, traditional dressing, antimicrobial dressing, anti-inflammatory and analgesic dressing, wound-drug delivery, medicated suture, or tissue-engineered skin substitute. In some embodiments, the Mutable Collagenous Tissue of the present technology is formulated as a wound healing formulation, including but not limited to, a lotion, ointment, gel, cream, liquid, emulsion, suppository, drop, spray, hydrogel, dressing, bioadhesive gel, aerosol, paste, foam, sunscreen, or powder.
[0126] The amount of Mutable Collagenous Tissue of the present technology in the wound healing formulation may be about 0.1 wt.%, about 0.2 wt.%, about 0.3 wt.%, about 0.4 wt.%, about 0.5 wt.%, about 0.6 wt.%, about 0.7 wt.%, about 0.8 wt.%, about 0.9 wt.%, about 1 wt.%, about 2 wt.%, about 3 wt.%, about 4 wt.%, about 5 wt.%, about 6 wt.%, about 7 wt.%, about 8 wt.%, about 9 wt.%, about 10 wt.%, about 11 wt.%, about 12 wt.%, about 13 wt.%, about 14 wt.%, about 15 wt.%, about 16 wt.%, about 17 wt.%, about 18 wt.%, about 19 wt.%, about 20 wt.%, about 22 wt.%, about 24 wt.%, about 26 wt.%, about 28 wt.%, about 30 wt.%, about 32 wt.%, about 34 wt.%, about 36 wt.%, about 38 wt.%, about 40 wt.%, about 42 wt.%, about 44 wt.%, about 45 wt.%, or any range including and/or in between any two of these values. In some embodiments, the formulations of the Mutable Collagenous Tissue of the
present technology may include additional ingredients, including, but not limited to, natural inert polymers, natural bioactive polymers, and synthetic polymers.
[0127] The wound healing formulation may include about 0.001 wt.% to about 5 wt.% of a wound healing promoter. Exemplary wound-healing promoters include, but are not limited to, an anti-inflammatory drug ( e.g ., acetaminophen), zinc, zinc oxide, an inorganic zinc salt e.g ., ZnCb), a zinc complex, vitamin E, vitamin C, a fibroblast growth factor, a platelet- derived growth factor (see, e.g., Gowda, San tosh, et al. "Topical application of recombinant platelet-derived growth factor increases the rate of healing and the level of proteins that regulate this response." International Wound Journal 12.5 (2015): 564-57), or a combination of any two or more thereof. The total amount of wound healing promoter(s) in wound healing formulation may be about 0.001 wt.%, about 0.002 wt.%, about 0.003 wt.%, about 0.004 wt.%, about 0.005 wt.%, about 0.006 wt.%, about 0.007 wt.%, about 0.008 wt.%, about 0.009 wt.%, about 0.01 wt.%, about 0.02 wt.%, about 0.03 wt.%, about 0.04 wt.%, about 0.05 wt.%, about 0.06 wt.%, about 0.07 wt.%, about 0.08 wt.%, about 0.09 wt.%, about 0.1 wt.%, about 0.2 wt.%, about 0.3 wt.%, about 0.4 wt.%, about 0.5 wt.%, about 0.6 wt.%, about 0.7 wt.%, about 0.8 wt.%, about 0.9 wt.%, about 1 wt.%, about 2 wt.%, about 3 wt.%, about 4 wt.%, about 5 wt.%, or any range including and/or in between any two of these values.
[0128] In any embodiment disclosed herein, the wound healing formulation may include a solvent and an effective amount of at least one agent selected from the group consisting of a growth factor, an antimicrobial agent, a peptide, a biopolymer, a binder, a colorant, a deodorant agent, a filler, a plasticizer, a viscosity modifier, or any combination thereof.
Additionally, or alternatively, in some embodiments, the solvent may be an aqueous solvent or an organic solvent. Additionally, or alternatively, in some embodiments, the aqueous solvent may include a dilute organic acid, for example, acetic acid, citric acid, or a combination thereof.
[0129] In any embodiment disclosed herein, the antimicrobial agent may include one or more of polyhexamethylene biguanide, acetic acid, benzoic acid, povidone iodine, natamycin, nisin, citric acid, sorbic acid, propionic acid, honey, sulfites, or any combination thereof. In any embodiment disclosed herein, the peptide may be one or more of defensins, histatins, cathelicidin LL-37, or any combination thereof.
[0130] The Mutable Collagenous Tissue of the present technology is useful in methods relating to cosmetics and skin health. Accordingly, in one aspect, the present technology relates to the treatment of skin in a subject in need thereof, through the administration of cosmetically effective amounts of a cosmetic composition comprising the Mutable
Collagenous Tissue of the present technology. In some embodiments, the methods include, but are not limited to, reducing skin wrinkles, enhancing skin moisture content, reducing skin moisture evaporation, inhibiting erythema, and suppressing the thickening of skin epidermis layers, exfoliating skin, enhancing skin elasticity, inhibiting erythema, and/or alleviating skin photoaging. In some aspects, the cosmetic composition is topically applied. In some embodiments, the cosmetic composition comprising the Mutable Collagenous Tissue of the present technology is formulated as a lotion, ointment, gel, cream, liquid, paste, drop, spray, hair restorer, lip cream, patch, thickening gel, water-in-oil emulsion, oil-in-water emulsion, solid, sheet, powder, gel, and mousse.
[0131] In some embodiments, the amount of Mutable Collagenous Tissue of the present technology present in the cosmetic composition is about 0.1 wt.%, about 0.2 wt.%, about 0.3 wt.%, about 0.4 wt.%, about 0.5 wt.%, about 0.6 wt.%, about 0.7 wt.%, about 0.8 wt.%, about 0.9 wt.%, about 1 wt.%, about 2 wt.%, about 3 wt.%, about 4 wt.%, about 5 wt.%, about 6 wt.%, about 7 wt.%, about 8 wt.%, about 9 wt.%, about 10 wt.%, about 11 wt.%, about 12 wt.%, about 13 wt.%, about 14 wt.%, about 15 wt.%, about 16 wt.%, about 17 wt.%, about 18 wt.%, about 19 wt.%, about 20 wt.%, about 22 wt.%, about 24 wt.%, about 26 wt.%, about 28 wt.%, about 30 wt.%, about 32 wt.%, about 34 wt.%, about 36 wt.%, about 38 wt.%, about 40 wt.%, about 42 wt.%, about 44 wt.%, about 45 wt.%, or any range including and/or in between any two of these values. In some embodiments, the amount of Mutable Collagenous Tissue of the present technology present in the cosmetic composition is about 0.1 wt.% to about 0.5 wt.%, about 0.25 wt.% to about 2 wt.%, about 1 wt.% to about 5 wt.%, about 2.5 wt.% to about 10 wt.%, about 5 wt.% to about 25 wt.%, or about 10 wt.% to about 50 wt.%.
[0132] In some embodiments, the cosmetic composition further comprises cosmetically acceptable carriers or additives selected from the group consisting of moisturizers, antioxidants, cell activators, whitening agents, UV inhibitors, active oxygen removing agents, metal sequestrants, anti-inflammatory agents, antihistamines, vitamins, plant extracts, skin astringents, skin function-enhancing agents, disinfectants, oils, solvents, buffers, bulking
agents, anti-microbial agents, thickeners, antioxidants, surfactants, emulsifiers, solubilizers, solubilizing aids, colorants (dyes and pigments), perfumes, and preservatives.
[0133] Suitable cosmetically acceptable carriers or additives are glycerol, 1,3-butylene glycol, proteins or their derivatives or hydrolyzates ( e.g ., elastin or keratin, etc.),
mucopolysaccharides and their derivatives (e.g., hyaluronic acid, hydrolyzed hyaluronic acid, chondroitin sulfate, etc.), amino acids and their derivatives (e.g, histidine, serine, glycine, theanine, aspartic acid, arginine, lysine, pyrrolidone carboxylic acid, N-methyl-L-serine, etc.), carbohydrates (e.g, sorbitol, erythritol, trehalose, inositol, glucose, xylitol, N-acetyl glucosamine, raffmose, sucrose and its derivatives, dextrin and its derivatives, honey, etc.), phosphorylated oligosaccharides and their mineral salts, D-panthenol and its derivatives, glycolipids, ceramides, glycosyl ceramides, sweet Hydrangea leaf extract, almond extract, angelica extract, avocado extract, Althaea officinalis extract, Arnica extract, hot spring water, Citrus peel extract, aloe extract, Malva sylvestris extract, Scutellaria baicalensis extract, Coptidis rhizoma extract, St. John's wort extract, Lamium album extract, Ononis extract, chamomile extract, oats extract, glabridin, glabrene, liquiritin, isoliquiritin and licorice extracts containing the same, water-soluble and oil-soluble licorice extracts, bramble extract, yellow Himalayan raspberry extract, honeysuckle (Lonicera japonica Thunb) extract, quince seed (Cydonia oblonga ) extract, Sophora flavescens extract, gardenia extract, Sasa veitchii extract, water-soluble chlorophyll, maple leaf extract, Citrus extract, grapefruit extract, watercress extract, Gentiana scabra extract, geranium herb extract, burdock extract, sesame extract, wheat extract, wheat germ extract, comfrey (Symphytum officinale ) extract, Asiasari radix extract, cactus extract, Saponaria officinalis extract, salvia (sage) extract, hawthorn extract, Rehmannia glutinosa extract, perilla extract, herb Robert extract, meadow sweet extract, Paeoniae radix extract, ginger extract, Japanese iris extract, white birch extract, mentha (peppermint, Mentha spicata, spearmint, etc.) extracts, Malva (marshmallow) extract, Equisetum arvense extract, Cnidium rhizome extract, Morus alba extract, Thymus vulgaris extract, camellia extract, Angelica acutiloba extract, plant worm extract, corn extract, Houttuynia cordata extract, hibiscus extract, white willow extract, Potentilla tormentilla extract, parsley extract, Job's tears (coix seed) extract, Hamamelis virginiana (witch-hazel) extract, rose extract, cypress extract, sunflower extract, Tussilago farfata extract, butcher's broom extract, grape extract, prune (Japanese plum) extract, sponge gourd extract, avocado
extract, okra extract, linden extract, Alpinia speciosa leaf extract, Paeonia suffruticosa extract, hop extract, jojoba leaf extract, jojoba oil, macadamia nut oil, olive oil, apricot-kernel oil, persic oil, safflower oil, sunflower seed oil, avocado oil, camellia oil, almond oil, perilla oil, sesame oil, borage ( Borago officinalis) oil, cacao butter, shea butter, pine extract, horse chestnut extract, Sapindus mukorossi extract, mucin, Lithospermi extract, meadowfoam oil, Melissa extract, cornflower extract, Saxifiaga stolonifera extract, lily extract, lime extract, lavender extract, apple extract, Gentiana scabra extract, phospholipids (from soybean, egg yolk, etc.), milk vetch extract, Sanguisorba officinalis extract, tea (oolong tea, green tea, black tea, etc.) extracts, Akebia stem extract, urea, Siraitia grosvenorii extract, white fungus polysaccharide, seaweed extracts (brown algae such as Laminariaceae Bory, Saccharina japonica, Undaria pinnatifida, Sargassum fusiforme, Fucus vesiculosus, Costaria costata, Saccharina gyrata, Ecklonia cava, Ecklonia stolonifera, Alaria crassifolia Kjellman,
Sargassum fukvellum, and giant kelp); red algae such as Ceylon moss, Kappaphycus striatum, Eucheuma denticulatum, Chondrus ocellatus Holmes, Chondracanthus tenellus, Nithophyllum, Pyropia tenera, Polyopes affinis, Grateloupia crispata, Gloiopeltis tenax, Gracilaria vermiculophylla, Ceratodictyon spongiosum, Ceramium kondoi, and
Campylaephora hypnaeoides; green algae such as chlorella, green laver, Dunaliella
Chlorococcales, Ulva pertusa, Prasiola japonica, Aegagropila linnaei, Cladophoraceae, Acetabularia ryukyuensis, Chaetomorpha crassa, Chaetomorpha moniligera, Monostroma nitidum, and Spirogyra; blue green algae such as spirulina), plant fermented liquids such as pear juice fermented liquid, hibiscus fermented liquid, rice fermented liquid, vitamin E and its derivatives, vitamin A and its derivatives, carotenoids ( e.g ., carotene, lycopene, astaxanthin, capsanthin, etc.), vitamin B (e.g., thiamine hydrochloride, thiamine sulfate, riboflavin, riboflavin acetate, pyridoxine hydrochloride, pyridoxine dioctanoate, flavin adenine nucleotide, cyanocobalamine, folic acids, nicotinamide, benzyl nicotinate and other nicotinic acids, cholines, etc.), ascorbic acid and its derivatives, vitamin D and its derivatives, mevalonolactone, rutin and its derivatives, thiotaurine, taurine, hydroquinone and its derivatives, catechin and its derivatives, glabridin, glabrene, liquiritin, isoliquiritin and licorice extracts containing the same, glutathione and its derivatives, gallic acid and its derivatives, Pycnogenol, bitter orange peel extract, Oenothera biennis extract, cucumber extract, Millettia reticulata extract, cholesterol and its derivatives, superoxide dismutase,
Ginkgo biloba extract, ginseng extract, Rosa maikwai extract, Chaenomeles sinensis extract, Alnus firma extract, stevia extract, lettuce extract, tea extracts (oolong tea, black tea, green tea, etc.), microorganism fermentation metabolites, Ganoderma lucidum extract, eggshell membrane extract, placenta extract, Siraitia grosvenorii extract..
[0134] In some embodiments, the cosmetic composition comprises ingredients one or more selected from the group consisting of the Mutable Collagenous Tissue of the present technology, organic aloe leaf juice (Aloe barbadensis ), coconut oil (Cocos nucifera ), apricot kernel oil (Prunus armeniaca ), glycerin, emulsifying wax (e.g., cetyl alcohol, stearyl alcohol, polysorbate 60), stearic acid, vitamin E (Tocopherol), sunflower seed oil (Helianthus annum ), phenoxyethanol, glycolic acid, tartaric acid, malic acid, organic shea butter
(Butyrospermum parkii ), mango seed butter (Mangifera indica ), organic sugar cane extract (Saccharum offwinarum ), organic bilberry fruit extract ( Vaccinium myrtillus ), organic sugar maple extract (Acer saccharinum ), organic orange peel extract (e.g., Citrus sinensis), organic lemon peel extract (Citrus limon), organic cranberry fruit extract (Vaccinium macrocarpon ). organic seaweed extract (Fucus vesiculosus), organic green tea leaf extract (Camellia sinensis), organic white willow bark extract (Salix alba), organic alcohol, organic neem seed oil (Melia azadirachta), organic rosemary leaf extract (Rosmarinus officinalis), xanthan gum, tetrasodium glutamate diacetate, tranexamic acid, and astaxanthin. In some embodiments, the cosmetic composition comprises ingredients one or more selected from the group consisting of ihe Mutable Collagenous Tissue of the present technology, organic aloe leaf juice, organic coconut oil, organic alcohol, cetearyl olivate, sorbitan olivate, cetyl palmitate, sorbitan palmitate, organic olive fruit oil (Olea europaea), stearic acid, organic green tea leaf extract (Camellia sinensis), pomegranate seed extract (Punica granatum), xanthan gum, soluble collagen, ascorbic acid, tocopheryl acetate, royal jelly, and astaxanthin. In some embodiments, the cosmetic composition comprises ingredients one or more selected from the group consisting of the Mutable Collagenous Tissue of the present technology, water, organic coconut oil, grapeseed oil (Vitis vinifera), emulsifying wax (e.g, cetyl alcohol, stearyl alcohol, polysorbate 60), stearic acid, glycerin, xanthan gum, phenoxyethanol, tetrasodium glutamate diacetate, soluble collagen, ascorbic acid, tocopheryl acetate, royal jelly, and astaxanthin.
[0135] In some embodiments, the cosmetic composition intensely hydrates skin to create a softer and smoother look, reducing the appearance of scars. In some embodiments, the composition hydrates and soothes skin to create a visibly supple texture around the eye, diminishing the appearance of puffmess, temporary redness and uneven skin tone. In some embodiments, the cream revitalizes skin on contact and helps improve skin appearance. In some embodiments, the composition promotes smooth and hydrated skin, reducing the appearance of dark spots and hyperpigmentation for a more radiant look.
[0136] In one aspect, the present technology relates to hydrogel compositions comprising the Mutable Collagenous Tissue of the present technology for injection. The hydrogel compositions and methods may be applied to subjects seeking a small/moderate enlargement, shape change or contour alteration of a body part or region. The conditions that are treated with the hydrogel compositions and methods include, but are not limited to, breast imperfections, e.g ., a breast augmentation, a breast reconstruction, defects due to implant complications; a facial imperfections, e.g., a facial augmentation, wrinkles, lines, a facial reconstruction, scars, sunken cheeks, hollow cheeks, thin lips, nasal imperfections or defects, retro-orbital imperfections or defects, a facial folds, nasolabial lines, perioral lines, and/or a marionette line; skin imperfections, e.g., an augmentation or a reconstruction of the upper arm, lower arm, hand, shoulder, back, neck, torso including abdomen, buttocks, upper leg, lower leg including calves, foot including plantar fat pad, eye, genitals, or other body part, region or area. In some embodiments, the method comprises intra-epidermal, intra-dermal, and/or subcutaneous injection of cosmetically sufficient amount of the hydrogel
compositions. In some embodiments, the cosmetically sufficient amounts of the hydrogel composition are determined based on the alteration and/or improvement desired, the reduction and/or elimination of a soft tissue condition symptom desired, the clinical and/or cosmetic effect desired by the individual and/or physician, and the body part or region being treated. In some embodiments, the injection of cosmetically sufficient amount of the hydrogel compositions causes one or more of gain of skin elasticity and recoil, improved barrier function, decreased transepidermal water loss, desired small/moderate enlargement, desired shape change or contour alteration, desired, reduction of wrinkles, firming of skin, etc. In some embodiments, the hydrogel compositions promote cartilage regeneration. In some embodiments, the hydrogel compositions are used for the treatment of osteoarthritis.
[0137] In some embodiments, the amount of Mutable Collagenous Tissue of the present technology present in hydrogel composition is about 0.1 wt.%, about 0.2 wt.%, about 0.3 wt.%, about 0.4 wt.%, about 0.5 wt.%, about 0.6 wt.%, about 0.7 wt.%, about 0.8 wt.%, about 0.9 wt.%, about 1 wt.%, about 2 wt.%, about 3 wt.%, about 4 wt.%, about 5 wt.%, about 6 wt.%, about 7 wt.%, about 8 wt.%, about 9 wt.%, about 10 wt.%, about 11 wt.%, about 12 wt.%, about 13 wt.%, about 14 wt.%, about 15 wt.%, about 16 wt.%, about 17 wt.%, about 18 wt.%, about 19 wt.%, about 20 wt.%, about 22 wt.%, about 24 wt.%, about 26 wt.%, about 28 wt.%, about 30 wt.%, about 32 wt.%, about 34 wt.%, about 36 wt.%, about 38 wt.%, about 40 wt.%, about 42 wt.%, about 44 wt.%, about 45 wt.%, or any range including and/or in between any two of these values. In some embodiments, the amount of Mutable Collagenous Tissue of the present technology present in the hydrogel composition is about 0.1 wt.% to about 0.5 wt.%, about 0.25 wt.% to about 2 wt.%, about 1 wt.% to about 5 wt.%, about 2.5 wt.% to about 10 wt.%, about 5 wt.% to about 25 wt.%, or about 10 wt.% to about 50 wt.%.
[0138] In some embodiments, the amount of the hydrogel composition administered is, e.g., about 0.01 g, about 0.05 g, about 0.1 g, about 0.5 g, about 1 g, about 5 g, about 10 g, about 20 g, about 30 g, about 40 g, about 50 g, about 60 g, about 70 g, about 80 g, about 90 g, about 100 g, about 150 g, or about 200 g. In some embodiments, the amount of a hydrogel composition administered is, e.g., about 0.01 g to about 0.1 g, about 0.05 g to about 0.5 g, about 0.1 g to about 1 g, about 0.5 g to about 5 g, about 1 g to about 10 g, about 5 g to about 50 g, about 10 g to about 100 g, or about 50 g to about 200 g. In some embodiments, the amount of a hydrogel composition administered is, e.g., about 0.01 mL, about 0.05 mL, about 0.1 mL, about 0.5 mL, about 1 mL, about 5 mL, about 10 mL, about 20 mL, about 30 mL, about 40 mL, about 50 mL, about 60 mL, about 70 g, about 80 mL, about 90 mL, about 100 mL, about 150 mL, or about 200 mL. In some embodiments, the amount of a hydrogel composition administered is, e.g., about 0.01 mL to about 0.1 mL, about 0.05 mL to about 0.5 mL, about 0.1 mL to about 1 mL, about 0.5 mL to about 5 mL, about 1 mL to about 10 mL, about 5 mL to about 50 mL, about 10 mL to about 100 mL, or about 50 mL to about 200 mL.
[0139] In one aspect, the present technology relates to nutritional supplements comprising the Mutable Collagenous Tissue of the present technology. In some embodiments, the nutritional supplement is formulated as powder, pill, tablet, capsule, beverage, frozen dessert, gelatin dessert, pudding, confectionery, soft gel, chewing gum, candy, gummi candy, gum, caramel,
chocolate, tablet sweet, snack, baked good, jelly, jam, yogurt, soup, or stew. The nutritional supplement may further comprise moisturizers, antioxidants, minerals, metal sequestrants, proteins, enzymes, vitamins, fats, oils, dietary fiber, fruit extracts, vegetable extracts, meat extracts, yeast extract, solvents, buffers, bulking agents, anti-microbial agents, thickeners, antioxidants, surfactants, emulsifiers, solubilizers, solubilizing aids, colorants (dyes and pigments), perfumes, flavoring agents, sugars, and preservatives.
[0140] In some embodiments, the nutritional supplement promotes joint health, supports connective tissues, helps maintain a strong immune system, supports restful sleep and/or healthy digestion. In some embodiments, the nutritional supplement corrects nutritional insufficiency. In some embodiments, the nutritional supplement stimulates testosterone production to maintain healthy libido, stamina and sexual performance.
[0141] In one aspect, the present technology relates to use of the Mutable Collagenous Tissue of the present technology, or any of the compositions disclosed herein, as an extracellular matrix for cell culture and tissue engineering. In one aspect, the present technology relates to use of the Mutable Collagenous Tissue of the present technology, or any of the compositions disclosed herein, as bio-ink for electrospinning and 3D-printing.
Kits and Articles of Manufacture
[0142] In one aspect, the present disclosure provides a kit comprising a mutable collagenous tissue purified according to any of the methods disclosed herein, and/or any of the compositions disclosed herein. In some embodiments, the kits comprise the mutable collagenous tissue and/ or the compositions that are packed in suitable containers, or a dispenser device. In some embodiments, the kits contain the composition along with instructions for use. In some embodiments, the kits these components may be stored in unit or multi-dose containers, for example, sealed ampoules, vials, bottles, syringes, and test tubes, as an aqueous, preferably sterile, solution or as a lyophilized, preferably sterile, composition for reconstitution. The kit may further comprise a second container which holds a diluent suitable for diluting the composition towards a higher volume. Suitable diluents include, but are not limited to, a pharmaceutically acceptable excipient of the composition and a saline solution. Furthermore, the kit may comprise instructions for diluting the composition and/or instructions for administering the composition, whether diluted or not.
The containers may be formed from a variety of materials such as glass or plastic and may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper which may be pierced by a hypodermic injection needle). The kit may further comprise more containers comprising a pharmaceutically acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, culture medium for one or more of the suitable hosts. The kits may optionally include instructions customarily included in commercial packages of therapeutic or cosmetic products, that contain information about, for example, the indications, usage, dosage, manufacture, administration, contraindications and/or warnings concerning the use of such therapeutic or cosmetic products.
[0143] The kit can also comprise, e.g ., a buffering agent, a preservative or a stabilizing agent. The kit can also contain a control sample or a series of control samples, which can be assayed and compared to the test sample. Each component of the kit can be enclosed within an individual container and all of the various containers can be within a single package, along with instructions for interpreting the results of the assays performed using the kit. The kits of the present technology may contain a written product on or in the kit container. The written product describes how to use the reagents contained in the kit. In certain embodiments, the use of the reagents can be according to the methods of the present technology.
[0144] In some embodiments, the kit includes a container comprising the compositions of the present disclosure. The container may be light impermeable, air-tight and/or leak resistant. Exemplary containers include, but are not limited to, syringes, vials, or pouches. In some embodiments, the kit comprises a handheld injection device.
[0145] In one aspect, the present disclosure provides a prefilled syringe comprising hydrogel comprising the Mutable Collagenous Tissue of the present technology.
[0146] In one aspect, the present disclosure provides applicators for applying the Mutable Collagenous Tissue of the present technology. In some embodiments, the applicator is selected from sponge, puff, tube, application nozzle, wipes, spray, a spreadable stick, pencil, and discharge pad. The applicator may be part of a kit for preparing and/or administering any of the compositions of the present disclosure.
Examples
[0147] The present technology is further illustrated by the following Examples, which should not be construed as limiting in any way. The examples herein are provided to illustrate advantages of the present technology and to further assist a person of ordinary skill in the art with preparing or using the compositions and systems of the present technology. The examples should in no way be construed as limiting the scope of the present technology, as defined by the appended claims. The examples can include or incorporate any of the variations, aspects, or embodiments of the present technology described above. The variations, aspects, or embodiments described above may also further each include or incorporate the variations of any or all other variations, aspects or embodiments of the present technology.
Example 1: Extraction of Mutable Collagenous Tissue from Sea Urchin
[0148] The following method was used to extract mutable collagenous tissue from sea urchin:
[0149] Step 1 : Sea urchin specimens ( Strongylocentrotus purpuratus and/or Paracentrotus lividus) were collected and stored at -20°C for transportation. The sea urchin specimens were thawed and dissected to eliminate internal tissue. Connective tissue from the body wall was isolated.
[0150] Step 2: Connective tissue from Step 1 was soaked in aqueous isopropyl alcohol (50% v/v) solution for 30 minutes at 4°C, cut into small pieces and stored at -20°C for 12 hours.
[0151] Step 3: The frozen connective tissue was then soaked in ice-cold deionized water at 4°C for 30 minutes, and centrifuged at 4,500 x g at 4°C for 15 minutes. The supernatant was discarded.
[0152] Step 4: The connective tissue from the pellet of Step 3 (50 g) was then suspended in a 2-liter ice-cold, aqueous solution of 1 mM EGTA in PBS buffer and incubated at 4°C for 12 hours with gentle stirring. The mixture was then centrifuged at 4,500 x g at 4°C for 30 minutes, and the supernatant was discarded.
[0153] Step 5: Solid connective tissue from the pellet of Step 4 was dispersed in 2 liters of an ice-cold, aqueous 1.0 M sodium bicarbonate solution and incubated at 4°C with gentle
stirring for 24 hours. The mixture was centrifuged at 4,500 x g, 4°C for 30 minutes, and the supernatant was discarded.
[0154] Step 6: The pellet from Step 5 of Example 1 was suspended in a 0.5 M citric acid solution containing trypsin (0.5% w/v) and reacted at 25°C with stirring for 48 hours. The reaction mixture was subjected to centrifugation at 9,000 x g, 4°C for 60 minutes. The supernatant is the extracted mutable collagenous tissue.
Example 2: Extraction of Mutable Collagenous Tissue from Sea Cucumber
[0155] The following method was used to extract mutable collagenous tissue from sea cucumber:
[0156] Step 1 : Sea cucumber specimens ( Thelenota ananas and/or Cucumaria frondosa ) were collected and stored at -20°C for transportation. As shown in Fig. 2, the sea cucumber specimens were thawed and dissected to eliminate internal tissue. Connective tissue from the body wall isolated.
[0157] Step 2: Connective tissue from Step 1 were then soaked in ice-cold, aqueous ethanol (45% v/v) solution for 30 minutes, cut into small pieces and stored at -20°C for 12 hours.
[0158] Step 3: Frozen connective tissue from Step 2 were soaked in deionized water for 30 minutes, centrifuged at 9,000 c g, 4°C for 30 minutes and the supernatant was discarded.
[0159] Step 4: Connective tissue from the pellet of Step 3 (50 g) was suspended in a 2-liter aqueous solution of 0.8 mM EDTA in 10 mM Tris buffer and mixed for 24 hours under gentle stirring. After the reaction time is completed the mixture is centrifuged at 9,000 x g, 4°C for 30 minutes and the supernatant is discarded.
[0160] Step 5: Solid connective tissue from Step 4 was dispersed in an aqueous 0.1 M sodium hydroxide solution and incubated with gentle stirring at 4°C for 48 hours. The resultant mixture was subjected to centrifugation at 9,000 x g, 4°C for 30 minutes, and the supernatant was discarded.
[0161] Step 6: Remaining collective tissue from Step 5 was suspended in an acetic acid solution (0.1 M) containing pepsin (0.5% w/v) and reacted with stirring for 72 hours. The reaction mixture was subjected to centrifugation at 12,000 x g at 4°C for 60 minutes. The supernatant is the purified mutable collagenous tissue (See the solution in the beaker in FIG. 2)·
[0162] Extraction of native collagen from sea urchin was performed using the following steps:
[0163] Step 1 : Extracted mutable collagenous tissue solution in 0.5 M citric acid from (See Example 1, Step 6, supra) was mixed with 0.5 M potassium chloride at a 1 :5 molar ratio, to induce protein precipitation. The mixture was then separated by centrifugation at 4,500 x g, 4°C for 60 minutes. The supernatant is discarded.
[0164] Step 2: Protein precipitate from Step 1 was dissolved in of 0.5 M citric acid solution and dialyzed against deionized water at 4°C for 72 hours using cellulose membranes with 10 kDa molecular weight cut-off to obtain mutable collagenous tissue solution.
[0165] Step 3 : Native mutable collagenous tissue solution from Step 2 was be frozen at - 20°C and subjected to freeze drying to obtain a sheet of mutable collagenous tissue from sea urchin, which had a fibrous character similar to collagen type I (data not shown). The mutable collagenous tissue collagen sheet was ground to prepare mutable collagenous tissue powder.
[0166] Step 4: to determine content and purity of the mutable collagenous tissue, it dissolved in 0.1 M acetic acid, resolved using SDS-PAGE. The gels were stained using Coomassie blue stain. As shown in FIG. 3 (MC-2), the mutable collagenous tissue contained protein bands at and above 150 kDa. Compared to commercially available pure samples of collagen type I from bovine, rat and human tissue (collectively, the controls), the purified sea urchin mutable collagenous tissue of the current disclosure did not show bands of impurities/ degradation products below 150 kDa. Moreover, as shown in FIG. 3 (MC-2), compared to the controls, the purified sea urchin mutable collagenous tissue featured higher levels of bands corresponding to al, a2 chains, as well as b bands. This pattern is consistent with the purified sea urchin mutable collagenous tissue being collagen type I. Densitometric analysis showed that the purified sea urchin collagen type I was more than 98% pure (data not shown).
[0167] Extraction of native collagen from sea urchin was performed using the following steps:
[0168] Step 1 : Extracted mutable collagenous tissue solution in 0.1 M acetic acid ( See FIG.
2 (third panel), and Example 2, Step 6, supra) was mixed with sodium chloride (0.1 M) to induce protein precipitation. The mixture was subjected to centrifugation at 9,000 x g, 4°C for 60 minutes. The supernatant was discarded.
[0169] Step 2: Protein precipitate from Step 1 was dissolved in 5 ml ice-cold 0.1 M acetic acid and dialyzed against deionized water at 4°C for 48 hours using cellulose membranes with 10 kDa molecular weight cut-off to obtain native collagen solution.
[0170] Step 3: Native collagen solution from Step 2 was frozen at -20°C followed by freeze drying to obtain a sheet of mutable collagenous tissue from sea cucumber. As shown in FIG.
1 A (lower panel) and FIG. 2 (lower panel), the sheet of mutable collagenous tissue from sea cucumber had a fibrous character similar to collagen type I. The mutable collagenous tissue collagen sheet was ground to prepare mutable collagenous tissue powder.
[0171] Step 4: to determine content and purity of the mutable collagenous tissue from sea cucumber, it dissolved in 0.1 M acetic acid, resolved using SDS-PAGE. The gels were stained using Coomassie blue stain. As shown in FIG. 3 (MC-1), the mutable collagenous tissue from sea cucumber contained protein bands at and above 150 kDa. Compared to commercially available pure samples of collagen type I from bovine, rat and human tissue (the controls), the purified mutable collagenous tissue from sea cucumber of the current disclosure did not show bands of impurities/ degradation products below 150 kDa.
Moreover, as shown in FIG. 3 (MC-1), compared to the controls, the purified sea urchin mutable collagenous tissue featured higher levels of bands corresponding to al, a2 chains, as well as b bands. This pattern is consistent with the purified sea cucumber mutable collagenous tissue being collagen type I. Densitometric analysis showed that the purified sea cucumber collagen type I was more than 98% pure (data not shown).
[0172] Mutable collagenous tissue and solid collagen type I from starfish was purified substantially as disclosed in Examples 1-4.
[0173] Mutable collagenous tissue from starfish was also subjected to SDS-PAGE. As shown in FIG. 3 (MC-3), the mutable collagenous tissue from starfish contained protein bands at and above 150 kE)a. Compared to commercially available pure samples of collagen type I from bovine, rat and human tissue (the controls), the purified mutable collagenous tissue from starfish of the current disclosure did not show bands of impurities/ degradation products below 150 kE)a. Moreover, as shown in FIG. 3 (MC-3), compared to the controls, the purified starfish mutable collagenous tissue featured higher levels of bands corresponding to al, a2 chains, as well as b bands. This pattern is consistent with the purified sea urchin mutable collagenous tissue being collagen type I. Densitometric analysis showed that the purified sea cucumber collagen type I was more than 98% pure (data not shown).
Example 6: Evaluation of Collagen Properties and Purity
[0174] Collagen content and purity was evaluated by SDS-PAGE. Collagen samples were dissolved in acetic acid (0.1 M) to a final concentration of 1 mg/mL and mixed 1 : 1 with Load Running Buffer (Bio Rad, USA). Running buffer (1 x) was prepared from concentrated 10* buffer stock solution Tris-Glycine-SDS (Bio Rad, USA). Liquid samples were filtered through a 0.45 pm filter and 7 pL were pipetted into each designated well on a pre-casted polyacrylamide 7.5% Mini-Protean TGX gels (Bio Rad, USA). Gel electrophoresis was conducted in a Bio Rad Mini-Protean Tetra SDS-PAGE chamber (Bio Rad, USA) under at 200 V, for about 40 min, until the blue marker run out of the gel. Proteins present in the gel were stained with Coomassie blue using standard protocol. The gel was imaged and subjected to densitometry.
[0175] As shown in FIG. 3, commercially available human type-I collagen (Advanced Biomatrix, USA), rat tail type-I collagen (Sigma Aldrich, USA) and bovine type-I collagen (Sigma Aldrich, USA) exhibited protein bands in 15 kDa to 100 kDa region, which are likely to be the degradation products of collagen, or small protein- or peptide-contaminants that were not removed by the extraction process. In comparison, the samples MC-1 through MC-
3 showed high molecular weight collagen protein bands, which appeared between 150 kDa and 300 kDa. These protein bands correspond to pure native collagen protein in its intact form. Based on molecular weights, distinctive signals for collagen type I were assigned to al, a2 and b-collagen, corresponding to the typical triple helix chains found in native collagen macrostructure.
[0176] These data show that the method disclosed herein produces pure collagen type I from echinoderms. The method disclosed herein does not lead to either chemical (acid/base) or enzymatic (proteases) degradation, producing pure high molecular weight collagen type I (See FIG. 3).
Example 7: Analysis of Purity and Stability
[0177] Collagen samples were subjected to electrophoretic characterization of collagen samples. Native collagen types I, II, III and V were used as controls for comparison.
Collagen type I collagen contains, (a 1 )(I)2(a2)(I) i . As shown in FIG. 4A, echinoderm mutable collagenous tissue corresponded with the typical profile of pure collagen type I, as evidenced from the molecular profile study. For example, SDS-PAGE pattern exhibited an intense band near 100 kDa followed by a faint band, which correspond to al and a2 chains, respectively. In addition, a band observed near 200 kDa corresponds to b-chain (dimers of al -chains; data not shown).
[0178] To confirm whether MCT from other sources also is collagen type I, SDS-PAGE was performed. As shown in FIG. 4B, for native collagen samples showed that mutable collagenous tissue samples from Asterias amurensis, Paracentrotus lividus , Thelenota ananas , and Cucumaria frondosa , isolated by methods described above, showed a mobility pattern showing both al and a2 chains. The band of al -chain was about twice as intense as that of a2-chain, consistent with the molecular formula (al)(I)2(a2)(I)i (See FIG. 4B). Other cross-linked subunits with high molecular weight, such as b-chain (dimers of al -chains) were also visible. On the basis of subunit composition and SDS-PAGE pattern, it was interpreted that echinoderm MCT is mainly composed of collagen type I, which was consistent with the human and bovine collagen type I collagen.
[0179] To understand stability of collagen during extraction process, SDS-PAGE was performed under reducing conditions by adding b-mercaptoethanol to the sample buffer to
promote hydrolysis of disulfide linkages. A sample of sea cucumber MCT was compared with rat, chicken, human and bovine collagen type I samples obtained from commercial sources. The rat, chicken, human and bovine collagen type I samples served as reference samples. As shown in FIG. 5, MCT collagen showed no bands under 150 kDa indicating that the sea cucumber collagen was intact. In contrast, the collagen reference samples showed multiple peptide bands along gel, indicating existence of chemical and /or enzymatic degradation during extraction. Sea cucumber MCT collagen showed its native collagen bands as shown in the previous SDS-PAGE analysis under native conditions. Accordingly, the MCT obtained by the process described herein protects the collagen from enzymatic and chemical degradation.
[0180] These data show that the method disclosed herein produces pure collagen type I from echinoderms that does not show chemical (acid/base) or enzymatic (proteases) degradation.
Example 8: Analysis of Chemical Profile
[0181] To further characterize sea cucumber mutable collagenous tissue, chemical profile of sea cucumber MCT was studied using Fourier-Transform Infrared Spectroscopy in the attenuated reflectron mode (FTIR-ATR). The FTIR analysis method, which uses infrared light to scan test samples and observe chemical properties, is an analytical technique used to identify organic, polymeric, and, in some cases, inorganic materials. Each molecule or chemical structure produces a unique spectral fingerprint, making FTIR analysis a great tool for chemical identification. FTIR spectra per collagen type could be obtained by using a combination of four spectral intervals [v(C=0) absorption of amide I (1,700-1,600 cm-1), 5(CH2), and 5(CH3) absorptions (1,480-1,350 cm-1), v(C-N), and d(N-H) absorptions of amide III (1,300-1,180 cm-1), and v(C-O) and v(C-O-C) absorptions of carbohydrate moieties (1,100-1,005 cm-1)] As shown in FIG. 6A, the FTIR spectrum of the bovine collagen exhibits a characteristic chemical profile for collagens, and sea cucumber mutable collagenous tissue also confirms with the typical profile of collagen type I. The slight differences in the FTIR profile of sea cucumber mutable collagenous tissue, compared to bovine collagen I are likely to be associated to different amino acid distributions and triple helix arrangements. Since FTIR analysis only shows the general chemical composition of collagen, no significant differences were expected. To find in the comparative analysis of
different MCT samples isolated from sea urchin and sea cucumber, FTIR-ATR analyses were performed. As shown in FIG. 6B, sea urchin and sea cucumber MCT showed very comparable profiles to each other, which included most of the characteristic FTIR peaks typically found in collagen type I. These data also show that the extraction process for mutable collagenous tissue disclosed herein produces for homogeneous echinoderm collagen type I.
[0182] To further elucidate the basis for the slight differences in FTIR profiles, amino acid composition of echinoderm mutable collagenous tissue from sea cucumber and sea urchin was analyzed. Bovine collagen isolated from calf skin was used as a standard. As shown in Table 1, the amino acid composition of echinoderm mutable collagenous tissue from sea cucumber and sea urchin was very similar to each other. However, there were slight differences between bovine collagen isolated from calf skin and echinoderm mutable collagenous tissue (See Table 1).
Table 1. Amino acid composition of mutable collagenous tissue, and bovine collagen isolated from calf skin.
[0183] As shown in Table 1, the major amino acids of MCT were glycine (19.0%), glutamic acid (14.0%), proline (12.0%), alanine (9.0%), aspartic acid (9.0%), Arginine (8.0%) and hydroxyproline (6.7%).
[0184] The primary structure of type I collagen is characterized as containing domains with continuous repeating of Gly-X-Y sequence (where X is mostly proline and Y is mostly hydroxyproline), and the very short N- and C-terminal regions called telopeptides (15 to 26 amino acid residues). The Gly-X-Y repeating sequence in al chain plays an important role in triple helix formation of secondary structure. Zitnay et al ., Acta Biomateralia, 65: 76-87 (2018); Leon-Mancilla et al ., Journal of Applied Research and Technology 14: 77-85 (2016). As an amino acid with the lowest molecular weight, glycine residues arranged in the center of triple helix can help helix structure to fold compactly. Cheng et al ., Plos One 12(1):
eO 169731 (2017). Therefore, glycine is the major amino acid in bovine collagen. According to previous references, the glycine content in bovine collagen ranges from 14 to 33%, about one-quarter of total amino acid, that was consistent with MCT glycine content (19%). Imino acids (proline and hydroxyproline) are important amino acids composing Gly-X-Y repeat sequences in a chain, based on that they could maintain the stability of collagen triple helix with their pyrrolidine rings. Nimptsch et al ., Cellular Tissue Research 343 : 605-617 (2011).
[0185] As shown in Table 1, and FIG. 7, The contents of proline and hydroxyproline in MCT were 12.0 and 7.0%, respectively, for a total imino acid content of 20.0%, which was slightly lower than the corresponding values found for bovine collagen. Similarly, as shown in Table 1, and FIG. 7, although bovine collagen had more glycine (33%), less glutamic acid (7.5%)
and less aspartic acid (4.5%) compared to the MCT samples, the overall amino acid content of collagen from the different sources were similar to each other.
[0186] The contents of proline and hydroxyproline are found to be related to environmental temperature. Zhong et al., Food Chem 80(4): C671-C679 (2015). However, when compared to bovine collagen, the ratio of Gly to imino acid (Hyp/Pro) in MCT content was lower, thus suggesting a more efficient stabilization of the Gly-based triple helix by imino acids in MCT.
Example 8: Scanning Electron Microscopy
[0187] Scanning electron microscopy (SEM) produces images of a sample by scanning the surface with a focused beam of electrons. The electrons interact with atoms in the sample, producing signals that contain information about the sample's surface topography and composition. The surface morphology of mutable collagenous tissue extracted from sea cucumber was characterized by SEM imaging, in comparison with collagen type I from calf skin, used as a reference. As shown in FIG. 8, mutable collagenous tissue exhibited a fibrillar collagen structure similar to that of the reference bovine collagen type I; however, the mutable collagenous tissue showed higher porosity and homogeneity than the reference collagen sample (See FIG. 8). The fibers in the mutable collagenous tissue were bigger and longer compared to the reference. Collagen porosity and pore homogeneity is an important performance parameter for wound dressing applications, due to its direct relation with cell attachment and proliferation.
[0188] These data show that the method disclosed herein produces pure collagen type I a pure high molecular weight collagen type I having bigger and longer fibers from
echinoderms, which is suitable for the compositions and kits disclosed herein for applications such as wound dressing, cosmetics, nutrition etc.
[0189] The present technology is not to be limited in terms of the particular embodiments described in this application, which are intended as single illustrations of individual aspects of the present technology. Many modifications and variations of this present technology can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods and apparatuses within the scope of the present technology, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing descriptions. Such modifications and variations are intended to fall within
the scope of the present technology. It is to be understood that this present technology is not limited to particular methods, reagents, compounds compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
[0190] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.
[0191] As will be understood by one skilled in the art, for any and all purposes, particularly in terms of providing a written description, all ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will also be understood by one skilled in the art all language such as“up to,”
“at least,”“greater than,”“less than,” and the like, include the number recited and refer to ranges which can be subsequently broken down into subranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member.
Thus, for example, a group having 1-3 cells refers to groups having 1, 2, or 3 cells. Similarly, a group having 1-5 cells refers to groups having 1, 2, 3, 4, or 5 cells, and so forth.
[0192] All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.
Claims
1. A method for producing a mutable collagenous tissue from an echinoderm, the method comprising treating a connective tissue from an echinoderm with:
(a) an aqueous solution of an organic solvent;
(b) a chelating agent; and
(c) an enzyme solution,
to thereby obtain a liquid mutable collagenous tissue.
2. The method of claim 1, wherein the organic solvent is selected from the group consisting of ethanol, isopropanol, acetone, ethyl acetate, and a combination thereof.
3. The method of claim 1 or claim 2, wherein the chelating agent is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), ethyleneglycol-bis-(beta - aminoethylether) N,N,N',N''-tetraacetic acid (EGTA), diethylenetriaminepentaacetic acid (DTP A), and a combination thereof.
4. The method of any one of claims 1-3, wherein the enzyme solution comprises trypsin, bromelain, pepsin, papain, or any combination thereof.
5. The method of any one of claims 1-4, wherein the method further comprises (d) treating the connective tissue with an alkaline solution.
6. The method of any one of claims 1-5, wherein the method further comprises (e) precipitating collagen from the liquid mutable collagenous tissue by adding an inorganic precipitation agent.
7. The method of claim 6, wherein the method further comprises (f) dialysis of the precipitated collagen from step (e).
8. The method of claim 7, wherein the method further comprises (g) freeze drying the dialyzed collagen of step (f) to produce a solid mutable collagenous tissue.
9. The method of claim 8, wherein the solid mutable collagenous tissue is a powder or a sheet.
10. The method of claim 8 or 9, wherein the solid mutable collagenous tissue is at least 90%, at least 95%, at least 96%, or at least 97%, at least 98%, at least 99% pure collagen type I.
11. A mutable collagenous tissue obtainable by the method of any of claims 1-10.
12. A pharmaceutical, cosmeceutical or cosmetic composition comprising the mutable collagenous tissue obtainable by the method of any one of claims 1-11.
13. The composition of claim 12, wherein the composition further comprises a pharmaceutically acceptable excipient, additive, preservative, and a mixture thereof.
14. The composition of claim 12 or claim 13, wherein the composition is formulated as an article or a carrier selected from the group consisting of a bandage, insert, syringe-like applicator, pessary, powder, talc, cleanser, and a patch.
15. A kit comprising a mutable collagenous tissue obtainable by the method of any one of claims 1-10 or the composition of claims 11-14 and one or more packaging agents, one or more agents for administering the mutable collagenous tissue, one or more cosmetic agents or therapeutic agents, or any combination thereof.
16. A method for treating wound in a subject in need thereof, comprising administering to the subject an effective amount of a wound healing formulation comprising (a) a mutable collagenous tissue obtainable by the method of any one of claims 1-10 or (b) a composition of any one or claims 11-14.
17. A method for treating skin in a subject in need thereof, comprising administering to the subject an effective amount of a cosmetic composition comprising (a) a mutable collagenous tissue obtainable by the method of any one of claims 1-10 or (b) a composition of any one or claims 11-14.
18. A method for treating a condition in a subject in need thereof, comprising administering to the subject an effective amount of a hydrogel composition comprising (a) a mutable collagenous tissue obtainable by the method of any one of claims 1-10 or (b) a composition of any one or claims 11-14.
19. An applicator comprising a mutable collagenous tissue obtainable by the method of any one of claims 1-10 or a composition of any one or claims 11-14.
20. A nutritional supplement comprising a mutable collagenous tissue obtainable by the method of any one of claims 1-10 or a composition of any one or claims 11-14.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2019/031194 WO2020226635A1 (en) | 2019-05-07 | 2019-05-07 | Mutable collagenous tissue from echinoderms |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2019/031194 WO2020226635A1 (en) | 2019-05-07 | 2019-05-07 | Mutable collagenous tissue from echinoderms |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020226635A1 true WO2020226635A1 (en) | 2020-11-12 |
Family
ID=66794079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/031194 WO2020226635A1 (en) | 2019-05-07 | 2019-05-07 | Mutable collagenous tissue from echinoderms |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020226635A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
WO2018220396A1 (en) * | 2017-06-02 | 2018-12-06 | Jellagen Pty Ltd | Method for the purification of collagen |
-
2019
- 2019-05-07 WO PCT/US2019/031194 patent/WO2020226635A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683195B1 (en) | 1986-01-30 | 1990-11-27 | Cetus Corp | |
WO2018220396A1 (en) * | 2017-06-02 | 2018-12-06 | Jellagen Pty Ltd | Method for the purification of collagen |
Non-Patent Citations (27)
Title |
---|
"Current Protocols in Molecular Biology", 2007 |
"Gene Transfer and Expression in Mammalian Cells", 2003 |
"Immobilized Cells and Enzymes", 1986, IRL PRESS |
"Immunochemical Methods in Cell and Molecular Biology", 1987, COLD SPRING HARBOR LABORATORY |
"Molecular Cloning: A Laboratory Manual", 2001 |
"Remington's Pharmaceutical Sciences", 1975, AMERICAN PHARMACEUTICAL ASSOCIATION, pages: 1405 - 1412,1461-1487 |
"Weir's Handbook of Experimental Immunology", 1996 |
ANDERSON, NUCLEIC ACID HYBRIDIZATION, 1999 |
CHENG ET AL., PLOS ONE, vol. 12, no. 1, 2017, pages e0169731 |
CRISTIANO BENEDETTO ET AL: "Production, Characterization and Biocompatibility of Marine Collagen Matrices from an Alternative and Sustainable Source: The Sea Urchin Paracentrotus lividus", MARINE DRUGS, vol. 12, no. 9, 24 September 2014 (2014-09-24), pages 4912 - 4933, XP055617493, DOI: 10.3390/md12094912 * |
E-PUBLICATIONS@RCSI ET AL: "Royal College of Surgeons in Ireland Novel freeze-drying methods to produce a range of collagen-glycosaminoglycan scaffolds with tailored mean pore sizes", 1 October 2010 (2010-10-01), XP055130974, Retrieved from the Internet <URL:http://epubs.rcsi.ie/cgi/viewcontent.cgi?article=1039&context=anatart> [retrieved on 20140722] * |
EVI SIAHAAN ET AL: "Cosmeceuticals Properties of Sea Cucumbers: Prospects and Trends", COSMETICS, vol. 4, no. 3, 4 August 2017 (2017-08-04), pages 26, XP055617476, DOI: 10.3390/cosmetics4030026 * |
FERRARIO CINZIA ET AL: "Marine-derived collagen biomaterials from echinoderm connective tissues", MARINE ENVIRONMENTAL RESEARCH, vol. 128, 31 March 2016 (2016-03-31), pages 46 - 57, XP085051788, ISSN: 0141-1136, DOI: 10.1016/J.MARENVRES.2016.03.007 * |
FRESHNEY: "Culture of Animal Cells: A Manual of Basic Technique", 2005 |
GOWDA, SAN TOSH ET AL.: "Topical application of recombinant platelet-derived growth factor increases the rate of healing and the level of proteins that regulate this response", INTERNATIONAL WOUND JOURNAL, vol. 12.5, 2015, pages 564 - 57 |
JOHN A. TROTTER ET AL: "Covalent composition of collagen fibrils from the dermis of the sea cucumber, Cucumaria frondosa, a tissue with mutable mechanical properties", COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY. PART A. COMPARATIVE PHYSIOLOGY., vol. 112, no. 3-4, 1 November 1995 (1995-11-01), US, pages 463 - 478, XP055617456, ISSN: 0300-9629, DOI: 10.1016/0300-9629(95)02015-2 * |
LEON-MANCILLA ET AL., JOURNAL OF APPLIED RESEARCH AND TECHNOLOGY, vol. 14, 2016, pages 77 - 85 |
MACPHERSON ET AL., PCR 2: A PRACTICAL APPROACH, 1995 |
MACPHERSON ET AL.: "PCR 1: A Practical Approach", 1991, IRL PRESS AT OXFORD UNIVERSITY PRESS |
MATSUMURA T: "COLLAGEN FIBRILS OF THE SEA CUCUMBER, STICHOPUS JAPONICUS: PURIFICATION AND MORPHOLOGICAL STUDY", CONNECTIVE TISSUE RESEARCH, TAYLOR & FRANCIS, US, vol. 2, no. 2, 1 January 1974 (1974-01-01), pages 117 - 125, XP008061842, ISSN: 0300-8207, DOI: 10.3109/03008207409152097 * |
NIMPTSCH ET AL., CELLULAR TISSUE RESEARCH, vol. 343, 2011, pages 605 - 617 |
PERBAL, A PRACTICAL GUIDE TO MOLECULAR CLONING, 1984 |
REDDY, ANN. PHARMACOTHER., vol. 34, no. 7-8, 2000, pages 915 - 923 |
STRACHANREAD: "Human Molecular Genetics", 1999, JOHN WILEY AND SONS, INC. |
VIEIRA R P ET AL: "OCCURRENCE OF A UNIGQUE FUCOSE-BRANCHED CHONDROITIN SULFATE IN THE BODY WALL OF A SEA CUCUMBER", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 263, no. 34, 5 December 1988 (1988-12-05), pages 18176 - 18183, XP001073596, ISSN: 0021-9258 * |
ZHONG ET AL., FOOD CHEM, vol. 80, no. 4, 2015, pages C671 - C679 |
ZITNAY ET AL., ACTA BIOMATERALIA, vol. 65, 2018, pages 76 - 87 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4033877B2 (en) | Composition for promoting type I collagen production | |
US8460721B2 (en) | Active ingredient that stimulates the proliferation and/or activity of fibroblasts | |
JP4388289B2 (en) | Skin aging prevention / improving agent and / or rough skin prevention / improving agent kit | |
US20060233738A1 (en) | Composition for promoting production of type 1 collagen and/or elastin | |
US20200354431A1 (en) | Mutable collagenous tissue from echinoderms | |
US20100233111A1 (en) | Gastropod biological fluid, method of making and refining and use | |
KR20200024235A (en) | Compounds useful for the treatment and / or care of skin, hair, nails and / or mucous membranes | |
CN109152724B (en) | Synergistic extract of palmaria palmiformis and jasmine, composition containing synergistic extract and application of synergistic extract | |
CN109998986A (en) | One kind two splits yeast freeze-dried powder preparation and preparation method thereof | |
WO2009002982A2 (en) | Gastropod biological fluid, method of making and refining and use | |
KR102139472B1 (en) | Anti-aging composition comprising functional peptides and fermented products | |
JP4286513B2 (en) | Anti-aging composition | |
KR20150120426A (en) | Cosmetic composition containing a brown alga extract, a yeast extract and ascorbic acid | |
KR101697152B1 (en) | Manufacturing method of cosmetic material having an anti-aging effect using mucin from eel skin | |
JPH07101871A (en) | Promoter for synthesis of hyaluronic acid in living body | |
ITTO970001A1 (en) | USE OF AN EXTRACT OF ERIOBOTRYA JAPONICA, PARTICULARLY IN THE FIELD OF COSMETICS, TO STIMULATE THE SYNTHESIS OF GLYCOSAMMINOGLICANS | |
KR100494229B1 (en) | manufacturing process of sericin and sericin mask pack | |
TWI601540B (en) | Human Skin Epidermal Cell Proliferator, Compositions Containing Its Skin, and Cosmetic Ingredients | |
KR102445188B1 (en) | A functional micro-n-recovery cosmetic composition for effective skin regeneration and anti-aging comprising microneedle, low molecular weight peptide and natural extracts | |
KR101662272B1 (en) | Natural cosmetic composition for skin moisturizing comprising Mixed extract of barley and germ and rice bran of black rice and preparation method thereof | |
KR102450862B1 (en) | Cosmetic composition containing Cnidium officinale exosome, Paeonia lactiflora exosome | |
WO2020226635A1 (en) | Mutable collagenous tissue from echinoderms | |
US11839682B2 (en) | IMAC-enriched microalgal culture supernatant and uses thereof | |
TWI576117B (en) | Hyaluronic acid production promoter | |
KR20180082058A (en) | A cosmetic composition for skin desquamation comprising natural complex extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19729394 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19729394 Country of ref document: EP Kind code of ref document: A1 |